---
title: "Varegacestat (AL102) in Desmoid tumors: Product information and disease description"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Product information and disease description. Covers Product description and Place of product in therapy. 394 evidence topics quoted from 160 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Under review; NDA submitted April 2026, PDUFA target action date April 2027

> “We acquired varegacestat from Ayala Pharmaceuticals, Inc., or Ayala, in March 2024. We submitted an NDA for varegacestat in April 2026. In July 2026, the FDA accepted the NDA and assigned a PDUFA target action date of April 28, 2027.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027.”

Source: [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Commercial launch preparation

> “We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA.”

Source: [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)

> “We are currently in the early stages of building our internal sales and marketing capabilities to prepare for the commercialization of varegacestat, if approved, and we have never commercialized a product.”
> “The increase was primarily related to increases in expenses related to commercialization readiness, personnel-related costs including share-based compensation from an increase in headcount to support overall growth, and other professional services expenses.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “Launch Strategy”
> “Become Standard of Care treatment of Desmoid Tumors”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “We are prioritizing regulatory, clinical, and operational activities to support a potential commercial launch of varegacestat for the treatment of desmoid tumors, subject to regulatory approval.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “We are focused on the regulatory, manufacturing, and commercial readiness activities necessary to position the program for approval and launch.”

Source: [Immunome press release, full year 2025 results (2026)](https://investors.immunome.com/immunome-reports-full-year-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-4"></a>

##### NDA submission, April 2026

> “today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.”
> “The NDA is supported by positive results from the global, randomized, double-blind, placebo-controlled Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors.”

Source: [Immunome press release, NDA submission (2026)](https://investors.immunome.com/immunome-announces-submission-of-new-drug-application-to-u-s-fda-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.1-5"></a>

##### FDA acceptance of the NDA and PDUFA target action date, July 2026

> “today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027.”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.1-6"></a>

##### NDA review under conventional FDA procedures and timeline

> “For example, the FDA is reviewing our NDA for varegacestat consistent with its conventional procedures and timeline.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm); [Immunome Form 10-Q, second quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm)

<a id="topic-2.1.1-7"></a>

##### EMA marketing authorization application submitted and validated, October 2026

> “today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. Validation confirms that the application is complete, and the EMA will initiate review under the centralized marketing authorization procedure.”

Source: [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

> “We submitted an MAA with the EMA in October 2026. The EMA has validated the MAA and will initiate review under the centralized marketing authorization procedure.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-8"></a>

##### FDA orphan drug designation, November 2023

| Field | Quoted record |
| --- | --- |
| Generic name | “varegacestat” |
| Date designated | “11/02/2023” |
| Orphan designation | “Treatment of desmoid tumors” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Immunome, Inc.” |

Source: [FDA orphan drug designation record for varegacestat (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=968423)

<a id="topic-2.1.1-9"></a>

##### FDA Fast Track designation

> “The FDA has granted Fast Track designation for varegacestat for progressing desmoid tumors.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-10"></a>

##### EMA orphan designation: company statement of July 2025 for desmoid tumors

> “In November 2023, the FDA granted Orphan Drug Designation to varegacestat for the treatment of desmoid tumors and the EMA granted this designation in July 2025, and we may seek additional Orphan Drug Designations for our other product candidates.”
> “For example, European orphan designation may be removed if varegacestat will not offer significant benefit relative to the authorized product nirogacestat.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “The European Medicines Agency granted Orphan Drug Designation to varegacestat in July 2025. Varegacestat previously received Orphan Drug Designation from the U.S. Food and Drug Administration in November 2023.”

Source: [Immunome press release, second quarter 2025 results (2025)](https://investors.immunome.com/immunome-reports-second-quarter-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-11"></a>

##### EMA orphan designation: EMA register entry of 22 August 2025 for soft tissue sarcoma

> “This medicine was designated as an orphan medicine for the treatment of soft tissue sarcoma in the European Union on 22 August 2025.”

Source: [EMA orphan designation EU/3/25/3127 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3127)

| Field | Quoted record |
| --- | --- |
| Active substance | “varegacestat” |
| Intended use | “Treatment of soft tissue sarcoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/25/3127” |
| Date of designation | “22/08/2025” |
| Sponsor | “Somerville Development Partners B.V.” |

Source: [EMA orphan designation EU/3/25/3127 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3127)

<a id="topic-2.1.1-12"></a>

##### Development history: Bristol-Myers Squibb phase 1 trial of BMS-986115

> “A Phase 1 dose-escalation clinical trial was conducted by Bristol-Myers Squibb, or BMS, in patients with solid tumors. In this trial, one patient with desmoid fibromatosis was enrolled.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “This study was sponsored and funded by Bristol-Myers Squibb.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.1-13"></a>

##### Development history: Ayala Pharmaceuticals license from Bristol-Myers Squibb and design of RINGSIDE

> “In connection with the Ayala Closing, we assumed the License Agreement dated as of November 29, 2017, with BMS, as amended by that certain First Amendment to License Agreement dated as of May 4, 2020, or the BMS License.”
> “Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of varegacestat in participants with progressing desmoid tumors who required therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.1-14"></a>

##### Development history: acquisition by Immunome from Ayala Pharmaceuticals, March 2024

> “On March 25, 2024, the Company and Ayala Pharmaceuticals, Inc., or Ayala, completed an Asset Purchase Agreement, or the Ayala Purchase Agreement, that was entered into in February 2024, pursuant to which the Company acquired Ayala’s AL101 and varegacestat (then known as AL102) programs and assumed certain liabilities associated with the acquired assets.”
> “Under the Ayala Purchase Agreement, the Company may pay Ayala up to an additional $27.5 million in the aggregate upon the achievement of certain future regulatory and commercial milestone events.”
> “In connection with the closing of the Ayala Purchase Agreement in March 2024, the Company assumed a license agreement, or the BMS License Agreement, with Bristol-Myers Squibb Company, or BMS, pursuant to which the Company obtained a worldwide, non-transferable, royalty-bearing, exclusive, sublicensable, license under certain patent rights and know-how of BMS to research, discover, develop, make, have made, use, sell, offer to sell, export, import and commercialize AL101 and varegacestat and products containing AL101 or varegacestat for all uses including the prevention, treatment or control of any human or animal disease, disorder or condition.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-15"></a>

##### Development history: Amendment No. 4 to the BMS license, October 2026

> “On October 2, 2026, the Company and BMS entered into Amendment No. 4 to the BMS License Agreement, or the Amendment, and a related stock issuance agreement, or the Stock Issuance Agreement. The Amendment removes the Company’s obligation to make any milestone and royalty payments under the BMS License Agreement and assigned to the Company patent rights related to varegacestat (formerly AL102) and AL101 that were previously licensed to the Company under the BMS License Agreement.”
> “As consideration for the Amendment, the Company paid BMS $20.0 million in cash and issued 4,425,487 shares of the Company's common stock, collectively the Amendment Consideration. The Company has no further milestone, royalty or other payment obligations to BMS under the BMS License Agreement or the Amendment.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-16"></a>

##### Patent expiry

> “The US composition of matter patent covering varegacestat will expire in 2038, which includes 5 years of expected patent term extension. Patent applications covering varegacestat and various derivatives, if issued, are expected to expire between 2033-2045, absent any patent term extensions or adjustments and without accounting for terminal disclaimers.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.1-17"></a>

##### No product approved for commercial sale

> “We have no drugs approved for commercial sale and have not generated any revenue from drug sales.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-18"></a>

##### MAA submission planned by the end of 2026, August 2026, superseded in October 2026

> “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.”

Source: [Immunome press release, second quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-second-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-19"></a>

##### MAA submission planned by the end of 2026, May 2026, superseded in October 2026

> “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.”

Source: [Immunome press release, first quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-first-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-20"></a>

##### NDA submission planned for the second quarter of 2026, March 2026, superseded in April 2026

> “We are completing the manufacturing, toxicology and pharmacology work required to support an NDA submission, and expect to submit an NDA to the FDA for varegacestat for the treatment of desmoid tumors in the second quarter of 2026.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration for varegacestat in the second quarter of 2026.”

Source: [Immunome press release, full year 2025 results (2026)](https://investors.immunome.com/immunome-reports-full-year-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-21"></a>

##### NDA submission planned for the second quarter of 2026, December 2025, superseded in April 2026

> “Based on these data, Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

<a id="topic-2.1.1-22"></a>

##### Launch preparation anchored to priority review, December 2025, superseded in August 2026

> “Launch preparation anchored to priority review”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-2.1.1-23"></a>

##### Topline data expected before the end of 2025, November 2025, superseded in December 2025

> “Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025.”

Source: [Immunome press release, third quarter 2025 results (2025)](https://investors.immunome.com/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-24"></a>

##### Topline data expected in the second half of 2025, January 2025, superseded in December 2025

> “Topline data for Phase 3 RINGSIDE study of varegacestat (formerly known as AL102) expected in second half of 2025.”

Source: [Immunome press release, J.P. Morgan 2025 pipeline update (2025)](https://investors.immunome.com/immunome-provides-pipeline-update-in-advance-of-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference/)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Immunome

> “We acquired varegacestat from Ayala Pharmaceuticals, Inc., or Ayala, in March 2024. We submitted an NDA for varegacestat in April 2026.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “We currently hold global commercial rights for varegacestat, our product candidate for the treatment of desmoid tumors. Subject to obtaining the necessary regulatory approvals, we plan to lead the global commercial strategy and commercialization efforts for this product.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.1-2"></a>

###### Proposed international nonproprietary name

> “varegacestatum”
> “(2R,3S)-N1-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-”
> “1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide”
> “C26H25F7N4O3”
> “1584647-27-7”

Source: [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Recommended international nonproprietary name

> “Recommended INN: List 92”
> “varegacestatum”

Source: [WHO Recommended INN List 92 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/rl92.pdf)

<a id="topic-2.1.2.1-4"></a>

###### Former company code AL102

> “Varegacestat, formerly AL102, is an investigational, oral, once-daily gamma secretase inhibitor, or GSI.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.2.1-5"></a>

###### Originator code BMS-986115 and synonyms

> “AL102”
> “BMS-986115”
> “GS/pan-Notch Inhibitor AL102”
> “LSK1L593UU”

Source: [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C118573?include=full)

> “BMS-986115 is a potent and selective inhibitor of gamma-secretase mediated Notch signalling and inhibits all 4 mammalian Notch receptors (Notch1 to 4) with low nanomolar median inhibitory concentrations (IC50s).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.1-6"></a>

###### Therapeutic class

> “varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.2.1-7"></a>

###### Brand name

No evidence found.

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Oral capsules in the RINGSIDE trial

> “Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.2-2"></a>

###### Dose administered in the RINGSIDE phase 3 trial

> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.2-3"></a>

###### Capsule formulations in clinical pharmacology studies

> “This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

> “as 2 oral capsules followed by approximately 240 mL room temperature filtered water on the morning of Day 1”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

<a id="topic-2.1.2.2-4"></a>

###### Capsule strengths of BMS-986115 in the Bristol-Myers Squibb phase 1 trial

> “BMS-986115 was supplied as grey hard gelatin capsules, including a size 1 capsule containing 0.3 mg BMS-986115 and a size 0 capsule containing 2 mg BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.2-5"></a>

###### Commercial dosage form and unit strengths

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### WHO functional classification

> “gamma-secretase inhibitor, antineoplastic”

Source: [WHO Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.4-2"></a>

###### National Cancer Institute Thesaurus classification

> “Gamma-Secretase Inhibitor”
> “Antineoplastic Enzyme Inhibitor”
> “An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity.”

Source: [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C118573?include=full)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication in the NDA

> “for the treatment of adults with desmoid tumors”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

> “In April 2026, Immunome submitted an NDA to the U.S. FDA for varegacestat for the treatment of adults with desmoid tumors.”

Source: [Immunome press release, first quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-first-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.2.5-2"></a>

###### Proposed indication in the MAA

> “In October 2026, the EMA validated Immunome’s MAA for varegacestat for the treatment of adults with desmoid tumors.”

Source: [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)

> “If approved, varegacestat could provide a meaningful new oral treatment option for adults with desmoid tumors in the European Union (EU)”

Source: [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.2.5-3"></a>

###### Population of the RINGSIDE phase 3 trial: adults with progressing desmoid tumors

> “RINGSIDE Phase 3 was a double-blind, placebo (PBO)-controlled study in adults with progressing DT per RECIST v1.1 (NCT04871282).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Adults with histologically confirmed DT that has progressed in the past 12 months per RECIST 1.1”
> “Treatment-naïve and previously treated patients”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.5-4"></a>

###### Registry eligibility for RINGSIDE Part B: age 12 years and older

> “≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.”
> “Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by ≥ 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Gamma secretase inhibition of Notch signaling

> “Varegacestat is an investigational, oral, once-daily GSI. GSIs alter signaling through the Notch pathway, which is involved in embryonic development and the renewal and maintenance of adult tissues.”
> “Gamma secretase-mediated cleavage of Notch releases the Notch intracellular domain which travels to the nucleus and activates the genes that mediate oncologic behavior. Inhibition of gamma secretase by varegacestat may block this cleavage and inhibits Notch pathway activation.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.6.1-2"></a>

###### Inhibition of all four Notch receptors

> “BMS-986115 is a potent and selective inhibitor of gamma-secretase mediated Notch signalling and inhibits all 4 mammalian Notch receptors (Notch1 to 4) with low nanomolar median inhibitory concentrations (IC50s).”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

> “AL101 (formerly BMS-906024) and AL102 (formerly BMS-986115) are structurally similar GSIs that are parenterally and orally administered, respectively, that inhibit activation of all four human Notch receptors”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

<a id="topic-2.1.2.6.1-3"></a>

###### Wnt/β-catenin and Notch pathway cross-talk in desmoid tumors

> “Desmoid tumors are driven by nuclear accumulation of β-CATENIN”
> “resulting from cross-talk between WNT and NOTCH pathways”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC, respectively. Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.”
> “Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Along with overexpression of β-catenin, desmoid tumors highly express Notch1, with cross-talk between these pathways putatively contributing to proliferation of desmoid tumors.”
> “Nonclinical studies have shown that γ-secretase inhibition prevents release of the Notch intracellular domain, which blocks Notch pathway signaling and cell growth.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.1.2.6.1-4"></a>

###### Notch target gene expression in desmoid tumor tissue

> “In DT, evidence for dysregulation of Notch signaling was observed in in vitro studies showing that DT tissues expressed higher levels of Notch1 and its downstream target HES1”
> “Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

<a id="topic-2.1.2.6.1-5"></a>

###### Mechanistic rationale for gamma secretase inhibitor therapy

> “Gamma secretase inhibitors (GSIs) target cellular proliferation in desmoid tumors, providing a mechanistic rationale for GSI therapy.”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Notch target gene inhibition in peripheral blood

> “Target inhibition of Notch pathway related genes was observed.”
> “Expression of Notch pathway-related genes in peripheral blood was measured as surrogate PD biomarkers for BMS-986115.”
> “After 2 weeks of dosing at the highest tolerated doses of 1.2 mg QD and 1.5 mg QD, geometric mean relative expression of Hes1 was continuously inhibited by >50% below baseline, with peak inhibition of >80% (Fig. 2). Similarly, geometric mean relative expression of Deltex1 was continuously inhibited by greater than 45% for the entire dosing interval, with peak inhibition of >60% (Fig. 2).”
> “At the highest tolerated dose level of 4 mg BIW, geometric mean relative expression of Hes1 was inhibited by >75% for at least 48 h of the weekly dosing cycle and Deltex1 was inhibited by greater than 50%.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.6.2-2"></a>

###### Exposure-response for efficacy in RINGSIDE

> “This analysis aimed to characterize the relationship between VAR plasma exposure and selected efficacy endpoints in patients with progressing desmoid tumors (DTs) and safety endpoints in patients with advanced solid tumors (ASTs) and DTs.”
> “Efficacy analysis included 198 participants from Ph2/3 RINGSIDE study (DT):”
> “Although exposure was not a statistically significant predictor of PFS and ORR, increasing trends were observed in ORR, TTV, and SLD with increasing VAR Cavg, supporting maximal efficacy at 1.2 mg QD.”
> “Trend toward increase in ORR with higher VAR Cavg, however not statistically significant (p = 0.0818).”
> “Trend toward decreasing ORR with lower starting dose compared to 1.2 mg QD.”
> “At 1.2 mg QD, TGI models predicted greater target attainment at Week 48 compared to 0.9 mg QD.”
> “Dose reduction had no apparent impact on PFS.”
> “No impact of dose reductions on TTV/SLD.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### Exposure-response for safety in a pooled phase 1 to phase 3 population

> “Safety analysis included 157 participants treated with VAR:”
> “36 from Ph1 Study CA002001 (solid tumors).”
> “Identified statistically significant (p < 0.05) ER relationships for VAR Cavg and the endpoints TESAEs, Grade 2+ TEAEs: nausea/vomiting, fatigue, diarrhea, hypophosphatemia and rash. No statistically significant relationship was observed between VAR exposure and Grade 2+ ALT elevation and ovarian toxicity.”
> “Safety ER models predicted no clinically meaningful reduction in AE rates at reduced starting doses of 0.9 or 0.6 mg QD.”
> “In clinical studies, dose modifications including dose reductions, were effective in managing these AEs.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

| Adverse event of interest | Incidence, n (%) |
| --- | --- |
| Treatment-emergent serious adverse events | “49 (31.2)” |
| Grade 2+ hypophosphatemia | “47 (29.9)” |
| Grade 2+ fatigue | “43 (27.4)” |
| Grade 2+ nausea/vomiting | “31 (19.7)” |
| Grade 2+ diarrhea | “59 (37.6)” |
| Ovarian toxicity | “32 (50.0)” |
| Grade 2+ rash | “58 (36.9)” |
| Grade 2+ ALT elevation | “9 (5.7)” |
| Note | “Safety analysis population count was (N = 157) for all endpoints except ovarian toxicity (N = 64).” |

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.6.2-4"></a>

###### Exposure-response modeling of tumor volume and dose selection

> “Exposure-response modeling evaluated time course of drug effect on tumor volume to support selection of 1.2 mg once daily for further study”
> “Exploratory exposure-response modelling suggested that 1.2 mg once daily dose achieves earlier and deeper response than the other dose regimens”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Nonclinical pharmacology and toxicology

> “Nonclinical experiments showed that BMS-986115 was effective as a single agent in the treatment of human T-ALL xenograft models, and demonstrated anti-tumour activity against 5 out of 7 solid tumour xenografts evaluated, including 3 breast, 1 NSCLC, and 1 pancreatic carcinoma. In animal studies, the main pharmacological toxicities included dose-dependent gastrointestinal (GI) toxicity, lymphoid depletion, and interruption of ovarian follicle maturation. Notch inhibitor mediated GI toxicity, which is characterized by goblet cell metaplasia throughout the intestines, is the result of on-target drug-induced differentiation of small intestinal and colonic progenitors to the secretory (goblet) cell fate.”
> “Subjects were required to have an adequate lipid profile as increases in triglycerides were seen in the multiple dose rat study with BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption, dose proportionality, and half-life with once-daily dosing

> “BMS-986115 was rapidly absorbed following single/multiple-dose administration over the 0.3-mg to 8-mg dose range, and the median Tmax was within a range of 1 h to 3 h. There was a dose-related increase for both Cmax and AUCtau after BMS-986115 administration following single/multiple-dose administration over the 0.3-mg to 8-mg dose range. Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.6.3-2"></a>

###### Accumulation with repeated dosing

> “BMS-986115 accumulated in plasma following once daily administration in Arms A and B. The median accumulation ratios (AUCtau ratio of Day 15/Day 1 values) of BMS-986115 after once daily dosing were 2.64, 3.9, 3.66, 2.33, and 2.19 for 0.3-, 0.6-, 1.2-, 1.5-, and 2-mg doses, respectively. Accumulation ratios (AUCtau ratio of Day 16/Day 1) of BMS-986115 after two consecutive days dosing in a week (Arm B) were 2.47, 3.01, and 2.77 for 2-, 4- and 8-mg doses, respectively.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.6.3-3"></a>

###### Active metabolite BMT-100948

> “Plasma concentration-time data for BMS-986115 and an equally active metabolite BMT-100948 were reported for subjects who received at least one dose of study medication.”
> “Plasma concentrations of BMT-100948 were low relative to plasma concentrations of the parent drug (BMS-986115). Median Cmax% ratios for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 5 to 13%, and after multiple doses on Day 15 ranged from 12 to 16%, respectively. Similarly, median AUCtau ratio for BMT-100948 to that of BMS-986115 after a single dose on Day 1 ranged from 14% - 22%, and after multiple doses on Day 15 ranged from 17% - 27%, respectively.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.6.3-4"></a>

###### Projected half-life and rationale for transient target engagement

> “As prolonged inhibition of the Notch pathway is associated with increased GI toxicity, an oral Notch inhibitor with a short half-life that allows transient rather than continuous target engagement is desirable. BMS-986115 has a projected human half-life of approximately 15 h”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.6.3-5"></a>

###### Half-life relative to nirogacestat as stated by the company

> “Varegacestat is a Gamma Secretase Inhibitor with a”
> “Differentiated Pharmacokinetic Profile”
> “78% Longer Half-Life than”
> “Nirogacestat”
> “Sustained Exposure Above”
> “1.2 mg Once Daily”
> “(3) Immunome data on file”
> “Aung et al., Investigational New Drugs. 2018; (5) Varegacestat Investigator’s Brochure Version 8.0”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Hepatic impairment: single-dose pharmacokinetic study design

> “This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.”
> “This is an open-label, single-dose, parallel study to evaluate the effects of varying degrees of impaired hepatic function on the PK, safety, and tolerability of varegacestat in adult participants.”
> “The study will enroll participants with mild (Group 2) and moderate (Group 3) hepatic impairment (HI) and healthy participants with normal hepatic function (Group 1) at a 1:1 ratio.”
> “Subsequently, if appropriate, the study will enroll participants with severe (Group 4) HI and healthy participants with normal hepatic function (Group 1), as needed, to provide 1:1 matches for Group 4. The decision to conduct Group 4 enrollment will be contingent upon the assessment of the feasibility, PK, and safety data from Groups 1-3.”
> “Has a score on the Child-Pugh scale at screening visit and confirmed at check-in as follows:”
> “Mild: ≥5 and ≤6 [Category A]; or”
> “Moderate: ≥7 and ≤9 [Category B]; or”
> “Severe: ≥10 and ≤15 [Category C].”

Source: [ClinicalTrials.gov NCT06841315](https://clinicaltrials.gov/study/NCT06841315)

<a id="topic-2.1.2.8-2"></a>

###### Hepatic and renal function thresholds for trial eligibility

> “Abnormal organ and marrow function at Screening defined as:”
> “Total bilirubin >1.5x upper limit of normal (ULN) (except known Gilbert's syndrome),”
> “Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5x ULN,”
> “Serum creatinine > ULN and creatinine clearance (CrCl) <60 mL/min (calculation of CrCl will be based on acceptable institution standard)”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.8-3"></a>

###### Pregnancy, breastfeeding, and contraception

> “Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Lactating or pregnant women were not eligible and all subjects were needed to comply with effective contraception methods as per protocol.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

> “Healthy, adult, male or female (of non-childbearing potential only), 18 to 55 years of age, inclusive, at the screening visit.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

> “Male participants must follow protocol-specified contraception guidance”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-2.1.2.8-4"></a>

###### Ovarian toxicity in premenopausal women

> “36/53 (67.9)”
> “A known class effect of GSI”
> “Varegacestat 56% | Placebo 5% of premenopausal women”
> “No women discontinued varegacestat due to ovarian toxicity”
> “Ovarian toxicity resolved in all participants with follow-up data after stopping treatment”
> “Ovarian toxicity includes the MedDRA preferred terms amenorrhea, premature menopause, menopause, ovarian failure.”
> “20 of 36 premenopausal women with ovarian toxicity (56%)”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

| Treatment disposition | Ovarian toxicity resolution |
| --- | --- |
| “8 off varegacestat, follow-up available” | “OT resolved in 8 (100%)” |
| “10 ongoing varegacestat” | “OT resolved in 3 (30%)”; “OT unresolved in 7 (70%)” |
| “2 off study, no follow-up available” | “OT resolution status unknown” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

> “Ovarian toxicity included amenorrhea, premature menopause, menopause, and ovarian failure; and all were Grade 2.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Age: eligibility and enrolled age ranges

> “At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).”
> “≥12 years of age (inclusive) and ≥ 40 kg at the time of signing the ICF.”
> “Minor subjects must be capable of giving written assent as appropriate per the applicable age (per local regulatory requirements).”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

| Population | Age (years), median (min-max) |
| --- | --- |
| Efficacy population, varegacestat (RINGSIDE Parts A and B), N = 121 | “40 (18-72)” |
| Efficacy population, placebo (RINGSIDE Part B), N = 77 | “39 (20-69)” |
| Safety population, varegacestat (CA002-001 and RINGSIDE), N = 157 | “45 (18-84)” |

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Age subgroups: objective response

> “We performed descriptive analyses of objective response rate (ORR) in the following subgroups with at least 5 participants: age (≤40 years vs. >40 years), tumor size (<70 mm vs. ≥70 mm), prior lines of therapy (0, 1, or 2+), tumor location (intra-abdominal vs. extra-abdominal) and mutational biomarkers (APC vs CTNNB1).”
> “Age ≤40 years (n=22) vs. >40 years (n=14)”
> “13 (59) vs. 10 (71)”
> “Response rates were comparable across all subgroups examined.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-2.1.2.8-7"></a>

###### Age subgroups: progression-free survival

> “PFS consistently favored VAR in all subgroups analyzed.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “Consistent PFS Benefit with Varegacestat Across Subgroups”
> “≤ 30 years”
> “> 30 years”
> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Varegacestat

<a id="topic-2.1.2.9.1-1"></a>

###### Itraconazole interaction study in healthy participants

> “This is a phase 1, open-label, fixed sequence, 1-way crossover study examining the effect of itraconazole on the pharmacokinetics, safety and tolerability after varegacestat single dose administration to healthy participants. This is a 2-period study. In period 1 a single dose of varegacestat will be administered with PK evaluated predose and up to 192 hours postdose. There will be a 14 -day washout between period 1 and period 2. In period 2, itraconzole will be administered once daily for 18 consecutive days. Beginning on Day 4 of Period 2 a single dose of varegacestat will be administered 30 minutes after itraconazole dosing. Blood samples for PK will be collected prior to varegacestat dosing and up to 744 hours post varegacestat dosing for varegacestat and its metabolite.”
> “Itraconazole (200 mg)”
> “AUC0-t for varegacestat administered with and without itraconazole.”
> “AUC0-inf for varegacestat administered with and without itraconazole.”
> “Cmax for varegacestat administered with and without itraconazole.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="topic-2.1.2.9.1-2"></a>

###### CYP3A4 and P-glycoprotein inhibitors and inducers as prohibited concomitant medications

> “The prohibited concomitant medications included herbal supplements, medications causing Torsades de Pointes, strong inhibitors or inducers of CYP3A4 or P-gp, and sensitive substrates of CYP3A4 with a narrow therapeutic window.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Varegacestat on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Sensitive CYP3A4 substrates as prohibited concomitant medications

> “sensitive substrates of CYP3A4 with a narrow therapeutic window”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.9.2-2"></a>

###### Itraconazole trough concentrations measured with varegacestat

> “Ctrough of itraconazole and hydroxy-itraconazole in combination with varegacestat in healthy participants.”

Source: [ClinicalTrials.gov NCT06677996](https://clinicaltrials.gov/study/NCT06677996)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Randomized dose and open-label extension dose

> “Participants in the study were randomized 1:1 and received either 1.2 mg varegacestat or placebo given once daily.”
> “Participants who progress while on study are eligible to enter an open-label extension whereby they may receive varegacestat at a dose of 1.2 mg once daily until disease progression or unacceptable toxicity.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose selection for the RINGSIDE phase III trial

> “Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose.”
> “The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

> “Overall, the ER analyses for efficacy and safety support 1.2 mg QD as the recommended dose.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.10.1-3"></a>

###### Dose reduction levels and time to first dose modification

> “Median Time to First Dose Reduction”
> “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months”
> “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months”
> “Median Time to First Dose Interruption”
> “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months”
> “Time to dose reduction or dose interruption is defined as the duration from the date of the first dose to the start date of the first dose reduction (to either dose) or dose interruption.”
> “Dose Reduction”
> “Varegacestat 80% | Placebo 9%”
> “Dose Interruption”
> “Varegacestat 65% | Placebo 14%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose levels and dose modification rules for BMS-986115

> “BMS-986115 was administered orally once daily (QD) at doses of 0.3, 0.6, 1.2, 1.5, and 2 mg (Arm A) or twice weekly (BIW) on consecutive days at doses of 2, 4, 8 mg (Arm B).”
> “Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral capsules

> “BMS-986115 was supplied as grey hard gelatin capsules, including a size 1 capsule containing 0.3 mg BMS-986115 and a size 0 capsule containing 2 mg BMS-986115.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

> “Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

> “Varegacestat 1.2 mg PO once daily (n=79)”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Fasting administration in clinical pharmacology studies

> “Following completion of Screening and Day -1 assessments and an overnight fast of at least 10 hours, eligible participants will be administered a single dose (containing ~100 µCi) [14C]varegacestat as 2 oral capsules followed by approximately 240 mL room temperature filtered water on the morning of Day 1.”

Source: [ClinicalTrials.gov NCT06845852](https://clinicaltrials.gov/study/NCT06845852)

> “This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.”
> “Able to swallow multiple capsules”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Planned U.S. commercialization through an internal commercial organization

> “In the United States, we expect to commercialize the product through a focused internal commercial organization, which would include capabilities in marketing, analytics, market access, and a targeted sales force designed to reach specialized treatment centers.”
> “Outside of the United States, we anticipate pursuing a flexible commercialization strategy. In certain key markets, including Europe, we may retain commercial rights and build a focused internal commercial team to support commercialization activities, subject to obtaining marketing approvals.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

###### Launch focus on sarcoma centers of excellence

> “~85 Sarcoma Centers-of-Excellence”
> “Efficiently expand reach across the community through treatment center growth”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “Launch focused on 85 sarcoma centers of excellence expected to drive efficiency and quick uptake”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-2.1.2.11-3"></a>

###### Distribution, supply chain, and commercial supply

> “Distribution & supply chain leverages prior oncology launches”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “We are also making investments intended to support commercial supply readiness for varegacestat.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Market access and patient support planning

> “early market access planning intended to support appropriate patient access; and a build-out of patient support capabilities aligned with the chronic nature of treatment in this population”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “>90% anticipated payer coverage”
> “US & EMA orphan designation has favorable pricing implications”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-2.1.2.11-5"></a>

###### Treatment duration expected in practice

> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.1.2.11-6"></a>

###### Expanded access before approval

> “Immunome is not making our investigational therapies available via expanded access at this time. We believe that participation in our clinical trials will be the most appropriate way to access our investigational therapies prior to their approval.”

Source: [Immunome expanded access policy](https://immunome.com/patients/)

<a id="topic-2.1.2.11-7"></a>

###### Specialty pharmacy or specialty distributor arrangements

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Prohibited concomitant medications and excluded co-medications

> “The prohibited concomitant medications included herbal supplements”
> “conditions requiring chronic systemic glucocorticoid use, therapeutic anticoagulation, and concomitant second malignancies”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.12-2"></a>

###### Electrolyte supplementation and medical management of diarrhea

> “excluding asymptomatic electrolyte abnormalities that were manageable with appropriate supplements, alopecia and fatigue lasting ≤5 days”
> “except hyperlipidemia in subjects not receiving maximum medical management or electrolyte abnormalities that may be managed with supplements”
> “Although Gr 3/4 diarrhoea related to the study treatment was observed in 2 of 7 patients (29%) treated at this dose level, these events resolved to Gr 1 within 24 h with appropriate medical management.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.12-3"></a>

###### Prior and concurrent desmoid tumor therapies excluded from trial eligibility

> “Any treatments for desmoid tumors within 4 weeks prior to first dose of investigational therapy; subject must have recovered from therapy related toxicity to < CTCAE Grade 2 or clinical baseline. Therapy includes:”
> “Locoregional tumor directed therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery”
> “Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-2.1.2.12-4"></a>

###### Analgesic use and anti-infective therapy in trial eligibility

> “Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication”
> “Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ≤7 days prior to administration of IP such as known active infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at Screening.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Varegacestat on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Dosing, dosing frequency, and form: varegacestat in RINGSIDE Part B

> “Varegacestat (VAR) is an investigational, once daily, oral gamma secretase inhibitor that previously showed antitumor activity in pts with DT in the RINGSIDE Phase 2 study.”
> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-2"></a>

###### Dosage form: varegacestat capsule formulations

> “This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-2.1.2.14-3"></a>

###### Dosing, dosing frequency, and form: nirogacestat

> “OGSIVEO® (nirogacestat) tablets, for oral use”
> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity. OGSIVEO may be taken with or without food.”
> “Tablets: 100 mg, and 150 mg. (3)”
> “One blister card with 14 tablets”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Dosing, dosing frequency, and form: sorafenib in the phase 3 desmoid tumor trial

> “In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.”
> “Dose interruptions (of up to 28 days) and one dose reduction (to 200 mg once daily) were permitted and described in the trial protocol.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.1.2.14-5"></a>

###### Half-life: BMS-986115 (varegacestat) in the phase 1 trial

> “Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.14-6"></a>

###### Half-life: company claim for varegacestat relative to nirogacestat

> “Varegacestat is a Gamma Secretase Inhibitor with a Differentiated Pharmacokinetic Profile”
> “78% Longer Half-Life than Nirogacestat”
> “(3) Immunome data on file”
> “1.2 mg Once Daily”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Half-life: nirogacestat

> “Terminal elimination half-life (t1/2)”
> “23 (37) hr”
> “Time to steady-state”
> “Approximately 6 days”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Phase 3 efficacy: varegacestat in RINGSIDE Part B

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”
> “VAR demonstrated significantly better PFS compared with PBO (hazard ratio [HR]: 0.16 [95% CI: 0.07, 0.38; P<0.0001]).”
> “ORR was significantly better with VAR vs PBO (55.7% vs 9.1%; P<0.0001), with 3 CRs in the VAR arm and 1 CR in the PBO arm.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-9"></a>

###### Phase 3 efficacy: nirogacestat in DeFi

> “The efficacy of OGSIVEO was evaluated in DeFi (NCT03785964), an international, multicenter, randomized (1:1), double-blind, placebo-controlled trial in 142 adult patients with progressing desmoid tumors not amenable to surgery.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

| DeFi outcome | OGSIVEO (N = 70) | Placebo (N = 72) |
| --- | --- | --- |
| Patients with a progression-free survival event, n (%) | “12 (17)” | “37 (51)” |
| Median progression-free survival, months (95% CI) | “NR (NR, NR)” | “15.1 (8.4, NR)” |
| Objective response rate, n (%) | “29 (41)” | “6 (8)” |
| Objective response rate, 95% CI | “(29.8, 53.8)” | “(3.1, 17.3)” |
| Complete response, n (%) | “5 (7)” | “0” |
| Partial response, n (%) | “24 (34)” | “6 (8)” |

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

> “Hazard ratio (95% CI)”
> “0.29 (0.15, 0.55)”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

###### Phase 3 efficacy: sorafenib

> “With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001).”
> “Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.”
> “The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.1.2.14-11"></a>

###### Phase 3 safety: varegacestat in RINGSIDE Part B

> “Overall, 95% of adverse events (AEs) were Grade 1-2 and there were no Grade 5 AEs. Grade 3/4 AEs were reported in 57% of VAR pts and 17% of PBO pts. AEs led to dose reduction in 63 (80%) VAR pts and 7 (9%) PBO pts; 16 (20%) VAR pts and 5 (7%) PBO pts discontinued due to AEs. In the VAR arm, the most frequently reported AEs were diarrhea (82%), fatigue (44%), and rash (43%).”
> “Ovarian toxicity occurred in 20/36 (56%) premenopausal women on VAR, resolved in 11/20 (55%), and did not lead to dose interruption or drug withdrawal.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-12"></a>

###### Phase 3 safety: nirogacestat in DeFi

> “In DeFi, diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients.”
> “Serious adverse reactions occurred in 20% of patients who received OGSIVEO.”
> “Permanent discontinuation of OGSIVEO due to an adverse reaction occurred in 20% of patients.”
> “Dosage interruptions of OGSIVEO due to an adverse reaction occurred in 51% of patients.”
> “Dose reductions of OGSIVEO due to an adverse reaction occurred in 42% of patients.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

> “Frequent adverse events with nirogacestat included diarrhea (in 84% of the patients), nausea (in 54%), fatigue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were of grade 1 or 2. Among women of childbearing potential receiving nirogacestat, 27 of 36 (75%) had adverse events consistent with ovarian dysfunction, which resolved in 20 women (74%).”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.1.2.14-13"></a>

###### Phase 3 safety: sorafenib

> “Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).”
> “dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.”
> “Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).”
> “Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.1.2.14-14"></a>

###### Company cross-trial comparison of phase 3 objective response rates, with its disclaimer

| Phase 3 trial | Year shown | Regimen | Trial and size | Objective response rate, active | Objective response rate, placebo |
| --- | --- | --- | --- | --- | --- |
| Sorafenib | “2018” | “400mg Once Daily Oral” | “NCT02066181; N=87” | “ORR: 33%” | “ORR: 20%” |
| Nirogacestat | “2023” | “150 mg Twice-Daily Oral” | “DeFi; n=142” | “ORR: 41%” | “ORR: 8%” |
| Varegacestat | “2025” | “1.2mg Once-Daily Oral” | “RINGSIDE; N=156” | “ORR: 56%” | “ORR: 9%” |

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “Phase 3 Studies in Desmoid Tumors”
> “FOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been conducted evaluating varegacestat against nirogacestat or other candidates or products. Differences exist between trial designs and subject characteristics, and strong caution should be exercised when comparing data across unrelated studies.”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.1.2.14-15"></a>

###### Company and investigator comparative statements

> “RINGSIDE is the largest and most comprehensive clinical trial conducted to date in patients with desmoid tumors, and the topline results represent the highest objective response rate observed in a randomized clinical trial in this patient population,”
> “These findings demonstrate the potential of varegacestat to offer best-in-class results in a convenient, once-daily, oral medicine that may help patients reclaim their lives.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

> “VAR demonstrated statistically significant and clinically meaningful antitumor activity and pain relief, achieving the highest ORR reported in a Phase 3 trial of systemic DT therapy, with no new safety signals.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-16"></a>

###### Wholesale acquisition cost of nirogacestat, January 2026

| Product | NDC | Dosage form and strength | Wholesale acquisition cost |
| --- | --- | --- | --- |
| OGSIVEO 100 mg | “82448-0100-14” | “Oral Tablet 100 MG” | “$7,746.58” |
| OGSIVEO 150 mg | “82448-0150-14” | “Oral Tablet 150 MG” | “$7,746.58” |

Source: [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf)

> “The WAC represents published catalogue or list price and may not represent actual transactional prices.”
> “01/05/2026”

Source: [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf)

<a id="topic-2.1.2.14-17"></a>

###### Wholesale acquisition cost of nirogacestat at introduction, December 2023, superseded in January 2026

> “OGSIVEO (Nirogacestat) 50mg tablets, 180-ct bottle”
> “12/4/2023”
> “WAC AT INTRODUCTION”
> “$29,000”

Source: [Vermont Attorney General new drug report (2024)](https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf)

<a id="topic-2.1.2.14-18"></a>

###### Other products in development for desmoid tumors: zolucatetide

> “With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including Merck KGaA (successor to SpringWorks Therapeutics, Inc.) and Parabilis Medicines, Inc.”
> “Parabilis is evaluating the small molecule zolucatetide in a Phase 1/2 study that includes patients with desmoid tumors and plans to initiate a phase 3 registrational trial in 2027.”
> “Desmoid tumor treatments also include surgery, hormonal therapy, cryotherapy, targeted therapy and chemotherapy.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: monoclonal fibroblastic proliferation with a variable clinical course

> “Desmoid tumor (DT; other synonymously used terms: Desmoid-type fibromatosis, aggressive fibromatosis) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterised by a variable and often unpredictable clinical course.”
> “In the International Classification of Diseases (ICD) it is classified as D48.1.”
> “According to the World Health Organisation (WHO), DT is a”
> “clonal fibroblastic proliferation that arises in the deep soft tissues and is characterised by infiltrative growth and a tendency toward local recurrence but an inability to metastasise”
> “even though it may be multifocal in the same limb or body part”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.1-2"></a>

###### WHO 2020 classification: intermediate, locally aggressive category

> “category of lesions that can be either locally aggressive (i.e. desmoid fibromatosis) or rarely metastasizing (i.e. plexiform fibrohistiocytic tumour).”

Source: [Sbaraglia et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/)

<a id="topic-2.2.1.1-3"></a>

###### Locally aggressive tumor without metastatic potential

> “Although lacking metastatic potential, DT is often locally aggressive and invasive, causing significant morbidity.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Desmoid tumors, also known as aggressive fibromatosis or desmoid-type fibromatosis, are rare, non-metastatic, locally aggressive sarcomas of fibroblastic origin.”
> “Desmoid tumors arise in connective tissue and can occur anywhere in the body where connective tissue is found. These tumors are locally aggressive, which means that while they do not metastasize to other parts of the body, they can grow into the surrounding or adjacent tissue.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.1-4"></a>

###### Sporadic and familial adenomatous polyposis-associated desmoid tumors

> “Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC , respectively.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “DT may occur at abdominal, intra-abdominal, and extra-abdominal locations and approximately 5–10% arise in the context of familial adenomatous polyposis (FAP).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “The vast majority (85-90%) of desmoid tumors are sporadic and of these, 85% result from somatic mutations in the CTNNB1 gene, which encodes β-catenin protein.”
> “Desmoid tumors may also result from germline mutation of the APC gene, which is also associated with familial adenomatous polyposis, that leads to accumulation of β-catenin in the nucleus and drives overexpression of its target genes.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.1-5"></a>

###### Proportion with familial adenomatous polyposis in a Dutch nationwide pathology registry, 1999 to 2009

> “Histopathology data of all Dutch patients with desmoid-type fibromatoses diagnosed between 1999 and 2009 were retrieved from PALGA, the nation-wide network and registry of histopathology in the Netherlands.”
> “A total number of 519 patients older than 10 years with a confirmed diagnosis of desmoid-type fibromatoses were included. Thirty-nine (7.5%) desmoid patients were documented of having FAP.”

Source: [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)

<a id="topic-2.2.1.1-6"></a>

###### Frequency of CTNNB1 mutations

> “CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids.”
> “Three discrete mutations in two codons of CTNNB1 exon 3 were identified: 41A (59%), 45F (33%), and 45P (8%, excluded from further analysis because of rarity).”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

> “ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.”
> “In 435 (84.3%) cases, there was one CTNNB1 molecular alteration: p.T41A, p.S45F, or p.S45P.”

Source: [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)

<a id="topic-2.2.1.1-7"></a>

###### Risk factor: antecedent trauma, including prior surgery

> “In 164 patients (32.7%), a trauma anteceding DT could be verified with a median lag time of 22.9 months (SD, 7.7 months; range, 9-44 months).”
> “A prior surgical procedure was relevant in 98 patients, a blunt trauma in 35 patients, a punctuated trauma (injections, trocar) in 18 patients, and site of an implant in 10 patients.”
> “The distribution of mutations in the CTNNB1 gene (codon 41 vs. 45) was similar in patients with and without a history of trauma before DT development.”

Source: [Hohenberger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37751183/)

<a id="topic-2.2.1.1-8"></a>

###### Risk factors: pregnancy and estrogen

> “In 220 patients, no trauma was reported (43.9%), and 58 females (11.6%) had a postpregnancy DT in the rectus abdominis muscle.”

Source: [Hohenberger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37751183/)

> “It has been observed that DT may occur in association with pregnancy and with the use of estrogen-containing oral contraceptives”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Risk factors for developing desmoid tumors in patients with these mutations include trauma (especially abdominal surgery), estrogen, and pregnancy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.1-9"></a>

###### Desmoid risk in familial adenomatous polyposis: U.S. community cohort

> “We conducted a retrospective cohort study of patients with pathogenic or likely pathogenic variants (PV/LPV) in APC identified through the Kaiser Permanente Northern California Electronic Database, a community-based system serving 4.6 million members.”
> “Among 328 patients with FAP, 36 (11.0%) developed DT. DT risk was highest when the APC variant was centrally located (codon 600-1600).”
> “All colorectal surgeries were associated with a significantly elevated DT risk: ileostomy (aOR 12.07; 2.10-69.47), subtotal colectomy with ileorectal anastomosis (aOR 9.03; 1.63-49.96), and total proctocolectomy with ileal pouch-anal anastomosis (aOR 10.98; 2.12-56.81).”
> “In this large community-based U.S. cohort, central APC variant location, family history, and colorectal surgery were associated with increased DT risk.”

Source: [Thomas et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42753019/)

<a id="topic-2.2.1.1-10"></a>

###### Desmoid risk after risk-reducing colectomy in familial adenomatous polyposis by APC genotype and family history

> “This study aimed to quantify absolute postoperative desmoid risk in FAP patients undergoing risk-reducing colectomy, stratified by APC genotype, and to assess the modifying effect of family history.”
> “This retrospective observational study used records from a prospectively maintained registry.”
> “Among 48 high-risk patients, 30 (63%) developed desmoid, with no significant difference between colectomy and proctocolectomy (54% versus 70%, respectively; χ 2 = 1.42; P = 0.233).”
> “Among the 1213 low-risk patients, 154 (12.7%) developed desmoids, with no significant effect of surgical procedure (13.9% versus 12.1% for proctocolectomy and total/partial colectomy, respectively; χ² = 0.77; P = 0.380).”
> “A family history of desmoid disease appears to be an important determinant of postoperative desmoid risk in FAP.”

Source: [Zare et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13591399/)

<a id="topic-2.2.1.1-11"></a>

###### Desmoid risk in a familial adenomatous polyposis cohort of 735 patients

> “The medical records of 735 FAP patients were analyzed for the occurrence of desmoids.”
> “Desmoid tumors were identified in 66 of the 735 patients (9%). The cumulative risk of developing desmoids was 14%.”
> “Patients with a positive family history for desmoids had a significant increased risk to develop this tumor (30% vs 6.7%, P < .001).”
> “Most desmoid patients (95%) had undergone previous abdominal surgery.”

Source: [Nieuwenhuis et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18237870/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Desmoid tumors

<a id="topic-2.2.1.2.1-1"></a>

###### Netherlands: extra-abdominal and abdominal wall aggressive fibromatosis, 1993 to 2013

> “In a population-based study in the Netherlands, we evaluated time trends for the incidence and treatment of AF.”
> “A total of 1134 patients were diagnosed with extra-abdominal or abdominal wall AF between January 1993 and December 2013; there were 326 men and 808 women.”
> “The incidence increased from 2.10 to 5.36 per million people per year.”
> “The male–female ratio showed an increasing female predominance, ranging from 68.6 % in 1993–1998 to 73.6 % in 2009–2013.”

Source: [van Broekhoven et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4531142/)

<a id="topic-2.2.1.2.1-2"></a>

###### Netherlands: sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses, 1999 to 2009

> “For calculation of incidence rates, person-years from the general matched population were used.”
> “The incidences of sporadic and FAP-related desmoid-type fibromatoses were 3.42 and 2,784 per million person-years, respectively.”

Source: [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)

<a id="topic-2.2.1.2.1-3"></a>

###### Denmark: desmoid tumor patients treated at two sarcoma centers, 2009 to 2018

> “Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018.”
> “Of the 179 DT patients identified, 76% were female and the median patient age was 38 years at diagnosis (interquartile range: 31-50).”
> “An average annual incidence of DTs over the study period was 3.2 per 1000,000 individuals with the observed annual incidence of DTs ranging from 2.2 (2011) to 4.3 (2017) per 1000,000 individuals. No notable linear time trend in incidence was observed.”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

<a id="topic-2.2.1.2.1-4"></a>

###### Finland: historical estimates

> “The reference standard on the incidence and epidemiology of AF are Finnish studies by Reitamo et al.”
> “An incidence of 2.4–4.3 per million people was reported in those studies, using three methods of estimation (local, regional, and national).”

Source: [van Broekhoven et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4531142/)

<a id="topic-2.2.1.2.1-5"></a>

###### Literature review of incidence estimates

> “The low incidence of DT (estimated 3–5 cases per million person-years) limits disease awareness.”
> “Five European sources [24–28] providing estimates on the incidence of DT were identified in the literature.”
> “Likewise, no epidemiological study of DT in the United States (US) was identified.”
> “The Orphanet Report Series [26] provides an average annual incidence of 3 cases of DT per million person-years in Europe.”
> “No estimates of incidence of DT in children are available in the literature; there is a lack of data on DT in children younger than 11 years old.”
> “Because all the epidemiological data are from European populations, a US population-based study will be necessary to compare incidence estimates between Europe and the US.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.2.1-6"></a>

###### Guideline estimate of incidence

> “DT is a distinctly rare entity (incidence 5–6 cases per 1 million of the population per annum”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.2.1-7"></a>

###### Age and sex distribution

> “The epidemiological studies reveal that most DT cases appear in the age range of 20–44 years, with a female predominance, and female cases 2.2–3.9 times the number of male cases”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

> “Onset of DT has been reported from infancy through adulthood, although it occurs most commonly between the ages of 15 and 60 years (with peak incidence between 30–40 years of age) and 2–3 times more frequently in women than men”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

<a id="topic-2.2.1.2.1-8"></a>

###### Company estimate: U.S. annual incidence, SpringWorks Therapeutics

> “Desmoid tumors typically occur in patients between the ages of 15 and 60 years old and are more commonly diagnosed in the third and fourth decades of life, with a two-to-three times higher prevalence in females. The annual incidence is estimated to be 1,000 to 1,650 new desmoid tumor patients diagnosed each year in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.1-9"></a>

###### Company estimate: U.S. annual incidence, Immunome

> “They often strike in young adulthood, with 1,000-1,650 patients diagnosed each year in the United States.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “Desmoid tumors often strike in young adulthood, with 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the US”
> “Bektas et al., Advances in Therapy, 2023”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.1.2.1-10"></a>

###### U.S. annual incidence, published estimate

> “These are rare or orphan cancers with an annual incidence of 1000 patients in the United States.”
> “The disease predominantly affects young adults and can arise in any anatomic location but favors the extremities, joints, and abdomen.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Desmoid tumors

<a id="topic-2.2.1.2.2-1"></a>

###### Literature review: no published prevalence study

> “No study evaluating the prevalence of DT was identified.”
> “Few epidemiological studies providing incidence estimates of DT were identified in the literature; all these studies were conducted in European countries, and no study provided prevalence estimates.”
> “In addition, no incidence or prevalence data on children are available.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.2.2-2"></a>

###### Company estimate: U.S. actively managed patients from physician market research, SpringWorks Therapeutics

> “Based on market research studies with feedback from over 400 physicians who manage patients with desmoid tumors, we believe that approximately 50% of patients receiving a locoregional intervention, such as surgery, or off-label systemic therapies will not have a satisfactory treatment outcome and will require subsequent treatment for their desmoid tumors.”
> “Additionally, we believe that up to 90% or more of patients will eventually receive an active intervention.”
> “Based on this market research, we estimate that, in any given year over the next decade, approximately 5,500 to 7,000 desmoid tumor patients will be actively managed in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.2-3"></a>

###### Company estimate: U.S. patients receiving physician care from ICD-10 claims, October 2023 to October 2024, SpringWorks Therapeutics

> “More recent analyses, including a review of International Classification of Diseases, Tenth Edition, or ICD-10, claims data between the introduction of desmoid tumor-specific ICD-10 codes in October 2023 and October 2024, reveals that there are approximately 11,000 desmoid tumor patients receiving physician care annually in the United States.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.2-4"></a>

###### Company statement: prevalent pool attributed to limited effect on mortality, SpringWorks Therapeutics

> “Desmoid tumors, despite being highly morbid, typically have a limited impact on mortality. Due to this limited impact on overall lifespan and historical lack of effective treatment options, we believe that there is a sizable prevalent pool of desmoid tumor patients who could potentially benefit from an effective, FDA-approved treatment.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.2.2-5"></a>

###### Company estimate: U.S. actively managed patients, Immunome

> “Desmoid tumors often strike in young adulthood, with 1,000-1,650 patients diagnosed each year and 10-11,000 actively managed patients in the US”
> “Bektas et al., Advances in Therapy, 2023”
> “10-11k Actively Managed Patients (US)”
> “1) Immunome Analysis”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Variable clinical course: growth, stabilization, and regression

> “According to estimates, approximately 10–28% of DT will resolve spontaneously without treatment (22% for extra-abdominal tumors to 28% for abdominal tumors)”
> “30% will cycle through progression and resolution, 50% will remain stable after diagnosis, and 10% will progress rapidly”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

> “Desmoid tumors exhibit a variable clinical course, but evidence suggests that the initial period of tumor growth is followed by a long period during which the tumor is stable or may even regress.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.3-2"></a>

###### Active surveillance: pooled analysis of three prospective observational studies, extra-abdominal desmoid-type fibromatosis

> “Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach.”
> “Patients ( n = 282) with a median follow-up of 53 months (IQR, 39–63) were included.”
> “The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.”
> “The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.”
> “This study confirms that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.”

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)

<a id="topic-2.2.1.3-3"></a>

###### Active surveillance: Italian prospective multicenter observational study, primary sporadic desmoid fibromatosis

> “This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.”
> “From 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm.”
> “At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%].”
> “TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).”

Source: [Colombo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35247923/)

<a id="topic-2.2.1.3-4"></a>

###### Active surveillance: prospective multicenter observational study of primary sporadic tumors of the extremity or abdominal or thoracic wall

> “This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.”
> “Between 2012 and 2015, 100 patients were enrolled.”
> “Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%).”
> “Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).”

Source: [Bonvalot et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37777684/)

<a id="topic-2.2.1.3-5"></a>

###### Active surveillance at all anatomic locations: United Kingdom sarcoma reference center

> “Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.”
> “The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.”
> “Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.”
> “Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).”

Source: [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)

<a id="topic-2.2.1.3-6"></a>

###### Surgery compared with wait-and-see: prospective cohort of 771 cases

> “We conducted a prospective study of 771 confirmed cases of DTF.”
> “Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).”
> “The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations.”

Source: [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)

<a id="topic-2.2.1.3-7"></a>

###### Event-free survival in the ALTITUDES nationwide prospective cohort

> “ALTITUDES (NCT02867033) was a nationwide prospective cohort study of DF diagnosed between January 2016 and December 2020.”
> “We enrolled 628 patients managed by active surveillance, surgical resection, or systemic treatment as first-line therapy.”
> “The first-line management was active surveillance in 352 (68.2%), surgical resection in 120 (23.3%), and systemic treatments in 44 (8.5%) patients.”
> “The median follow-up period was 24.7 (range, 0.4-59.7) months. The estimated 3-year EFS rate was 66.2% [95% confidence interval (CI), 60.5%-71.2%].”

Source: [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)

<a id="topic-2.2.1.3-8"></a>

###### Spontaneous regression in the placebo group of a prospective trial

> “Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.”
> “Spontaneous regression is reported in up to 20% of patients.”
> “Our prospective trial, in which desmoid tumors in patients who were taking placebo were evaluated, provides evidence in support of an initial period of observation in patients with newly diagnosed desmoid tumors, given that 20% of the patients in the placebo group had disease regression.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.2.1.3-9"></a>

###### Local recurrence after complete gross resection: nomogram cohort of 439 patients

> “Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence.”
> “Five-year local recurrence–free survival (LRFS) was 69%.”
> “In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin.”
> “Abdominal wall tumors had the best outcome (5-year LRFS 91%).”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.1.3-10"></a>

###### Local recurrence after surgery: participant-reported data

> “Continued tumor regrowth or recurrence following any DT treatment was reported for 46% (92/202) of participants, with a higher rate post-surgery (63%, 103/163), regardless of tumor location”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.3-11"></a>

###### Recurrence by tumor location and familial adenomatous polyposis status

> “Tumors on extremities are believed to be locally aggressive and have recurrence rates ranging from 24% to 77%”
> “Local recurrence rates of intra-abdominal tumors in patients with FAP are higher than those for extra-abdominal tumors and reported to be 57–86%”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

> “Up to ~60-80% of patients experience recurrence, which can be exacerbated by surgery.”
> “The recurrence rate of desmoid tumors is associated with tumor location and underlying genetic mutation. For example, tumors on the extremities have recurrence rates of up to 77% and intra-abdominal tumors recur much more frequently than extra-abdominal tumors in patients with familial adenomatous polyposis.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.3-12"></a>

###### Disease duration: company presentation

> “~50% of patients have desmoid tumors for more than 5 years”
> “K Mercier et al.”
> “ESMO Sarcoma 2024 Poster”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.1.3-13"></a>

###### Mortality: desmoid tumors overall

> “While lacking metastatic potential, the natural history of DT is variable and ranges from an asymptomatic, indolent course to aggressive infiltration of neurovascular structures and vital organs resulting in pain, disfigurement, organ dysfunction, and— rarely—death (usually related to complications such as intestinal obstruction associated with progression of intra-abdominal tumors)”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Desmoid tumors (DTs) are rare soft tissue mesenchymal neoplasms that may be associated with impairments, disfigurement, morbidity, and (rarely) mortality.”

Source: [Riedel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9546183/)

> “Desmoid tumors, despite being highly morbid, typically have a limited impact on mortality.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.3-14"></a>

###### Mortality after resection: nomogram cohort

> “Eight patients died of disease, all after R2 resection.”
> “Overall, 44 patients were dead at last follow-up, but only 8 died of disease.”
> “Two patients died following intestinal transplant.”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.1.3-15"></a>

###### Mortality: Danish patients compared with a healthy matched cohort

> “that has reported a 5-year mortality rate of 7 per 1000 [95% confidence interval (CI) 3–16] among Danish patients with DT as compared with 5 per 1000 (95% CI, 4–7) in a healthy matched cohort.”
> “The authors state that most deaths occurred in patients with FAP, though they represented only 7% of patients in the DT cohort.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.3-16"></a>

###### Mortality: intra-abdominal desmoid tumors in familial adenomatous polyposis by stage

> “Intra-abdominal desmoid tumors are one of the leading causes of death in patients with familial adenomatous polyposis.”
> “A total of 154 patients with intra-abdominal desmoid tumors were included in the study.”
> “Five-year survival of patients with stage I, II, III, and IV intra-abdominal desmoid tumor were 95%, 100%, 89%, and 76% respectively (P < 0.001). Severe pain/narcotic dependency, tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define survival within stages. Five-year survival rate of stage IV patient with all of the above-mentioned risk factors was only 53%.”

Source: [Quintini et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22323009/)

<a id="topic-2.2.1.3-17"></a>

###### Mortality: home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids

> “Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).”
> “The need for HPN represented a strong predictor of mortality (5-year survival HPN = 72% vs non-HPN = 95%), but duration of HPN did not affect mortality.”

Source: [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)

<a id="topic-2.2.1.3-18"></a>

###### Desmoid disease as a cause of death in familial adenomatous polyposis

> “Desmoid is a major source of mortality in FAP.”

Source: [Zare et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13591399/)

> “Desmoid tumours (DT) are one of the main causes of death in patients with familial adenomatous polyposis (FAP).”

Source: [Aelvoet et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9636104/)

> “Desmoid tumors (DT) are a leading cause of morbidity and mortality in patients with familial adenomatous polyposis (FAP), yet available data on DT risk remain limited and have been largely derived from large registries or tertiary referral centers.”

Source: [Thomas et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42753019/)

Additional sources: [Salas et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21844500/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Constitutive activation of the Wnt/β-catenin pathway

> “Approximately 85–90% of sporadic cases of DT show activating mutations in the N-terminal region of CTNNB1 (all of them in exon 3)”
> “making β-catenin more resistant to proteolytic degradation, leading to cytoplasmic accumulation of the protein and its subsequent translocation to the nucleus.”
> “In ~5–10% of patients, DT results from germline (i.e., in FAP) or sporadic loss-of-function mutations in the APC tumor suppressor gene.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Although the molecular pathogenesis of desmoid tumors is not fully understood, dysregulation of the Wnt/β-catenin pathway and consequent transcription of prosurvival and proliferative genes likely play a critical role.”

Source: [Kummar et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455706/)

<a id="topic-2.2.1.4-2"></a>

###### Nuclear β-catenin accumulation

> “Nuclear β-catenin expression was observed in 98% of specimens and intensity was inversely correlated with incidence of desmoid recurrence (P < 0.01).”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

<a id="topic-2.2.1.4-3"></a>

###### Mutual exclusivity of CTNNB1 and APC mutations

> “CTNNB1 mutations and APC mutations are mutually exclusive in DT, thus, detection of a somatic CTNNB1 mutation can help to exclude a syndromic condition.”
> “Either APC loss or CTNNB1 mutation can lead to DT development.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.4-4"></a>

###### Notch pathway cross-talk and overexpression

> “Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.”
> “Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue”
> “Dysregulation of the Wnt signaling pathway plays a key role in DT pathogenesis, however, as the result of crosstalk, Wnt dysregulation may lead to activation of the Notch pathway.”
> “The overexpression of Notch pathway components in DT provides a rationale for development of pharmacologic agents targeting Notch.”
> “Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.”

Source: [Federman (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9448813/)

> “Activation of Notch pathway components in tumor samples from patients with aggressive fibromatosis has been demonstrated previously”

Source: [Kummar et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5455706/)

> “Desmoid tumors are driven by nuclear accumulation of β-CATENIN resulting from cross-talk between WNT and NOTCH pathways”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.1.4-5"></a>

###### Hormonal influence on tumor biology

> “It also recognised that desmoid tumour biology is influenced by oestrogen exposure, which may be relevant to people with current or prior oestrogen exposure, regardless of gender identity.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.4-6"></a>

###### CTNNB1 genotype and tumor behavior

> “Five-year recurrence-free survival was significantly poorer in 45F-mutated desmoids (23%, P < 0.0001) versus either 41A (57%) or nonmutated tumors (65%).”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

> “DF harboring p.S45F was significantly associated with male sex (P = 0.03), non-abdominal wall sites (P = 0.05), pain (P = 0.007), and large tumor size (P = 0.025). CTNNB1 p.S45F mutation was not significantly associated with EFS, either in univariate (HR, 1.06; 95% CI, 0.65-1.73; P = 0.81) or in multivariate analysis (HR, 0.91; 95% CI, 0.55-1.49; P = 0.71).”

Source: [Penel et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35294527/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Histopathologic confirmation by core needle biopsy

> “The histopathologic confirmation of DF is mandatory before initiating treatment.”
> “A diagnosis of DF can be readily established on core biopsies using 14G or 16G needles, while neither incisional nor excisional biopsy is recommended as the initial diagnostic modality.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “It has to be taken into account that a potential post-biopsy increase in size or pain may be due to bleeding from the biopsy rather than true tumor growth.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.5-2"></a>

###### Expert soft tissue pathology review

> “Diagnosis of DT should be confirmed by an expert soft tissue pathologist.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “Second opinion by an expert pathologist as well as clinical management by an expert team is highly recommended”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.1.5-3"></a>

###### CTNNB1 mutational analysis: guideline recommendation

> “Vice versa, CTNNB1 wild-type status in DT, especially in an intra-abdominal tumour, should raise suspicion for FAP, with more extensive diagnostic clinical work-up (e.g. colonoscopy or germline testing).”
> “Therefore, our group gives a strong recommendation to perform a mutational analysis in DT biopsy specimens to confirm diagnosis and guide the work-up when appropriate.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.5-4"></a>

###### CTNNB1 testing and screening for familial adenomatous polyposis in 226 patients

> “226 patients were identified and 67% (n = 152) were female.”
> “Colonoscopy was requested in 65 patients (28.8% of all cases) and was completed in forty-six (20.4%). Molecular testing of CTNNB1 testing was requested in 35 cases (15.5%). APC germline test was requested in 12 cases. Four patients in our cohort had an FAP-associated DF.”
> “CTNNB1 molecular testing should be performed in all cases of newly diagnosed DF. Negative CTNNB1 results, alongside clinical assessment, should prompt APC testing and/or colonoscopy.”

Source: [Cojocaru et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33547536/)

<a id="topic-2.2.1.5-5"></a>

###### Referral for colonoscopy by tumor location and age

> “In conclusion, patients with desmoid-type fibromatoses are at risk of underlying FAP. Especially cases with desmoid localization intra-abdominal or in the abdominal wall, and all patients younger than 60 years, have a substantial increased risk and should be referred for colonoscopy.”

Source: [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)

<a id="topic-2.2.1.5-6"></a>

###### CTNNB1 sequencing in β-catenin-negative desmoid fibromatosis

> “A single-center, large retrospective analysis of 780 patients with DF was performed.”
> “77.3% of DF cases exhibited nuclear β-catenin positivity.”
> “Molecular analysis revealed that 74.1% of β-catenin negative cases harbored CTNNB1 mutations, primarily at codon 41 (p.T41A).”
> “Notably, β-catenin IHC showed higher positivity in resected specimens (79.7%) compared to biopsies (62.0%), whereas CTNNB1 mutational detection was higher in biopsies (93.5%) than resections (76.8%).”

Source: [Wang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41586907/)

<a id="topic-2.2.1.5-7"></a>

###### CTNNB1 testing documented at a U.S. academic center

> “Therefore, we aimed to characterize the patient journey in DTs from diagnosis to treatment at an academic center in the United States.”
> “A much smaller proportion of patients had documentation of CTNNB1 testing ( n = 10, 6.7%), including seven with CTNNB1 mutation (4.7%) and three who were demonstrated to have the wild-type, nonmutated variant, which results in production of normal β-catenin (2%).”
> “Diagnostic methods, such as CTNNB1 testing, may also shorten the diagnostic journey.”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.5-8"></a>

###### Imaging: magnetic resonance imaging for diagnosis, local staging, and follow-up

> “MRI is the mainstay of imaging in DF and can be used for diagnosis, local staging and follow-up”
> “The lack of radiation exposure makes targeted MRI ideal for follow-up.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “Histopathological diagnosis is mandatory, and evaluation is guided with imaging studies ranging from ultrasound, computed tomography or magnetic resonance.”
> “Ultrasound (US) serves as the initial evaluation especially for tumors in the extremities or abdominal wall.”
> “Its appearance depends on the cellular composition where more fibrotic areas, with a greater amount of collagen, show a low signal intensity in T2 with moderate contrast enhancement.”

Source: [Garcia-Ortega et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7408653/)

> “Desmoid tumors are generally routine to diagnose and are usually first noted upon physical examination or by using various imaging techniques, such as ultrasound, computed tomography, or CT, or magnetic resonance imaging, or MRI.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.5-9"></a>

###### Imaging schedule during active surveillance

> “Active surveillance means that patients need to be continuously monitored with a first MRI (or alternatively CT if MRI is not possible) within 1-2 months, then in 3-6 months intervals.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.5-10"></a>

###### Response assessment: RECIST and magnetic resonance imaging signal

> “Assessment of treatment effects in DT remains an unresolved issue and no standard validated response criteria are available as of today.”
> “RECIST does not robustly identify all clinically relevant responses, though the majority of prospective trials report efficacy using RECIST.”
> “Contrast-enhanced MRI or alternatively CT are the preferred modalities for monitoring DT.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “MRI surveillance has been used to assess response to treatment with a decrease in T2W signal and lesion size”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.1.5-11"></a>

###### Response assessment: T2-weighted signal intensity and tumor volume in the RINGSIDE phase 2 study

> “The Phase 2 part of the RINGSIDE study (NCT04871282) demonstrated early and continued MRI-based improvements in DTs with varegacestat (AL102) therapy”
> “T2-weighted (T2W) signal intensity and tumor volume on MRI may be more sensitive than RECIST for assessing treatment effect in desmoid tumors (DTs)”
> “On T2W images, hyperintense areas are associated with active fibroblast proliferation and hypointense areas are associated with loss of tumor cells and an increase in collagenous tissue”
> “These data add to a growing body of work showing T2W signal intensity and tumor volume may play a key role in evaluating treatment response in DT”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-2.2.1.5-12"></a>

###### Response assessment: quantitative T2 mapping

> “However, the primary imaging endpoints based on RECIST1.1 used in these studies are determined only by changes in maximum tumor diameter.”
> “Analysis of T2 relaxation time maps of DF may offer a feasible quantitative biomarker for assessing the extent of response to treatment.”

Source: [Souza et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10766853/)

<a id="topic-2.2.1.5-13"></a>

###### Misdiagnosis and time to diagnosis: participant-reported data

> “A total of 162 participants (41%, 162/399) reported a prior misdiagnosis.”
> “The median age at the first sign or symptom of DT was 32 years, and the average time from the first sign or symptom to confirmed DT diagnosis was 4 years ( n = 292; median = 1 year).”
> “The most reported differential diagnoses (70%, 113/162) were benign tumors or other conditions, including muscle injury, lipoma, colon polyps, postoperative scars, early-onset arthritis, hernia, and Baker’s cyst.”
> “Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58/126) reported having received surgery before a definitive DT diagnosis.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.5-14"></a>

###### Misdiagnosis before confirmed diagnosis: U.S. academic center

> “Therefore, we aimed to characterize the patient journey in DTs from diagnosis to treatment at an academic center in the United States.”
> “A total of 43 patients (29.1%) potentially had a misdiagnosis prior to a final confirmed diagnosis of DT based on tissue histology”
> “Most common misdiagnoses included other benign tumors ( n = 31, 20.3%), low-grade sarcomas ( n = 11, 7.2%), nodular fasciitis ( n = 4, 2.6%), and procedure-related scars ( n = 3, 2%).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.5-15"></a>

###### Histologic misdiagnosis in published series

> “Based on pathologic similarities with other myofibroblastic diseases (e.g., sarcoma, gastrointestinal stromal tumor, nodular fasciitis, leiomyoma) and the low incidence of DT, 30–40% of DT cases are reported to be misdiagnosed following histologic analysis”
> “A French nationwide survey demonstrated that one-third of DT are misdiagnosed (the most challenging differential diagnoses are nodular fasciitis and low-grade fibromyxoid sarcoma)”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Variability of presentation: asymptomatic to symptomatic tumors

> “Symptom presentation among DTF patients, however, is highly variable, ranging from no symptoms at all to extreme pain and functional limitations, regardless of tumour behaviour or size.”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

> “While some people with desmoid tumors do not experience symptoms, others may experience pain, swelling, difficulty sleeping and reduced mobility. Symptoms largely depend on the location of the tumor and the extent of invasion or compression of surrounding tissue.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.6-2"></a>

###### Tumor-related signs: unexplained bump or mass

> “Signs and symptoms reported at diagnosis included an unexplained bump (60%, 238/399), pain (57%, 226/399), and fatigue (14%, 54/399).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.6-3"></a>

###### Pain: tumor pain

> “Pain was the most common reported symptom (57.4%).”
> “DT-related symptoms that were most documented in the clinical notes were tumor pain ( n = 85, 57.4%), fullness ( n = 23, 15.5%), loss of function ( n = 22, 14.9%), and paresthesia ( n = 17, 11.5%).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

> “The patients younger than 50 years were more likely to progress (p = 0.046), whereas the patients with chest wall or upper-extremity tumors reported significantly more pain (p = 0.01).”

Source: [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)

> “Insomnia, unable to lean on tumour site, fatigue and pain were the most frequently reported symptoms for all DTF patients.”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

<a id="topic-2.2.1.6-4"></a>

###### Neurological symptoms: nerve pain and paresthesia

| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Nerve pain (localized/radiating) | “22” | “6.00” |
| Muscle pain (localized/radiating) | “20” | “6.75” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “Symptomatic disease was ascertained based on documentation of symptoms, including tumor-related pain, paresthesia, fatigue, swelling, muscle weakness, loss of function (such as difficulty in moving limbs or walking), nausea, and fullness.”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.6-5"></a>

###### Physical function: decreased range of motion and loss of mobility

> “Desmoid tumors (or aggressive fibromatosis) are locally infiltrative connective-tissue tumors that can arise in any anatomic location; they can be asymptomatic, or they can result in pain, deformity, swelling, and loss of mobility and/or threaten visceral organs with bowel perforation, hydronephrosis, neurovascular damage, and other complications.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Decreased range of motion | “21” | “4.00” |
| Stiffness | “10” | “3.00” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “Those with the current presence of DT at the time of survey completion reported significantly worse pain (dull pain, shooting pain), swelling around the tumor, and difficulty moving body areas near the tumor (compared with those without the current presence of DT).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

> “Depending on tumor size, aggressiveness of growth pattern and location, desmoid tumors can cause severe morbidities such as pain, disfigurement, internal bleeding and debilitating impairment on range of motion.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.6-6"></a>

###### Appearance: disfigurement and swelling

| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Disfigurement/altered appearance | “25” | “5.00” |
| Swelling | “6” | “5.00” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.6-7"></a>

###### Fatigue and sleep disturbance

> “In addition to pain and functional impairments, health care workers should also address fatigue, insomnia, anxiety, fear, and body dysmorphia.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

| Symptom or impact elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Fatigue | “20” | “5.00” |
| Lack of energy | “15” | “5.50” |
| Difficulty sleeping | “24” | “7.50” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.6-8"></a>

###### Intra-abdominal symptoms: nausea, early satiety, bowel obstruction, perforation, and hydronephrosis

> “Depending on its location, patients can present with pain, a loss of range of movement or immobility, bowel obstructions and/or perforations, hydronephrosis, and a host of other symptoms.”
> “As expected, the symptoms and impacts preliminarily show variation by anatomical location, as seen with abdominal desmoids, which cause nausea and early satiety.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “The HPN group was more likely to have advanced-stage disease and significantly higher incidence of chronic abdominal pain, narcotic dependency, bowel obstruction, ureteral obstruction, deep vein thrombosis, pulmonary embolism, fistulae, and sepsis (P < .05).”

Source: [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)

<a id="topic-2.2.1.6-9"></a>

###### Psychological symptoms: fear, anxiety, and depression

| Impact elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Fear | “26” | “6.50” |
| Anxiety | “22” | “6.75” |
| Depression | “20” | “8.00” |
| Altered body image/function | “12” | “4.75” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Morbidity from local infiltration and recurrence

> “The lesions do not have the ability to metastasize, but progressive disease and local recurrence can lead to significant morbidity.”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

> “The morbidity and mortality associated with DT largely depend on the tumor location, as this determines the adjacent structures that the DT will infiltrate or compress.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.7-2"></a>

###### Functional deficits and disfigurement after surgery

> “Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function.”
> “Tumors in the extremities have the highest risk of recurrence (30%-90%).”
> “Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.”

Source: [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)

<a id="topic-2.2.1.7-3"></a>

###### Amputation

> “Amputation was reported for 7% (12/163) of participants who underwent surgery, with most (83%, 10/12) experiencing tumor regrowth or recurrence post-amputation.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.7-4"></a>

###### Long-term use of analgesics and other medications

> “A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical).”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

| Medication for desmoid tumor symptom management | Overall (N = 322), n (%) | Current presence of a desmoid tumor (n = 225), n (%) | No current desmoid tumor (n = 97), n (%) |
| --- | --- | --- | --- |
| NSAIDs | “151 (47)” | “103 (46)” | “48 (49)” |
| Opioids | “61 (19)” | “45 (20)” | “16 (16)” |
| Antidepressants | “60 (19)” | “41 (18)” | “19 (20)” |
| Anticonvulsants | “36 (11)” | “26 (12)” | “10 (10)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.7-5"></a>

###### Chronic pain and dependency on analgesics

> “Pain can further debilitate patients with DT and lead to functional limitations, while the management of pain with narcotics can lead to potential dependency on painkillers”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

> “Severe pain/narcotic dependency, tumor size larger than 10 cm, and need for total parenteral nutrition were shown to further define survival within stages.”

Source: [Quintini et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22323009/)

<a id="topic-2.2.1.7-6"></a>

###### Persistent symptoms with current disease

> “Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT ( P < 0.05).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.7-7"></a>

###### Intestinal failure and home parenteral nutrition in familial adenomatous polyposis-associated intra-abdominal desmoids

> “Intra-abdominal desmoid tumors (IADTs) are a common complication of familial adenomatous polyposis (FAP).”
> “Medical and surgical treatments may be ineffective in preventing complications, which can cause intestinal failure.”
> “One hundred fifty-four patients were included and divided into 2 groups: HPN (n = 41, 26.6%) and non-HPN (n = 113, 73.4%).”
> “HPN, although a life-saving treatment, is an independent poor prognostic factor associated with high morbidity and mortality.”

Source: [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)

<a id="topic-2.2.1.7-8"></a>

###### Constraints on colorectal surgery in familial adenomatous polyposis

> “In a substantial proportion of patients with an ileorectal anastomosis, it was impossible to convert the ileorectal anastomosis to an ileal pouch-anal anastomosis as a result of desmoid development.”

Source: [Nieuwenhuis et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18237870/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Desmoid tumors

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### GODDESS development: concept elicitation and cognitive interviews

> “CE interviews with desmoid patients (n = 31) helped to identify salient concepts and led to a draft scale that included symptom and impact scales. Cognitive interviews were completed with additional patients (n = 15) across 3 phases. Patient input was used to refine instructions, revise and/or remove items, and modify the response scale. This resulted in an 11-item symptom scale and a 17-item impact scale.”
> “This is the first disease-specific PRO instrument developed for desmoid tumors.”
> “Thirty-one patients (mean age, 44 years; standard deviation, 13 years; 77% female) completed the CE phase, and the demographics are described in Table 1. The majority of the patients had at least a college degree (71%) and were symptomatic (84%).”
> “A total of 33 unique symptoms were identified (Table 2).”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.8.1-2"></a>

###### Disease impacts reported in GODDESS concept elicitation interviews

| Impact | Frequency of mentions (n = 31) | Median disturbance rating (0 to 10) |
| --- | --- | --- |
| Fear | “26” | “6.50” |
| Difficulty sleeping | “24” | “7.50” |
| Anxiety | “22” | “6.75” |
| Inability to do daily activities | “20” | “6.75” |
| Depression | “20” | “8.00” |
| Isolation | “17” | “7.00” |
| Financial difficulties | “16” | “8.00” |
| Hopelessness | “14” | “8.50” |
| Inability to do work | “14” | “6.75” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.8.1-3"></a>

###### GODDESS psychometric properties and meaningful change thresholds in the DeFi trial

> “DeFi participants (N = 142) had a median age of 34 years (range: 18–76) and were mostly female (64.8%), with extra-abdominal (76.8%) or intra-abdominal tumors (23.2%). The GODDESS© symptom/impact scales showed internal consistency at baseline, cycles 4 and 7 (Cronbach’s α > 0.70) and test–retest reliability (intra-class correlation coefficient > 0.85).”
> “For the total symptom score, a 1.30-point decrease was estimated as the within-person MCT and a 1.00-point decrease as the between-group MCT. For the physical functioning impact score, estimated within- and between-group MCTs were 0.60-point and 0.50-point decreases, respectively.”

Source: [Gounder et al. (2023c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10474203/)

<a id="topic-2.2.1.8.1-4"></a>

###### Desmoid Tumor Research Foundation natural history study, 2017 to 2023

> “Surveys were completed by 399 participants between September 2017 and August 2023. The median age of participants was 38 years; most were female (72%, 288/399), White (84%, 334/399), or resided in North America (86%, 345/399).”
> “Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT (P < 0.05).”
> “The overall mean Total Symptom Score for all participants was 4.1.”
> “The symptoms and impact of DT in a joint/extremity were reported to be significantly worse for the DTSS Total Symptom Score, DTSS Pain domain, and the DTIS Physical Functioning domain compared with other DT locations (all P < 0.05; Fig. 7a-c).”
> “Conversely, regardless of the current presence of DT, participants reported similar mean scores (P > 0.05) for the DTIS Emotional Impact domain (4.4 with current DT vs. 3.9 without current DT) and all Emotional Impact domain item scores, including Fear of Desmoid Tumor Growth/Recurrence (5.8 vs. 5.2), Anger (3.4 vs. 3.1), Anxiety (4.5 vs. 4.0), and Frustration (4.8 vs. 4.0), except Hopelessness (3.7 vs. 2.7; P = 0.007; data not shown).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.1-5"></a>

###### Physical symptom burden clusters in the United Kingdom and the Netherlands

> “Desmoid‐type fibromatosis patients from the United Kingdom and the Netherlands received cross‐sectional questionnaires on HRQoL (EORTC QLQ‐C30), DTF‐specific HRQoL (DTF‐QoL) and healthcare utilisation.”
> “Among 235 DTF patients, four symptom burden clusters were identified, with low symptom burden (24%), intermediate symptom burden‐low pain (20%), intermediate symptom burden‐high pain (25%) and high symptom burden (31%). DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001)”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

<a id="topic-2.2.1.8.1-6"></a>

###### DTF-QoL development in the United Kingdom and the Netherlands

> “The aim of this study was to pre-test the psychometric properties of the DTF-QoL by administering it together with the EORTC Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) to 236 DTF patients from the United Kingdom and the Netherlands.”
> “Ninety-six items were selected, conceptualised into three symptom scales, eleven disease-impact scales and six single items, together forming the final DTF-QoL.”

Source: [Schut et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8833407/)

<a id="topic-2.2.1.8.1-7"></a>

###### Characteristics associated with poorer disease-specific quality of life

> “A total of 235 DTF patients completed the questionnaires. Female patients, patients with more than two comorbidities, or patients who received treatment other than only active surveillance (AS) or surgery scored significantly worse on the subscales of both the EORTC QLQ-C30 and DTF-QoL.”

Source: [Schut et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9221474/)

<a id="topic-2.2.1.8.1-8"></a>

###### Quality of life, anxiety, and depression compared with healthy controls

> “Two hundred four subjects (102 DTF patients and 102 healthy controls) were recruited. The median age of DTF patients at recruitment into the study was 31 years (IQR, 25-37 years).”
> “The mean global health status in DTF patients was 65.58 ± 22.64, significantly lower than healthy controls. Similarly, DTF patients scored low on all functional scales except cognitive functioning. The symptom scale showed a significantly higher symptom burden of fatigue, pain, insomnia, and financial difficulties. Anxiety and depression was observed in 39.22% and 50% of DTF patients respectively.”

Source: [Garg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36350382/)

<a id="topic-2.2.1.8.1-9"></a>

###### Focus groups and interviews at a United Kingdom sarcoma unit

> “Twenty-seven DF patients were purposively sampled from The Royal Marsden Hospital. Two focus groups and 13 interviews (males 12, females 15; mean age at study 39.5 years) explored health-related quality of life issues and experiences of healthcare.”
> “Pain was the most debilitating symptom and dependency on painkillers was a significant concern. Functional limitation and restricted mobility frequently affected daily activities.”
> “low on all functioning scales (physical 74.4; role 55.8; social 52.8; cognitive 70.1; and emotional 56.9) and global QoL scale (56.9) of the EORTC QLQ-C30 and exceptionally high on the symptom scales pain (59.0), insomnia (56.9), fatigue (53.6) and financial difficulties (31.9).”

Source: [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)

<a id="topic-2.2.1.8.1-10"></a>

###### Literature review and focus groups on quality of life issues in sporadic desmoid-type fibromatosis

> “The search strategy identified thirteen articles reporting HRQL measures using a wide variety of cancer-specific HRQL tools, functional scores, symptom scales (e.g. NRS), and single-item outcomes (e.g. pain and functional impairment). No DTF-specific HRQL tool was found. Qualitative analysis of three focus groups (6 males, 9 females) showed that participants emphasised the negative impact of DTF and/or its treatment on several HRQL domains.”

Source: [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)

<a id="topic-2.2.1.8.1-11"></a>

###### Anxiety and depression compared with malignant sarcoma

> “Despite its limited impact on survival, patients with DT may have anxiety and depression levels commensurate with those associated with malignant sarcomas.”
> “Interestingly, investigators found that anxiety and depression in patients with DT were significantly (P = 0.01) greater in patients with abdominal wall DT than in the sarcoma group, and among patients with DT outside of the abdominal wall, distress levels were equivalent to those of patients with malignant sarcomas.”

Source: [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)

<a id="topic-2.2.1.8.1-12"></a>

###### Pain at diagnosis in the ALTITUDES cohort

> “Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first-line treatment (P = .18).”
> “Pain at baseline was significantly associated with poor quality of life (P < .001), depression (P = .02), lower performance status (P = .03) and functional impairment (P = .001)”

Source: [Penel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883417/)

<a id="topic-2.2.1.8.1-13"></a>

###### Pain burden survey by the French patient advocacy group SOS Desmoid

> “The pain occurrence was approximately 63%. In one-third of the cases, the pain was permanent. This pain led to severe social and economic consequences.”

Source: [Rigaux et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25747890/)

<a id="topic-2.2.1.8.1-14"></a>

###### Pain and its consequences: systematic literature review

> “Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases).”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.1-15"></a>

###### Patient and clinical expert testimony to NICE

> “The patient experts explained that it is difficult to live with desmoid tumours and that the most debilitating symptom is usually pain.”
> “The clinical experts added that pain is a major issue with sporadic desmoid tumours, especially extra-abdominal tumours, but was less of an issue in FAP-associated desmoid tumours.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.8.1-16"></a>

###### Health state utility values in the NICE appraisal of nirogacestat

> “Although the De‑Fi trial did not collect EQ-5D data, it did collect quality-of-life data using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.”
> “The utility values in the company base case were instead informed by published utility values from people with soft-tissue sarcoma (Shingler et al. 2013).”
> “The EAG stated that the utility value for progressed disease in the company base case was implausibly low for people with desmoid tumours (0.263).”
> “But, because this data was not provided, the EAG preferred to use utility values based on EQ-5D data from a clinical trial of people with soft-tissue sarcoma (Reichardt et al. 2012). This resulted in a utility value of 0.560 for progressed disease.”
> “The company acknowledged that the true utility value of progressed disease was likely to be between the company (0.263) and the EAG (0.560) base cases.”
> “At the second committee meeting, the company presented the EORTC QLQ-C30 quality-of-life data from De‑Fi, mapped to EQ-5D using the method from Young et al. (2015). These utilities are considered confidential by the company and so cannot be reported here.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Direct and indirect costs: systematic literature review

> “No studies evaluating direct or indirect costs of patients with DT were identified in the literature.”
> “No monetary costs from loss of employment and hospital travel expenses were reported in these studies.”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.2-2"></a>

###### Danish registry healthcare resource utilization and medication use, 2009 to 2018

> “Using Danish health registers, we studied DT patients treated at two sarcoma centers between 2009 and 2018. For each patient, ten persons from the general population were randomly matched on birth year, sex, and region of residence.”
> “A total of 56% of DT patients used chemotherapeutic agents, tyrosine kinase inhibitors, NSAIDs, opioids, antidepressants, or steroids at some point during the three years before their DT diagnoses. In contrast, 70% of surgically treated and 63% of non-surgically treated patients used one of these drugs in the subsequent three years, including NSAIDs (45% surgical vs. 33% non-surgical), opioids (39% surgical vs. 27% non-surgical), and steroids (22% surgical vs. 18% non-surgical). The average number of inpatient and outpatient visits, days of hospitalization, and additional surgical procedures were higher among DT patients than the comparison cohort.”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

<a id="topic-2.2.1.8.2-3"></a>

###### Danish registry visits and hospital days within 3 years of diagnosis

> “Healthcare resource utilization of patients with DT was substantially higher than that in the comparison cohort, both 1 and 3 years after the diagnosis. Within 3 years after the index date, patients with DT had, on average, 1 inpatient and 7.1 outpatient visits as well as 7.5 days in the hospital compared with an average of 0.8 inpatient and 0.1 outpatient visits and 0.8 days in the hospital in the comparison cohort. The median duration of hospitalization for DT-related surgery was 5 days (interquartile range, 3–7).”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.2-4"></a>

###### United States academic center resource utilization, 2011 to 2023

> “A retrospective cohort study was conducted at the University of Utah Health network. Eligible patients were diagnosed with DTs between January 1, 2011, and July 31, 2023, were ≥18 years old at diagnosis, and had ≥2 DT-related encounters.”
> “Healthcare resource utilization was quantified using administrative claims.”
> “88.5% of patients had at least one outpatient visit related to DTs, with an average number of 2.4 visits per patient per year. In contrast, only a small proportion of patients had emergency visits related to DTs (n = 5, 3.4%). Approximately one fifths of patients (n = 30, 20.3%) required hospitalizations related to DTs with a median length of stay per year of 4.5 days (IQR: 3–8, range: 1–35).”
> “Although there was no increase in the proportion of patients who engaged outpatient services, the median number of outpatient visits almost tripled in the event of symptomatic disease (7.2 per patient per year) and doubled during active disease (4.7 per patient per year).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.8.2-5"></a>

###### Healthcare use by physical symptom burden in the United Kingdom and the Netherlands

> “DTF patients with high symptom burden had clinically relevant lower HRQoL scores compared to patients with low and intermediate symptom burden (p < 0.001) and reported more general and DTF‐related visits to their general practitioner compared to the low symptom burden cluster (p < 0.01). In the multivariate analyses, symptom burden was independently associated with both HRQoL and healthcare utilisation.”
> “DTF patients in the intermediate symptom burden–high pain and high symptom burden clusters were more frequently receiving additional care, mostly from a physiotherapist or psychologist (Table S4).”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

<a id="topic-2.2.1.8.2-6"></a>

###### Medications for symptom management in the Desmoid Tumor Research Foundation natural history study

| Medication class | Overall (N = 322), n (%) | Current desmoid tumor (n = 225), n (%) | No current desmoid tumor (n = 97), n (%) |
| --- | --- | --- | --- |
| NSAIDs | “151 (47)” | “103 (46)” | “48 (49)” |
| Antidepressants | “60 (19)” | “41 (18)” | “19 (20)” |
| Anticonvulsants | “36 (11)” | “26 (12)” | “10 (10)” |
| Muscle relaxants | “39 (12)” | “28 (12)” | “11 (11)” |
| Opioids | “61 (19)” | “45 (20)” | “16 (16)” |
| None | “104 (32)” | “69 (31)” | “35 (36)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.2-7"></a>

###### Monitoring frequency in the Desmoid Tumor Research Foundation natural history study

> “As expected, a higher proportion of participants (77%, 181/235) with a current DT were monitored (regular clinic visits and radiologic assessment, including computed tomography and magnetic resonance imaging) at least every 6 months relative to those without (54%, 49/91).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.2-8"></a>

###### Work loss attributed to pain: SOS Desmoid survey as summarized in a systematic review

> “Studies [4, 41] assessing the impact of DT on employment and job productivity have reported that patients experience a negative impact on their employment due to their disease and find it frustrating being unable to work (26% stopped working and 10% worked part- time; see Table 1).”
> “Pain-related work disturbances included 17 patients (26%) who stopped working altogether and 7 (10%) who worked only part time due to pain”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

<a id="topic-2.2.1.8.2-9"></a>

###### Employment and financial difficulty at a United Kingdom sarcoma unit

> “DF patients experienced changes to their employment due to their disease and found it frustrating being unable to work and wanting to feel ‘normal’. Some patients felt discriminated due to enforced sick leave, which was demoralising and led to loss of progression within their job role. In addition, financial difficulty resulting from loss of employment and hospital travel expenses was a significant concern for several patients.”

Source: [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)

<a id="topic-2.2.1.8.2-10"></a>

###### Interruption of work after treatment: Dutch focus groups

> “Participants reported that DTF had influenced their working life, as they had to stop working temporarily after treatment. This period ranges from a couple of weeks to two years and in one case not being able to work at all.”

Source: [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)

<a id="topic-2.2.1.8.2-11"></a>

###### Economic burden of surgery: literature review

> “Since economic data related to DT surgery is lacking, reviews of surgery costs in soft-tissue sarcomas and of general costs of amputations were conducted.”
> “Tumors in the extremities have the highest risk of recurrence (30%-90%).”
> “Although effective in specific cases, surgery may be associated with poor long-term functional outcomes and higher economic costs.”

Source: [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)

<a id="topic-2.2.1.8.2-12"></a>

###### Cost of 10-year active surveillance in NHS Scotland

> “To estimate the direct costs associated with active surveillance (AS), we adopted a conservative costing approach based on current NHS tariffs, focusing on imaging and clinic visit expenses. The study assumes a 10-year follow-up period. The current cost per MRI was £130. Based on current NHS tariffs, each appointment costs approximately £233.”
> “At a cost of roughly £130 per MRI scan, this translates to a total imaging cost of £2340 per patient. Assuming an equal number of clinic visits throughout the follow-up period, with each consultant-led clinic appointment costing £233 as per current NHS Scotland figures, the total combined cost of imaging and appointments exceeds £6500 per patient.”

Source: [Saraf et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12191607/)

<a id="topic-2.2.1.8.2-13"></a>

###### Cost per outcome of sorafenib at Medicare Part D rates

> “Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day).”
> “At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year.”

Source: [Johns et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/35112974/)

<a id="topic-2.2.1.8.2-14"></a>

###### German statutory health insurance target population and annual treatment cost of nirogacestat

> “Adults with progressing desmoid tumours who require systemic treatment”
> “Approx. 350 to 630 patients”
> “Nirogacestat”
> “260,760.82”
> “Costs after deduction of statutory rebates (LAUER-TAXE® as last revised: 1 February 2026)”

Source: [G-BA resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/39-1464-7764/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_EN.pdf)

<a id="topic-2.2.1.8.2-15"></a>

###### Basis of the German patient numbers and treatment cost calculation for nirogacestat

> “The G-BA takes into account the patient numbers stated in the pharmaceutical company's dossier, which are, however, subject to uncertainty overall. There were methodological limitations and uncertainty regarding the percentages of desmoid tumours, which also relate exclusively to inpatients, under ICD-10 code D48.1. Furthermore, patients who had been ill for more than 5 years were not considered.”
> “If no maximum treatment duration is specified in the product information, the treatment duration is assumed to be one year (365 days), even if the actual treatment duration is different from patient to patient and/or is shorter on average.”
> “Nirogacestat 150 mg”
> “56 FCT”
> “€ 21,213.56”
> “€ 20,003.57”
> “No additionally required SHI services are taken into account for the cost representation.”

Source: [G-BA justification to the resolution on nirogacestat (2026)](https://www.g-ba.de/downloads/40-1465-12520/2026-04-02_AM-RL-XII_Nirogacestat_D-1255_TrG_EN.pdf)

<a id="topic-2.2.1.8.2-16"></a>

###### Nirogacestat list price in England

> “The anticipated list price is £15,189.04 per 56 pack of 150‑mg tablets (company submission).”
> “The company has a commercial arrangement. This makes nirogacestat available to the NHS with a discount. The size of the discount is commercial in confidence.”

Source: [NICE TA1199 information about nirogacestat (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/2-Information-about-nirogacestat)

<a id="topic-2.2.1.8.2-17"></a>

###### Resource use assumptions and intra-abdominal care needs in the NICE appraisal of nirogacestat

> “The EAG also noted that the company did not apply any resource use for complete response, and underestimated specialist visits with the other health states. Informed by clinical opinion, the EAG preferred a higher number of specialist visits for all health states, and an increased number of GP visits for stable disease.”
> “The committee preferred to apply higher resource-use values from the EAG base case, because this better reflected clinical practice.”
> “The clinical expert also explained that people with desmoid tumours, particularly intra-abdominal tumours, may need stomas, ureteric stents and home intravenous nutrition.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Desmoid tumors on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Age and sex distribution: women of childbearing and working age

> “Additionally, the burden of DT is disproportionately borne by women of childbearing and working age, and because it is associated with low mortality and a relatively young patient population, it typically continues for decades.”

Source: [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)

<a id="topic-2.2.1.8.3-2"></a>

###### Age and sex at diagnosis in Danish registers

> “Of the 179 DT patients identified, 76% were female and the median patient age was 38 years at diagnosis (interquartile range: 31-50).”

Source: [Anneberg et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35121405/)

<a id="topic-2.2.1.8.3-3"></a>

###### Impact on careers, family, and carers: NICE committee discussion

> “They highlighted the emotional impact and that many people with desmoid tumours experience anxiety and depression. They also explained that desmoid tumours can affect careers, relationships and social lives, and the ability to have a family. The committee acknowledged the significant impact on quality of life that desmoid tumours can have for people living with the condition and their families and carers.”
> “This means that people with desmoid tumours are expected to live with the tumour and the associated pain, loss of function and mobility and the impact on work and family life.”
> “In addition, the committee noted that desmoid tumours are more commonly diagnosed in younger people, particularly people of reproductive age.”
> “It noted that desmoid tumours can have a severe impact on carers' quality of life.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.8.3-4"></a>

###### Parental role and dependence on family members

> “DF patients also felt that their parental role was affected including difficulty breastfeeding, playing games with their children and depending on their partner or parent for childcare.”
> “Financial strain due to lost productivity and medical costs, including travelling costs to the hospital can lead to dependence on family members and have an adverse effect on patients’ social relationships.”

Source: [Husson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6373240/)

<a id="topic-2.2.1.8.3-5"></a>

###### Family planning: Dutch focus groups

> “One participant reported that DTF restricted her from having another child, which had a major impact on her family.”
> “Another participant reported the feeling that he missed out on starting a family because of extensive treatments which started at a young age.”

Source: [Timbergen et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6244798/)

<a id="topic-2.2.1.8.3-6"></a>

###### Family-related impacts reported in GODDESS concept elicitation interviews

| Impact | Frequency of mentions (n = 31) | Median disturbance rating (0 to 10) |
| --- | --- | --- |
| Concern for other family members | “20” | “6.25” |
| Worry over becoming pregnant | “7” | “6.00” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.8.3-7"></a>

###### Pregnancy and desmoid fibromatosis: international multicenter study

> “This international, multicenter, retrospective observational study included data from 157 women with DF, contributing 177 pregnancies.”
> “Among 177 pregnancies, Group A exhibited the highest rates of DF progression (68.7 % during pregnancy, 40.6 % postpartum), while Groups B and C had lower progression rates (9.5 % during pregnancy, 8.3 % postpartum). Active treatment was required in 5.6 % of cases. Spontaneous regression occurred in 23.7 % of pregnancies, particularly following progression. Obstetric complications were comparable to those in the general population.”
> “Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.”

Source: [Fiore et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40328165/)

<a id="topic-2.2.1.8.3-8"></a>

###### Pregnancy-related desmoid fibromatosis: four sarcoma centers

> “Ninety-two women were included. Forty-four women (48%) had pregnancy-related DF (A + B), whereas 48 (52%) had a history of DF before conception (C + D).”
> “DF does not increase obstetric risk, and it should not be a contraindication to future pregnancy.”

Source: [Fiore et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24477160/)

<a id="topic-2.2.1.8.3-9"></a>

###### Pregnancy-associated desmoid fibromatosis: Dutch multicenter study

> “Overall, 62 patients were included. The most common locations were abdominal wall (74%), pelvis (10%) and extremities (10%).”
> “Ten patients (16%) were diagnosed during pregnancy, while the remainder were diagnosed after pregnancy with a median time from delivery to diagnosis of 19 months (1-60). The frontline management was AS in 38 patients (61%) of whom 12 (33%) developed progressive disease and surgery in 23 patients (37%).”

Source: [Drabbe et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36404250/)

<a id="topic-2.2.1.8.3-10"></a>

###### Recent pregnancy and risk of progression or relapse in the ALTITUDES cohort

> “A total of 242 patients (median age, 34.7 years) were included in the present study.”
> “Pregnancy occurred within 24 months before, at the time of, and after DF diagnosis in 33%, 5%, and 10% of the cases, respectively.”
> “After adjusting for DF location, tumor size, front-line treatment strategy, and hormonal contraception, we observed an increased risk of events occurring at 24 months after pregnancy [hazard ratio (HR) = 2.09, P = 0.018].”

Source: [Debaudringhien et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9588892/)

<a id="topic-2.2.1.8.3-11"></a>

###### Fertility considerations across treatment options: NICE committee discussion

> “Patient experts highlighted that people with desmoid tumours face fertility challenges across the other treatment options, including chemotherapy. Menopause and fertility issues need to be considered regardless of which treatment is offered.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.1.8.3-12"></a>

###### Fertility preservation in familial adenomatous polyposis-associated desmoid tumours

> “The study included women with FAP-associated desmoid tumours who underwent fertility treatments at the authors' tertiary medical centre between the years 2011 and 2021.”
> “Overall, 17 women were identified suitable for this study. A total of 117 mature oocytes were vitrified for fertility preservation and 106 embryos were submitted to PGT-M. One patient returned to claim her cryopreserved oocytes, and five patients who underwent PGT-M embryo transfer reported three live births.”
> “Ovarian stimulation for women with desmoid tumours was characterized in some patients with an acceleration in tumour growth, regardless of the use of aromatase inhibitors.”

Source: [Fouks et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34429254/)

<a id="topic-2.2.1.8.3-13"></a>

###### Oocyte cryopreservation before systemic therapy in young adults

> “With a peak incidence in young adulthood, desmoid tumors (DTs) often cause pain, loss of function, and diminished quality of life.”
> “Eleven young adult (YA) patients with DT who received nirogacestat were identified for the study. The median patient age was 26 years.”
> “Out of nine female patients, two elected to undergo oocyte cryopreservation prior to starting therapy.”

Source: [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)

<a id="topic-2.2.1.8.3-14"></a>

###### Treatment schedule for children: Pediatric Oncology Group phase 2 study

> “To determine the efficacy and safety of using vinblastine (Vbl) and methotrexate (Mtx) in children with desmoid-type fibromatosis that is recurrent or not amenable to treatment with radiation or surgery.”
> “Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks.”

Source: [Skapek et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17290057/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Cost of centralized histological review in the French RRePS network

> “A decision tree was used to assess the expected costs of two strategies of disease management: one based on revised diagnoses after centralized histological review (option 1), the other on diagnoses without centralized review (option 2).”
> “The time horizon was 12 months and the perspective of the French National Health Insurance (NHI) was retained. Costs were expressed in Euros for 2013.”
> “A total of 2,425 patients were included. Three hundred forty-one patients (14%) had received discordant diagnoses.”
> “The probability of discordance was higher for a final diagnosis of desmoid tumors when compared to liposarcomas (odds ratio = 5.1; 95%CI [2.6–10.4]). The expected costs per patient for the base-case analysis (low- and high-case scenarios) amounted to €8,791 (€7,033 and €10,549, respectively) for option 1 and €8,904 (€7,057 and €10,750, respectively) for option 2.”
> “Centralized histological reviews are likely to provide cost-savings for the French NHI.”

Source: [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="topic-2.2.1.8.4-2"></a>

###### Molecular testing and unit costs of review in the French RRePS network

> “Each center reviewed cases from the corresponding area using systematic molecular testing for every tumor that was suspected to have a specific genomic abnormality (e.g., KIT and PDGFRA mutations for GIST, CTNNB1 mutation for desmoid tumors, specific translocations for sarcomas with a recurrent translocation, and MDM2/CDK4 amplifications for atypical/well-differentiated and dedifferentiated liposarcomas).”
> “RRePS network organization (per patient)”
> “€103”
> “Histological review (per patient)”
> “€228”

Source: [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="topic-2.2.1.8.4-3"></a>

###### Concordance and 12-month management cost by initial and final diagnosis involving desmoid tumors

| Initial diagnosis and final diagnosis | Mean cost of disease management, base case (2013 euros) | High scenario | Low scenario |
| --- | --- | --- | --- |
| Initial desmoid tumor, final desmoid tumor | “€1,219” | “€1,462” | “€975” |
| Initial desmoid tumor, final sarcoma | “€4,963” | “€5,955” | “€3,970” |
| Initial desmoid tumor, final benign tumor | “€640” | “€767” | “€512” |
| Initial sarcoma, final desmoid tumor | “€1,469” | “€1,762” | “€1,175” |
| Initial GIST, final desmoid tumor | “€839” | “€1,006” | “€671” |
| Initial benign tumor, final desmoid tumor | “€1,380” | “€1,655” | “€1,104” |

Source: [Perrier et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5886412/)

<a id="topic-2.2.1.8.4-4"></a>

###### CTNNB1 and APC testing uptake at a United Kingdom specialist center

> “226 patients were identified and 67% (n = 152) were female. Median age at diagnosis was 37.5 (range 2-81) years.”
> “Colonoscopy was requested in 65 patients (28.8% of all cases) and was completed in forty-six (20.4%). Molecular testing of CTNNB1 testing was requested in 35 cases (15.5%). APC germline test was requested in 12 cases. Four patients in our cohort had an FAP-associated DF.”
> “CTNNB1 molecular testing should be performed in all cases of newly diagnosed DF. Negative CTNNB1 results, alongside clinical assessment, should prompt APC testing and/or colonoscopy.”

Source: [Cojocaru et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33547536/)

<a id="topic-2.2.1.8.4-5"></a>

###### CTNNB1 testing uptake, cost, and reimbursement at a United States academic center

> “A much smaller proportion of patients had documentation of CTNNB1 testing (n = 10, 6.7%), including seven with CTNNB1 mutation (4.7%) and three who were demonstrated to have the wild-type, nonmutated variant, which results in production of normal β-catenin (2%).”
> “Therefore, CTNNB1 testing is useful to diagnose or rule out DTs when APC mutations are not detected or morphologic features of DTs are inconclusive in the biopsy specimen (29). Notably, the proportion of patients with CTNNB1 testing was low in our participant cohort, potentially due to cost and reimbursement issues.”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.8.4-6"></a>

###### Resource utilization before diagnosis among patients with potential misdiagnosis

> “A total of 43 patients (29.1%) potentially had a misdiagnosis prior to a final confirmed diagnosis of DT based on tissue histology (Table 4).”
> “In the first year prior to DT diagnosis, healthcare resource utilization was higher among patients with prior misdiagnoses, with a higher proportion of patients requiring outpatient visits (65.1% vs. 30.3%, P < 0.001), emergency room visits (14% vs. 2.6%, P = 0.03), and hospitalization (25.6% vs. 2.6%, P < 0.001; Table 4).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.8.4-7"></a>

###### Surgery before a definitive diagnosis in the Desmoid Tumor Research Foundation natural history study

> “A total of 162 participants (41%, 162/399) reported a prior misdiagnosis.”
> “Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58/126) reported having received surgery before a definitive DT diagnosis.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.8.4-8"></a>

###### Misdiagnosis during initial work-up and its consequences

> “misdiagnosis rates for DT may be as high as 30–40% during an initial work-up,”
> “which can result in additional treatments (eg, surgical excision) and delays for patients in receiving appropriate disease management.”

Source: [Kasper et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166168/)

<a id="topic-2.2.1.8.4-9"></a>

###### CTNNB1 genotyping and germline APC testing in children

> “Forty-four desmoids in pediatric patients were identified in the pathology files of 2 large referral centers (1995-2009).”
> “CTNNB1 mutations were observed in 29 of 44 (66%) desmoids, with 3 mutations identified: T41A (64%), S45F (29%), and S45P (7%). Germline APC mutations were present in 7 (16%) desmoid patients.”
> “Given the implications, genetic counseling is recommended for children diagnosed with desmoid tumors lacking CTNNB1 mutations because this population is enriched for FAP patients.”

Source: [Wang et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22372443/)

Additional sources: [Brueckl et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15793634/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Active Surveillance

<a id="topic-2.2.2.1.1-1"></a>

###### Active surveillance as the primary approach

> “Active surveillance is the well-established primary approach to primary/recurrent sporadic/familial desmoid tumours (DT).”
> “Previously surgery was the standard primary treatment modality; however, in recent years a paradigm shift towards a more conservative management has been introduced”
> “Neither surgery nor other forms of active treatments are proposed as primary therapy at diagnosis. Considering the biology and unpredictable course of the disease, active treatments should be considered only in case of persistent progression.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.1-2"></a>

###### Monitoring schedule and threshold for starting active treatment

> “Active surveillance means that patients need to be continuously monitored with a first MRI (or alternatively CT if MRI is not possible) within 1-2 months, then in 3-6 months intervals.”
> “A decision towards an active treatment should be postponed until the occurrence of subsequent progression or increase of symptoms burden, assessed with at least two further assessments and possibly not before one year from diagnosis in the absence of fulfilling RECIST progressive disease.”
> “However, when the disease is located close to a critical structure that may pose significant problems to the patient's life (such as mesenteric or head & neck DT) an earlier decision towards an active therapy may be taken simply because there is a potentially higher risk of morbidity prior to disease stabilisation.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.1-3"></a>

###### Referral to experienced centers during active surveillance

> “Of note, patients not progressing for 2 years were very unlikely to need any further active treatment”
> “Clearly, patients need to be referred to centres with experience in DT to minimize the risk of active surveillance and avoid unnecessarily debilitating or mutilating surgery when possibly needed.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.1-4"></a>

###### Consensus update of June 2023: shift toward less-invasive management

> “To update the 2020 global evidence-based consensus guideline on the management of patients with DT, the Desmoid Tumor Working Group convened a 1-day consensus meeting in Milan, Italy, on June 30, 2023”
> “Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been made.”
> “Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="topic-2.2.2.1.1-5"></a>

###### Watch and wait as the front-line approach for newly diagnosed patients

> “Immediate surgery is no more the standard treatment of DF.”
> “There is clear consensus that a conservative watch and wait strategy should be the front-line approach to newly diagnosed patients, irrespective of existing pain or other clinical symptoms, offering a way to understand the behavior of the disease and tailor next treatment steps.”
> “The time interval for a watch and wait approach could be 1–2 years and patients should be closely followed, preferably using contrast enhanced MRI.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.1-6"></a>

###### Active surveillance in line with Desmoid Tumour Working Group and NCCN recommendations

> “Active Surveillance is increasingly being utilized as the initial treatment of choice (in line with recommendations from the Desmoid Tumour Working Group and NCCN),”
> “Active Surveillance may not be appropriate if progression could”
> “be life-threatening or pose a risk for mutilation (adjacent nerves or vessels).”
> “Patients should be monitored every 3-6mo initially, and if the disease is stable this can be extended.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### Pooled analysis of three prospective observational studies: treatment-free survival and progression

> “In this pooled analysis from three prospective observational studies on patients with extra-abdominal desmoid-type fibromatosis, we confirm that spontaneous regression occurs in a significant proportion of patients and that two-thirds are treatment free at 5 years.”
> “Patients (n = 282) with a median follow-up of 53 months (IQR, 39–63) were included. The 3- and 5-year TFS rates were 67% and 66%, respectively; the 3- and 5-year crude cumulative incidences were 33% and 34% for RECIST progression, 26% and 34% for RECIST regression, and 33% and 38% for regression post-RECIST progression, respectively.”
> “The 3- and 5-year PFS rates (95% CI) were 54% (48%–60%) and 51% (45%–58%), respectively”
> “In total, 93 of 282 (33.0%) patients received AT after initial AS, of which 45 (48.4%) patients received AT after RECIST progression, and 48 (54.6%) patients received AT after symptomatic progression alone.”
> “The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.”

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)

<a id="topic-2.2.2.1.1-8"></a>

###### Prospective multicenter observational study of peripheral primary sporadic tumors

> “This prospective, multicenter, observational study (NCT01801176) included patients ≥18 years of age with primary sporadic DF located in an extremity or the abdominal/thoracic wall.”
> “Between 2012 and 2015, 100 patients were enrolled.”
> “Median follow-up was 46.6 months (IQR 36.8-61.1) and the 3-year PFS was 53.4% (95% confidence interval 43.5-63.1%). At progression (48 patients), 23 patients received active treatment.”
> “Fifty-eight patients (58%) presented with spontaneous tumor regression (decrease > 0% compared with the initial size) during the first 3 months (n = 35, 35%) or after an initial progression (n = 23, 23%), of whom 26 (26%) had partial responses (PRs).”

Source: [Bonvalot et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37777684/)

<a id="topic-2.2.2.1.1-9"></a>

###### Italian prospective multicenter observational study at any site

> “This is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site.”
> “At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%).”

Source: [Colombo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35247923/)

<a id="topic-2.2.2.1.1-10"></a>

###### GRAFITI prospective cohort study of non-intraabdominal tumors

> “In this multicenter prospective cohort study (NTR4714), adult patients with non-intraabdominal DTF were followed during an initial AS approach for 3 years.”
> “A total of 105 patients started with AS.”
> “At 3 years, cumulative incidence of the start of active treatment was 30% (95% confidence interval [CI] 21–39) and PFS was 58% (95% CI 49–69). Median time to start active treatment and PFS were not reached at a median follow-up of 33.7 months. During AS, 32% of patients had stable disease, 28% regressed, and 40% demonstrated initial progression.”
> “Larger tumor size (≥5 cm; hazard ratio = 2.38 [95% CI 1.15–4.90]) and S45F mutation (hazard ratio = 6.24 [95% CI 1.92–20.30]) were associated with the start of active treatment.”
> “The follow-up protocol of the GRAFITI trial consisted of follow-up visits and imaging examinations (Ultrasound [US] and MRI) at baseline, 3,6,9,12,18,24, and 36 months (window ±3 months).”

Source: [Schut et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9994811/)

<a id="topic-2.2.2.1.1-11"></a>

###### Single sarcoma reference center cohort at all anatomic locations

> “Patients with a primary desmoid tumor at any anatomic location diagnosed between 1998 and 2016 were identified in a prospectively maintained database from a single sarcoma reference center in the United Kingdom.”
> “The study identified 168 patients with a primary desmoid tumor initially managed with active surveillance.”
> “Of all the patients, 36% experienced radiologic progressive disease, 36% had stable disease, and 27% regressed.”
> “Eventually, 46% of the patients proceeded to treatment. The median time to start of treatment after initial surveillance was 31 months, whereas the median follow-up time for the patients not receiving any treatment was 40.5 months. The indications for initiation of treatment were pain (32%), progression (31%), or both (13%).”

Source: [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)

<a id="topic-2.2.2.1.1-12"></a>

###### Use of active surveillance before treatment among survey participants

> “Following a confirmed diagnosis of DT, a total of 383 participants completed the treatment survey, with 136 (36%) reporting active surveillance before treatment initiation.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

Additional sources: [Gronchi et al. (2021)](https://www.annalsofoncology.org/article/S0923-7534%2821%2902184-0/fulltext); [Salas et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21844500/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Surgery

<a id="topic-2.2.2.1.2-1"></a>

###### Surgery as second-line treatment for abdominal wall tumors

> “Surgery is the accepted second-line treatment only for sporadic tumour DT located in the abdominal wall failing observation.”
> “For abdominal wall DT, surgery is still the first option in case of progression.”
> “For extremity/girdles/chest wall DT, again surgery should not be the first treatment option unless the expected morbidity is very low (and only following MDT discussion); medical therapy should be administered preferably.”
> “Surgery may still be considered as a second-line treatment for AW tumours as morbidity and risk of recurrence are limited, while other modalities should be preferred for DT located at other sites.”
> “Surgery by surgeons without significant experience in the management of DT is strongly discouraged.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.2-2"></a>

###### Resection margins

> “Wide (R0) microscopic margins resection should be the goal, but positive (R1) microscopic margins can be accepted when function or cosmesis is an issue. However, if positive microscopic margins can be anticipated, other managements than surgery should be preferred.”
> “In addition, if R1 resection is obtained in first-line management, there is insufficient evidence to recommend either perioperative radiotherapy or re-operation.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.2-3"></a>

###### Surgery compared with observation

> “The results did not show any difference in event-free survival (EFS, 53% versus 58%; p = 0.415) and long-term disease control between patients undergoing surgery and those managed with a conservative approach.”
> “Among patients with unfavorable locations, defined as chest wall, head & neck and upper limb, the 2-year EFS was significantly better in those patients managed non-surgically (52%) compared to those who underwent initial surgery (25%; p = 0.001).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.2-4"></a>

###### Surgery after failure of the surveillance approach

> “Multiple retrospective single institution case series have reported local control rates after complete surgical resection to be ∼80% at 5 years.”
> “When the surveillance approach fails, surgery is still a valid option (IV, A).”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.2-5"></a>

###### NCCN and Desmoid Tumor Working Group positions on first-line surgery

> “However, while surgery has historically represented the primary treatment modality for patients with DT, the NCCN Guidelines® and DTWG guidelines no longer support surgery as the first-line option in most situations, given high postsurgical recurrence rates”
> “However, consensus guidance also positions surgery as a primary treatment consideration for patients experiencing complications from sporadic mesenteric DT or for those with non-mesenteric DT that progress despite active surveillance or medical treatment”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.2-6"></a>

###### Indications for surgery and expected recurrence after resection

> “Surgery can be considered as a local therapy option when complete resection with negative margins is technically feasible without undue morbidity and in symptomatic patients; however, RT may also be considered as control rates (85%) are similar to surgery (77-94%).”
> “If R0 margins are achieved the patient should be observed.”
> “Note that a recurrence up to 25% is expected with a median time to recurrence of 16-22mo.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.2-7"></a>

###### Surgical morbidity, postsurgical recurrence, and the criterion of tumors not amenable to surgery or radiotherapy

> “Surgery used to be the mainstay of treatment; however, due to high morbidity and postsurgical recurrence rates of up to 50% to 88%, it is used less frequently.”
> “The desmoid tumors are not amenable to surgery or radiotherapy; AND”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.2-8"></a>

###### Prospective cohort of 771 cases: surgery compared with wait-and-see

> “We conducted a prospective study of 771 confirmed cases of DTF.”
> “Overall, the 2-year EFS was 56%; this value did not differ between patients undergoing an operation and those managed by the wait-and-see approach (53% versus 58%, p = 0.415).”
> “Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).”

Source: [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)

<a id="topic-2.2.2.1.2-9"></a>

###### Recurrence after complete gross resection in a single-institution database

> “Patients undergoing resection during 1982-2011 for primary or locally recurrent desmoids were identified from a single-institution prospective database.”
> “Desmoids were treated surgically in 495 patients (median follow-up 60 months). Of 439 patients undergoing complete gross resection, 100 (23%) had recurrence. Five-year local recurrence–free survival (LRFS) was 69%. Eight patients died of disease, all after R2 resection.”
> “In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.2.1.2-10"></a>

###### Resection margins and local recurrence across sixteen reports

> “Sixteen reports were included, consisting of a total of 1295 patients with DF. In patients treated by surgical resection alone, the risk of local recurrence was almost twofold higher for those with microscopically positive resection margins (risk ratio (RR) 1·78, 95 per cent c.i. 1·40 to 2·26).”

Source: [Janssen et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28199014/)

<a id="topic-2.2.2.1.2-11"></a>

###### Recurrence and amputation after surgery reported by participants

> “Continued tumor regrowth or recurrence following any DT treatment was reported for 46% (92/202) of participants, with a higher rate post-surgery (63%, 103/163), regardless of tumor location (Fig. 4). Amputation was reported for 7% (12/163) of participants who underwent surgery, with most (83%, 10/12) experiencing tumor regrowth or recurrence post-amputation.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.2-12"></a>

###### Literature review of recurrence and functional deficits after surgery

> “We conducted a literature review to assess the burden of surgery in patients with DT, focusing on recurrence rates and functional deficits resulting from surgeries.”
> “Although surgery is a potential treatment option, complete excision with negative margins is not often possible, the postsurgery recurrence rate is high, and surgery can result in disfigurement and/or loss of function.”
> “Tumors in the extremities have the highest risk of recurrence (30%-90%). Lower rates of recurrences have been reported when radiotherapy was used after surgery (14%-38%).”

Source: [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Radiotherapy

<a id="topic-2.2.2.1.3-1"></a>

###### Moderate-dose definitive radiotherapy when surgery is not an option

> “When surgery is not an option and active management is required, moderate dose definitive radiotherapy has also been shown to provide adequate local control in a majority of progressive patients and could be considered if medical therapies are not available or not active.”
> “More recently, moderate dose definitive radiotherapy has been employed as an alternative to surgery for symptomatic/growing tumours located at critical sites such as head & neck, scapular girdle, etc.”
> “For head & neck/intrathoracic DT, medical therapy is generally considered the first line option. However, in selected conditions (elder age, patient intolerance/preference, comorbidities, lesion growing rapidly and threatening vital organs, etc.) radiotherapy is a reasonable and effective first line alternative.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.3-2"></a>

###### Radiotherapy combined with or compared with surgery

> “While some reduction in the anticipated absolute risk of recurrence after surgery has been observed with the addition of radiotherapy (37% versus 25%), this reduction is not statistically significant (RR 0.69, 95% CI 0.41–1.17).”
> “The level of evidence for adjuvant radiotherapy is low and this strategy is not devoid of risk in this young patient population (radiation-induced sarcoma).”
> “the anticipated absolute risk of progressive disease after radiotherapy alone is 19% versus 29% after surgery alone, however, not being statistically significant (RR 0.65, 95% CI 0.35–1.22).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.3-3"></a>

###### Dose of 56 Gy in 28 fractions and post-operative radiotherapy

> “Radiotherapy to a dose of 56 Gy in 28 once-daily fractions of 2 Gy has been shown to provide adequate local control in the majority of progressive patients (III, A)”
> “Post-operative radiation has not demonstrated a conclusive benefit after first surgery regardless of resection margins.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.3-4"></a>

###### Radiotherapy dose, local control, and late effects

> “Radiotherapy is an effective treatment option, especially if patients are symptomatic and progressing.”
> “A dose of 50-56 Gy alone or in combination with surgery in patients with incomplete resection can achieve adequate local control at 5 years in 70–80% of patients with unresectable tumors or following incomplete resection.”
> “Post-operative RT after complete surgical resection is not typically recommended in the adjuvant setting.”
> “For young adults, RT should be discussed individually with consideration of its late toxic effects and risk of secondary malignant neoplasms.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### EORTC 62991-22998 multicenter prospective phase II trial: local control and response

> “To determine the activity of radiotherapy in patients with inoperable desmoid-type fibromatosis (DF) a multicenter prospective phase II trial was carried out.”
> “(EORTC 62991-22998)”
> “Patients with inoperable progressive disease of primary, recurrent or incompletely resected lesions received a dose of 56 Gy in 28 fractions.”
> “Forty-four patients (27 F/17 M) were enrolled from 2001 to 2008. Median age was 39.5 years.”
> “Median follow-up was 4.8 years. The 3-year local control rate was 81.5% (90% one-sided confidence interval 74% to 100%). Best overall response during the first 3 years was complete response (CR) 6 (13.6%), partial response (PR) 16 (36.4%), stable disease 18 (40.9%), progressive disease 3 (6.8%) and nonassessable 1 (2.3%).”
> “Response after radiation therapy is slow with continuing regression seen even after 3 years.”

Source: [Keus et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23868907/)

<a id="topic-2.2.2.1.3-6"></a>

###### EORTC 62991-22998 multicenter prospective phase II trial: acute and late toxicity

> “Acute grade 3 side-effects were limited to skin, mucosal membranes and pain. Late toxic effect consisted of mild edema in 10 patients.”

Source: [Keus et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23868907/)

<a id="topic-2.2.2.1.3-7"></a>

###### Review of six studies of definitive radiotherapy for unresectable tumors: local control and late complications

> “Among 218 identified studies, only 6 were finally included in this review. Local control was achieved in 253 of 317 patients with unresectable or unresected tumors who underwent definitive radiation therapy (the crude rate of local control was 79.8%).”
> “Frequent late complications of radiation therapy included fibrosis/contracture/joint stiffness, skin disorders, lymphedema and pain. Six patients developed secondary malignancies in the radiation field.”

Source: [Matsunobu et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32115624/)

<a id="topic-2.2.2.1.3-8"></a>

###### Adjuvant radiotherapy after resection with negative or positive margins

> “Adjuvant radiotherapy after surgery with negative margins had no detectable benefit on recurrence. In contrast, after incomplete surgical resection, adjuvant radiotherapy improved recurrence rates both in patients with primary tumours (RR 1·54, 1·05 to 2·27) and in those with recurrent DF (RR 1·60, 1·12 to 2·28).”

Source: [Janssen et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28199014/)

<a id="topic-2.2.2.1.3-9"></a>

###### Adjuvant radiation in a surgical series

> “In our series, there was no improvement in outcomes in patients who had received radiation therapy during the course of their treatment (5-year LRFS 68% vs 72% without radiation; Figure 3A).”
> “LRFS among patients with extremity tumors was 71% with radiation vs. 56% without (p=0.029).”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.2.1.3-10"></a>

###### Criterion of tumors not amenable to surgery or radiotherapy

> “C) The desmoid tumors are not amenable to surgery or radiotherapy; AND”

Source: [Express Scripts nirogacestat criteria (2023)](https://express-scripts.com/sites/default/files/policies/Oncology%20-%20Ogsiveo%20PA%20Policy.pdf)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Cryoablation and Other Local Ablative Therapies

<a id="topic-2.2.2.1.4-1"></a>

###### Local ablative treatments as an alternative to medical therapies

> “Local ablative treatments such as cryotherapy or radiotherapy are options that can be considered as an alternative to medical therapies on an individual basis.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.4-2"></a>

###### Consensus update of 2023: positioning of local ablative therapies

> “The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.”
> “The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery;”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="topic-2.2.2.1.4-3"></a>

###### Cryoablation for small and moderately sized extra-abdominal tumors

> “Cryoablation has been reported in case series to be an effective alternative treatment of small and moderately sized extra-abdominal DF. It is of limited use in patients with larger tumors that can only be partially treated due to the involvement of vital structures.”
> “Of note, both approaches are not available in every center and do require particular expertise.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.4-4"></a>

###### Isolated limb perfusion for progressive locally advanced extremity tumors

> “In patients with progressive, locally advanced extremity DF, where resection would result in important functional sacrifice, isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan seems to be a very effective treatment option”
> “With a median follow-up of 7 years, 90% of 25 patients had disease control; of these, 40% developed disease progression after a median of 2 years”
> “This modality can be followed by substantial side effects, although the use of low dose TNF (1 mg) and moderate temperature (never above 39 °C) have made this procedure safer than in the past.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.4-5"></a>

###### Cryotherapy in selected patients

> “Cryotherapy may be considered in selected patients to achieve symptom relief and disease control through tumour stabilization or reduction.”
> “Clinical benefit is most likely when at least 50% of the tumour volume is targeted, which may be difficult when the tumour is located near critical structures.”
> “Cryotherapy is a highly specialized procedure and should only be performed by a well-trained expert interventional radiologist.”

Source: [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### CRYODESMO-01 phase II study: design and non-progression rate at 12 months

> “CRYODESMO-01 (ClinicalTrials.gov Identifier: NCT02476305) is a prospective, open-label, non-randomised, non-comparative, multicenter study assessing cryoablation in non-abdominopelvic progressing DT.”
> “The primary end-point was the non-progression rate at 12 months; secondary end-points included safety, quality of life (QoL), assessment of pain and functional status.”
> “50 pts were enrolled (78% female) from four French centres and all were treated.”
> “The median tumour largest diameter was 89 mm. The rate of non-progressing disease at +12 months was 86% [confidence level (CI) 95% 73-94%]. Median PFS was not reached at a median follow-up of 31 months.”

Source: [Kurtz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33290994/)

<a id="topic-2.2.2.1.4-7"></a>

###### CRYODESMO-01 phase II study: toxicity, pain, and function

> “Grade 1 and 2 toxicity occurred in 32.8% and 44.5% of patients, grade 3-4 in 22% and no Grade 5 toxicity was observed. Cryoablation significantly improved functional status and pain scores.”

Source: [Kurtz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33290994/)

<a id="topic-2.2.2.1.4-8"></a>

###### Matched comparison of cryoablation and surgery

> “Twenty-two cryoablation patients were matched with 33 surgical patients (n = 55). Median follow-up after cryoablation was 16.3 months versus 14.9 months after surgery. Two-year local recurrence-free survival (LRFS) was 59% after cryoablation and 71% after surgery, and median LRFS was 26.6 months after cryoablation but was not reached after surgery.”
> “There was no significant difference in LRFS or disease control between matched cryoablation and surgical patients.”

Source: [Mandel et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9391920/)

<a id="topic-2.2.2.1.4-9"></a>

###### Retrospective study of local recurrence after cryoablation

> “Eighty-four patients treated for nonabdominopelvic desmoid tumors by cryoablation from July 2012 to July 2020 were included in a retrospective study.”
> “Local relapse was found in 19 (22.62%) of 84 patients. The 12-, 24-, and 36-month progression-free survival rates were 89% (95% confidence interval [CI], 79-94), 74% (95% CI, 60-83), and 68% (95% CI, 53-79), respectively.”

Source: [Bouhamama et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37182669/)

<a id="topic-2.2.2.1.4-10"></a>

###### Systematic review of cryoablation: response, local progression-free survival, and complications

> “Five studies were included in the systematic review accounting for 146 patients. Only 18.5% patients received cryoablation as a first-line treatment.”
> “Major complications were noted for 13.3-30% patients and following 2.4-6.7% interventional sessions. The rates of complete tumour response ranged between 0 and 43.3%. 1- and 3-year local progression-free survival rates were 85.1-85.8%, and 77.3-82.9%, respectively. Complete pain relief was reported in 40-66.7% symptomatic patients.”

Source: [Cazzato et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35237861/)

<a id="topic-2.2.2.1.4-11"></a>

###### Cryoablation in pediatric and young adult patients

> “Twenty-one patients (age 2-22 years; median 14 years), with 21 desmoid tumors, underwent a total of 34 percutaneous cryoablation procedures between August 2013 and August 2023.”
> “According to modified response evaluation criteria in solid tumors (mRECIST), 71%( 15/21) had partial response (PR), 19% (4/21) had complete response (CR), and 10% (2/21) had stable disease. Four (12%) treatments were associated with minor complications, which self-resolved.”

Source: [Shaikh et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39237782/)

<a id="topic-2.2.2.1.4-12"></a>

###### Pooled symptom relief and local control across 23 studies of cryoablation, high-intensity focused ultrasound, and microwave ablation

> “After literature selection, 694 DF tumors were identified in 23 studies. In terms of modality, 13 studies used cryoablation, 9 studies used high-intensity focused ultrasound (HIFU), and 1 study used microwave ablation (MWA).”
> “The pooled symptom relief rate was 90% [95% confidence interval (CI): 80–97%], with that for HIFU being 100% (95% CI: 85–100%), that for cryoablation being 87% (95% CI: 74–97%), and that MWA being 89% (95% CI).”
> “In the subgroup analysis, the rate of local control of MWA was 78% (14), that of HIFU was 99% (95% CI: 99–100%), and that of cryoablation was 80% (95% CI: 68–90%), with these differences being statistically significant”

Source: [Huang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10585570/)

<a id="topic-2.2.2.1.4-13"></a>

###### Major complications across 694 lesions treated with cryoablation, high-intensity focused ultrasound, or microwave ablation

> “Of the 694 lesions, 40 were associated with major complications, among which severe nerve injury was the most common (26.3%) (Figure 4).”
> “The major complication rates for MWA, HIFU, and cryoablation were 11% (14), 2% (95% CI: 0–6%), and 4% (95% CI: 1–8%), respectively. However, the difference was not statistically significant”

Source: [Huang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10585570/)

<a id="topic-2.2.2.1.4-14"></a>

###### Review of high-intensity focused ultrasound in 15 studies of desmoid tumors

> “We review the evidence for high-intensity focused ultrasound (HIFU) in the treatment of soft tissue sarcoma (STS) and desmoid tumour (DT).”
> “We identified 12 studies pertaining to STS (n=178) and 15 studies pertaining to DT (n=417). These were prospective phase I/II open-label trials and retrospective case series or reports. The commonest adverse effects were skin burns, transient pain, and fever. Less common adverse effects of nerve injury and bowel perforation were depended on anatomic relations of the tumour.”
> “There was a high degree of variability in the reporting of outcomes making quantitative analysis challenging.”

Source: [Chetan et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40570819/)

<a id="topic-2.2.2.1.4-15"></a>

###### Arterial doxorubicin eluting embolization

> “We investigated arterial doxorubicin eluting embolization (DEE), an approach characterized by high drug concentrations in the tumor alongside limited systemic drug exposure.”
> “The study included 24 patients (median age, 24; interquartile range, 16–34 years). Data were collected prospectively for 9 patients and retrospectively for 15 patients.”
> “Of 23 patients, 9 (39%), 12 (52%), and 2 (9%) had a partial response, stable disease, and progressive disease, respectively. DEE was safe and well tolerated, with one reported grade 3–4 adverse event (cord injury).”

Source: [Elnekave et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599870/)

Additional sources: [ClinicalTrials.gov NCT02476305](https://clinicaltrials.gov/study/NCT02476305)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Gamma Secretase Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

###### Nirogacestat: FDA-approved indication and mechanism

> “Initial U.S. Approval: 2023”
> “OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.”
> “Nirogacestat is a gamma secretase inhibitor that blocks proteolytic activation of the Notch receptor. When dysregulated, Notch can activate pathways that contribute to tumor growth.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Nirogacestat: recommended dosage and dose modifications

> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity.”
> “Instruct patients to swallow OGSIVEO tablets whole and not to break, crush, or chew prior to swallowing.”
> “For other severe adverse reactions, life-threatening adverse reactions, or persistent intolerable Grade 2 adverse reactions, withhold drug until resolved to Grade ≤ 1 or baseline. Only restart at a dosage of 100 mg twice daily after considering the potential benefit and likelihood of recurrence of the adverse reaction.”
> “Permanently discontinue OGSIVEO for recurrence of severe or life-threatening adverse reaction upon rechallenge at the reduced dose.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Nirogacestat warnings: diarrhea

> “Diarrhea, sometimes severe, can occur in patients treated with OGSIVEO”
> “Median time to first diarrhea event for patients treated with OGSIVEO was 9 days (range: 2 to 434 days). Monitor patients and manage using antidiarrheal medications.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### Nirogacestat warnings: ovarian toxicity

> “Female reproductive function and fertility may be impaired in patients being treated with OGSIVEO. Impact on fertility may depend on factors including the duration of therapy and the state of gonadal function at the time of treatment. The long-term effects of OGSIVEO on fertility have not been established.”
> “Monitor patients for changes in menstrual cycle regularity or the development of symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.”
> “OGSIVEO can affect ovarian function and the development of the ovarian follicle and therefore may reduce the effectiveness of hormonal contraceptives. Addition of a barrier method is recommended for females using hormonal contraceptives.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-5"></a>

###### Nirogacestat warnings: hepatotoxicity

> “ALT or AST elevations occurred in 30% and 33% of patients who received OGSIVEO in DeFi, respectively. Grade 3 ALT or AST elevations (> 5 × ULN) occurred in 6% and 2.9% of patients, respectively”
> “Monitor liver function tests regularly and modify dose as recommended”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-6"></a>

###### Nirogacestat warnings: non-melanoma skin cancers

> “New non-melanoma skin cancers can occur in patients treated with OGSIVEO. In DeFi, cutaneous squamous cell carcinoma and basal cell carcinoma occurred in 2.9% and 1.4% of patients, respectively”
> “Perform dermatologic evaluations prior to initiation of OGSIVEO and routinely during treatment.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-7"></a>

###### Nirogacestat warnings: electrolyte abnormalities

> “Electrolyte abnormalities can occur in patients treated with OGSIVEO. In DeFi, these included decreased phosphate (65%) and decreased potassium (22%). Phosphate <2 mg/dL occurred in 20% of patients who received OGSIVEO. Grade 3 decreased potassium occurred in 1.4% of patients”
> “Monitor phosphate and potassium levels regularly and supplement as necessary.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

###### Nirogacestat warnings: hypersensitivity reactions, added August 2026

> “Warnings and Precautions (5.6)”
> “08/2026”
> “Hypersensitivity reactions, including severe hypersensitivity reactions, have been reported with postmarketing use of OGSIVEO.”
> “Interrupt dosing or permanently discontinue OGSIVEO depending on the severity”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

###### Nirogacestat warnings: embryo-fetal toxicity

> “Based on findings from animal studies and its mechanism of action, OGSIVEO can cause fetal harm when administered to pregnant women.”
> “Advise females and males of reproductive potential to use effective contraception during treatment with OGSIVEO and for 1 week after the last dose”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

###### Nirogacestat: drug interactions

> “Strong or moderate CYP3A inhibitors: Avoid concomitant use. (7.1)”
> “Strong or moderate CYP3A inducers: Avoid concomitant use. (7.1)”
> “Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors and H2-receptor antagonists.”
> “Nirogacestat Cmax increased 2.5-fold and AUC 8.2-fold following coadministration of a single dose of OGSIVEO (100 mg) with itraconazole (a strong CYP3A inhibitor).”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.1.5-11"></a>

###### DeFi phase 3 trial: design

> “We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with progressing desmoid tumors according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were assigned in a 1:1 ratio to receive the oral γ-secretase inhibitor nirogacestat (150 mg) or placebo twice daily. The primary end point was progression-free survival.”
> “From May 2019 through August 2020, a total of 70 patients were assigned to receive nirogacestat and 72 to receive placebo.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.1.5-12"></a>

###### DeFi phase 3 trial: efficacy

> “The risk of disease progression or death was 71% lower in the nirogacestat group than in the placebo group (hazard ratio, 0.29; 95% confidence interval [CI], 0.15 to 0.55; P<0.001)”
> “The likelihood of being event-free at 1 year was 85% (95% CI, 73 to 92) with nirogacestat and 53% (95% CI, 40 to 64) with placebo. The likelihood of being event-free at 2 years was 76% (95% CI, 61 to 87) with nirogacestat and 44% (95% CI, 32 to 56) with placebo.”
> “The percentage of patients with a confirmed objective response was 41% in the nirogacestat group and 8% in the placebo group (P<0.001). Complete responses were observed in 7% of the patients in the nirogacestat group and no patients in the placebo group”
> “Significant between-group differences in secondary patient-reported outcomes, including pain, symptom burden, physical or role functioning, and health-related quality of life, were observed (P≤0.01).”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.1.5-13"></a>

###### DeFi phase 3 trial: safety

> “Dose reductions due to adverse events were more frequently reported among patients receiving nirogacestat (42%) than among those receiving placebo (0%) and were attributed primarily to diarrhea, stomatitis, maculopapular rash, hypophosphatemia, hidradenitis, ovarian failure, and folliculitis. Adverse events led to discontinuation of the trial regimen in 14 patients (20%) in the nirogacestat group and 1 patient (1%) in the placebo group.”
> “Ovarian dysfunction (defined by the MedDRA preferred terms of amenorrhea, premature menopause, menopause, and ovarian failure) occurred in 27 of 36 women of childbearing potential (75%) receiving nirogacestat and in 0 of 37 receiving placebo. The median time to first onset of ovarian dysfunction was 8.9 weeks, and the median duration across ovarian dysfunction events was 19.1 weeks.”
> “Although long-term treatment with nirogacestat was shown to be feasible (median treatment duration, 20.6 months), the appropriate treatment duration is unknown.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.1.5-14"></a>

###### DeFi long-term follow-up through December 2024

> “Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024.”
> “The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis.”
> “Of the 70 patients randomly assigned to nirogacestat in the DB phase, 39 continued in the OLE”
> “Overall, 33 and 15 patients received nirogacestat for at least 3 and 4 years, respectively.”
> “No additional events (progression or death) occurred with additional exposure after year 2”
> “The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.”
> “Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4.”
> “Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

<a id="topic-2.2.2.1.5-15"></a>

###### DeFi ovarian toxicity: onset and resolution in females of reproductive potential

> “This analysis further describes the incidence, presentation, and resolution of OT.”
> “OT was identified in 75% (27 of 36) receiving nirogacestat and 0% (0 of 37) receiving placebo. As of October 24, 2022, investigators reported OT resolution in 78% (21 of 27) of patients, with median OT duration of 19.1 weeks.”
> “Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment”
> “Resolution was reported in 10 of 14 (71%) while on nirogacestat”
> “Most FORP treated with nirogacestat experienced OT, with the majority resolving, including all who stopped treatment, suggesting that OT is transient.”

Source: [Loggers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38703010/)

<a id="topic-2.2.2.1.5-16"></a>

###### Duration of nirogacestat treatment: DeFi investigators' reply on long-term use

> “We do not endorse long-term uninterrupted treatment with nirogacestat as the standard of care. Still, as both groups of authors have acknowledged, the optimal treatment duration remains undefined.”
> “However, patients in DeFi were censored at the time nirogacestat was discontinued and were followed for no more than 30 days after treatment discontinuation. Therefore, the absence of progression events after year 2 reflects only the cohort of patients who continued treatment.”

Source: [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/)

<a id="topic-2.2.2.1.5-17"></a>

###### Real-world nirogacestat use in the French compassionate use program (DeNi study)

> “The DeNi study reports outcomes of patients treated with nirogacestat through the French compassionate use program. DeNi is a retrospective, real-world study.”
> “Between February and June 2024, 55 patients with desmoid tumors were included (37 women).”
> “Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions.”
> “Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.”
> “The most frequent side effects (all grades) were diarrhea (53%), fatigue (47%), and rash (29%). Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.”

Source: [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)

<a id="topic-2.2.2.1.5-18"></a>

###### NCCN guideline status as restated in a payer policy and in a DeFi publication

> “The National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 1.2025 – May 2, 2025) recommend the following therapies as”
> “regimens for desmoid tumors (aggressive fibromatosis):”
> “Ogsiveo (category 1), sorafenib (category 1), methotrexate and vinorelbine, methotrexate and vinblastine, imatinib, pazopanib, doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection) [except for Ogsiveo and sorafenib, all other agents listed are category 2A recommendations].”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

> “Nirogacestat, an oral, targeted gamma secretase inhibitor, is the only US Food and Drug Administration–and European Commission–approved therapy for adults with progressing DT who require systemic treatment and is recommended as a preferred therapy by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

<a id="topic-2.2.2.1.5-19"></a>

###### European marketing authorisation of nirogacestat

> “Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.”
> “Marketing authorisation issued”
> “14/08/2025”

Source: [EMA Ogsiveo EPAR (2025)](https://www.ema.europa.eu/en/medicines/human/EPAR/ogsiveo)

> “Approval from the European Commission was obtained in August 2025 and from the UK Medicines and Healthcare Products Regulatory Agency in January 2026.”
> “However, as of this writing, nirogacestat is still not widely available outside of the United States.”

Source: [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/)

<a id="topic-2.2.2.1.5-20"></a>

###### NICE technology appraisal TA1199 recommendation, October 2026

> “14 October 2026”
> “Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults. Nirogacestat can only be used if the company provides it according to the commercial arrangement.”
> “Usual treatment for progressing desmoid tumours that need systemic treatment is non-curative and aims to manage symptoms. This can include chemotherapy, which is not licensed for treating desmoid tumours.”
> “Nirogacestat has not been directly compared with chemotherapy in a clinical trial. Indirect comparisons suggest that nirogacestat is likely to work as well as chemotherapy, but this is uncertain.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

Additional sources: [Dossa et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42030529/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Tyrosine Kinase Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### NCCN placement of sorafenib, imatinib, and pazopanib as quoted in a payer policy

> “The National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 1.2025 – May 2, 2025) recommend the following therapies as”
> “Ogsiveo (category 1), sorafenib (category 1), methotrexate and vinorelbine, methotrexate and vinblastine, imatinib, pazopanib, doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection) [except for Ogsiveo and sorafenib, all other agents listed are category 2A recommendations].”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Guideline updates naming sorafenib a category 1 preferred regimen

> “After this analysis ended in August 2023 and the United States Food and Drug Administration (FDA) approval of nirogacestat, the NCCN Guidelines and DTWG guidelines were updated to include sorafenib and nirogacestat as Category 1, Preferred systemic regimens [14, 16, 18].”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.6-3"></a>

###### Desmoid Tumor Working Group assessment of tyrosine kinase inhibitors

> “All three prospective, single-arm, phase II trials demonstrated activity of imatinib with high rates of disease stabilisation (60–80%) despite rather low response rates (6–19%) and with the expected well-known toxicity profile of imatinib.”
> “Imatinib should clearly not be the treatment of first choice if DT remission is intended.”
> “Sorafenib is an active agent and currently the best-studied TKI in DTs.”
> “Limitations of the study are the inclusion of patients with very modest increase in tumour size (10%), no central radiological review and no guidelines to assess symptoms severity suggesting that many patients included in this study would probably not have required an active treatment.”
> “Taken together, these findings show clear clinical benefit of TKIs in DT. The effect appears to be more pronounced with sorafenib and pazopanib compared to imatinib and likely achievable with even low dosages, limiting the potential adverse effects.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.6-4"></a>

###### Sorafenib phase 3 trial: design and efficacy

> “In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.”
> “With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001). Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.”
> “The median time to an objective response among patients who had a response was 9.6 months (interquartile range, 6.6 to 16.7) in the sorafenib group and 13.3 months (interquartile range, 11.2 to 31.1) in the placebo group.”
> “On the basis of the predictable toxic-effects profile and substantial progression-free survival advantage conferred by sorafenib, the drug has antitumor activity as first-line therapy or as subsequent therapy for desmoid tumors.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.2.2.1.6-5"></a>

###### Sorafenib phase 3 trial: adverse events, dose modification, and discontinuation

> “Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).”
> “Dose interruptions occurred in 65% of the patients in the sorafenib group (32 of 49) and 34% of the patients in the placebo group (12 of 35), and dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.”
> “Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).”
> “Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group. Grade 4 events that were associated with sorafenib included thrombocytopenia (2%) and anemia (2%).”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.2.2.1.6-6"></a>

###### Pazopanib in the DESMOPAZ randomized phase 2 trial

> “DESMOPAZ was a non-comparative, randomised, open-label, phase 2 trial conducted at 12 centres from the French Sarcoma Group.”
> “Participants were randomly assigned (2:1) to oral pazopanib 800 mg per day for up to 1 year or to an intravenous regimen combining vinblastine (5 mg/m2 per dose) and methotrexate (30 mg/m2 per dose), administered weekly for 6 months and then every other week for 6 months.”
> “In the first 43 patients assessable for the primary endpoint in the pazopanib group, the proportion of patients who had not progressed at 6 months was 83·7% (95% CI 69·3-93·2).”
> “The most common grade 3 or 4 adverse events in the pazopanib group were hypertension (n=10, 21%) and diarrhoea (n=7, 15%)”
> “11 patients (23%) had at least one serious adverse event related to study treatment in the pazopanib group”

Source: [Toulmonde et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31331699/)

<a id="topic-2.2.2.1.6-7"></a>

###### Imatinib in the German Interdisciplinary Sarcoma Group phase 2 trial

> “We initiated a phase II trial within the German Interdisciplinary Sarcoma Group (GISG) evaluating imatinib to induce progression arrest”
> “Thirty-eight patients (median age 44 years [range: 19-80]; 68% female; 90% Eastern Cooperative Oncology Group (ECOG) performance status 0) were treated with a daily dose of 800 mg imatinib planned over 2 years.”
> “The final analysis for the primary end-point in the evaluable patients of the full analysis set revealed a PAR6mo of 65%. Subsequent progression arrest rates at 9, 12, 15, 18, 21 and 24 months were 65%, 59%, 53%, 53%, 50% and 45%, respectively.”
> “Best reported response was seven partial responses at 21 months revealing an overall response rate of 19%.”
> “In general imatinib adverse events were mild to moderate.”

Source: [Kasper et al. (2017a)](https://pubmed.ncbi.nlm.nih.gov/28282612/)

<a id="topic-2.2.2.1.6-8"></a>

###### Imatinib in a two-stage phase 2 study

> “Forty patients with unresectable and progressive symptomatic AF/DT were treated with imatinib (400 mg/day for 1 year) in a Simon's optimal two-stage phase II study”
> “The non-progression rates at 3, 6 and 12 months were, respectively, 91%, 80% and 67%. The 2-year progression-free and overall survival rates were 55% and 95%, respectively.”

Source: [Penel et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20622000/)

<a id="topic-2.2.2.1.6-9"></a>

###### Real-world sorafenib and pazopanib in an 11-institution retrospective cohort

> “Patients diagnosed with DTs and treated with sorafenib or pazopanib between 2011 and 2022 at 11 institutions were reviewed.”
> “142 patients with DT treated with sorafenib (n = 126, 88.7 %) or pazopanib (n = 16, 11.3 %) were analyzed.”
> “The overall response rate and the disease control rate were 26.0 % and 95.1 %, respectively.”
> “The 1-year and 2-year progression-free survival rates were 82 % and 80 %. Dose reductions were necessary in 34 (23.9 %) patients. Grade 3 or higher adverse events were reported in 36 (25.4 %) patients.”
> “Treatment discontinuation (n = 85, 59.9 %) was mainly for toxicity (n = 35, 45.9 %) or radiological or clinical progression (n = 30, 35.3 %).”

Source: [Noujaim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38759389/)

<a id="topic-2.2.2.1.6-10"></a>

###### Sorafenib discontinuation after response in the SORASTOP phase 2 study

> “The SORASTOP study reports long-term outcomes following planned sorafenib discontinuation in responding patients with extremity desmoid-type fibromatosis (DTF).”
> “In this prospective, single-arm phase 2 Simon's two-stage trial, adults with non-progressive, extremity DTF, ESAS pain < 2, after ≥ 12 months of sorafenib were enrolled.”
> “PFS at 12, 24 and 36 months were 90.8 %, 74.5 % and 74.5 % respectively; with median follow-up of 37 months.”

Source: [Singh et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41610807/)

<a id="topic-2.2.2.1.6-11"></a>

###### Tyrosine kinase inhibitor use reported by study participants

> “Most participants (76%, 281/369) received systemic therapy (any line), including nonsteroidal anti-inflammatory drugs (NSAIDs; 40%, 112/281), tyrosine kinase inhibitors (32%, 91/281), chemotherapy (31%, 87/281), and hormone antagonists (17%, 47/281; Table 2).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.6-12"></a>

###### Funding status of tyrosine kinase inhibitors in England

> “Current treatment options include off-label chemotherapy, off-label tyrosine kinase inhibitors (TKIs) and surgery. The NHS England clinical lead noted that TKIs are not commissioned in the NHS in England for desmoid tumours, so would only be used through compassionate access or company-sponsored programmes.”
> “Sorafenib and pazopanib are both TKIs, and clinical expert advice to the EAG was that these could be considered similarly effective.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

Additional sources: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Agresta et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29384266/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Chemotherapy

<a id="topic-2.2.2.1.7-1"></a>

###### NCCN placement of methotrexate-based and doxorubicin-based regimens as quoted in a payer policy

> “regimens for desmoid tumors (aggressive fibromatosis):”
> “methotrexate and vinorelbine, methotrexate and vinblastine,”
> “doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection)”
> “all other agents listed are category 2A recommendations”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.7-2"></a>

###### Guideline updates naming chemotherapy regimens category 2A

> “Additionally, the NCCN Guidelines were updated to include methotrexate with vinorelbine; methotrexate with vinblastine, imatinib, and liposomal doxorubicin; doxorubicin with or without dacarbazine; and pazopanib as Category 2A regimens [14].”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.7-3"></a>

###### Desmoid Tumor Working Group assessment of chemotherapy

> “Chemotherapy options include a “low-dose” regimen with methotrexate plus vinblastine or vinorelbine, or conventional dose chemotherapy using anthracycline-based regimens as similarly instituted for the treatment of soft tissue sarcomas, and pegylated liposomal doxorubicin.”
> “Response rates are in the range of 35–40%, but usually occur as late as several months after the start of therapy. Shrinkage can continue even after treatment withdrawal, and long-term disease control is usually achieved in up to 50–70% of the patients depending on the series.”
> “Conventional dose chemotherapy using anthracycline-based regimens is another option and is expected to achieve more rapid tumour responses.”
> “Finally, the administration of pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks has also been reported in two uncontrolled patient series (1 credit each) with a response rate of approximately 35% and an acceptable toxicity level and - importantly in this young patient population - less cardiac toxicity than conventional doxorubicin [51,60].”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.7-4"></a>

###### Desmoid Tumor Working Group approach to sequencing systemic therapies

> “In summary, due to the lack of comparative studies we are still not able to propose a definitive sequence of the existing systemic treatment options. Randomised data only exist for sorafenib, pazopanib and methotrexate plus vinblastine.”
> “In general, it is reasonable to employ less toxic therapy initially followed by more toxic agents in a stepwise fashion.”
> “As an example, in a worst-case scenario with a mesenteric, potentially life-threatening DT there is consensus to administer more aggressive therapies.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.7-5"></a>

###### Methotrexate plus vinblastine in the DESMOPAZ randomized phase 2 trial

> “The proportion of patients treated with methotrexate-vinblastine who had not progressed at 6 months was 45·0% (95% CI 23·1-68·5).”
> “in the methotrexate-vinblastine group were neutropenia (n=10, 45%) and liver transaminitis (n=4, 18%).”
> “six patients (27%) in the methotrexate-vinblastine group.”

Source: [Toulmonde et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31331699/)

<a id="topic-2.2.2.1.7-6"></a>

###### Methotrexate plus vinblastine or vinorelbine in a 25-year institutional series

> “Herein, we report on our institutional experience with low-dose methotrexate (MTX) + vinca alkaloids in this disease over the last 25 years.”
> “We identified 75 patients treated with MTX + vinblastine (40%), MTX + vinorelbine (57%), and vinorelbine alone (3%).”
> “Eight patients interrupted chemotherapy because of toxicity. According to RECIST (Response Evaluation Criteria in Solid Tumors) complete response, partial response, stable disease, and progressive disease were observed in 1%, 47%, 51%, and 1% of patients, respectively. Symptomatic relief was obtained in 80% of symptomatic cases. The median progression-free survival (PFS) was 75 months; it was 136 months in responding patients.”

Source: [Palassini et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28410293/)

<a id="topic-2.2.2.1.7-7"></a>

###### Methotrexate plus vinorelbine in a retrospective institutional series

> “Patients with biopsy‐proven DF, treated with MTX/VNL from 1997 to 2015 were reviewed.”
> “Among 48 patients treated for a median 19 months MTX/VNL, only nine (19%) had previous surgery.”
> “The median progression‐free survival (PFS) was 120 months, (95%CI 84‐155 months).”
> “Most common grade 1/2 toxicities included nausea (n = 12, 25%) and fatigue (n = 9,19%) with no grade 3/4 toxicities.”

Source: [Ingley et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6718598/)

<a id="topic-2.2.2.1.7-8"></a>

###### Methotrexate plus vinblastine in children in a Pediatric Oncology Group phase 2 trial

> “A phase II study was conducted within the Pediatric Oncology Group.”
> “Patients were treated using Vbl (5 mg/m2/dose) and Mtx (30 mg/m2/dose), both administered by intravenous injection weekly for 26 weeks and every other week for an additional 26 weeks.”
> “A measurable response was documented in eight patients (31%), and 10 patients had stable disease documented as the best response to treatment. Eighteen patients had disease progression at a median time of 9.1 months.”
> “Neutropenia was the most common toxicity (n = 22) and the most common grade 4 toxicity (n = 5).”

Source: [Skapek et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17290057/)

<a id="topic-2.2.2.1.7-9"></a>

###### Biweekly methotrexate plus vinblastine in a single-institution prospective cohort

> “The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution.”
> “Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m2) + VBL (6 mg/m2).”
> “Nineteen (51%) patients showed partial response (PR). Clinical benefit rate was 95%. PFS at 5 y was 80.8%. In PR cases, median time to response was 10 mo.”
> “Only 3 AEs of grade 3/4 were observed. Tumor regrowth after MTX + VBL discontinuation was observed in 5 (20%) of 25 patients.”

Source: [Nishida et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7648024/)

<a id="topic-2.2.2.1.7-10"></a>

###### Methotrexate plus vinblastine after meloxicam failure in an institutional cohort

> “Since March 2003, patients pathologically diagnosed with extraperitoneal desmoid tumors have been prospectively treated with meloxicam, a COX-2 inhibitor, at our institution.”
> “Patients with inoperable tumors who were resistant to meloxicam treatment underwent MTX and VBL therapy every other week.”
> “MTX + VBL therapy was administered in 15 patients. Six patients showed a partial response. Only one patient presented disease progression.”

Source: [Nishida et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25899770/)

<a id="topic-2.2.2.1.7-11"></a>

###### Systematic review of low-dose methotrexate plus vinblastine

> “There were three prospective case series but no randomized controlled trials among the nine studies.”
> “According to Response Evaluation Criteria in Solid Tumors criteria, the mean response rate (complete remission or partial response) was 36% (11-57%). Including stable disease, namely, clinical benefit was consistently as high as 85% (69-100%). Mean adverse event rate of G3 or G4 according to CTCAE was 31%.”
> “However, the overall evidence was weak, and this chemotherapy is not covered by insurance in Japan; we only weakly recommend low-dose chemotherapy with methotrexate and vinblastine in patients with extra-abdominal desmoid-type fibromatosis.”

Source: [Shimizu et al. (2020a)](https://pubmed.ncbi.nlm.nih.gov/31845730/)

<a id="topic-2.2.2.1.7-12"></a>

###### Doxorubicin-based chemotherapy in a French Sarcoma Group series

> “Records of patients with DT who were treated with CT in centers from the French Sarcoma Group were reviewed.”
> “Sixty-two patients entered the study.”
> “Thirteen patients (21%) received an anthracycline-containing regimen. The most frequent nonanthracycline regimen was the methotrexate-vinblastine combination (n=27).”
> “The response rate was higher with anthracycline-containing regimens: 54% versus 12%, P=0.0011. Median progression-free survival (PFS) was 40.8 months.”

Source: [Garbay et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21444357/)

<a id="topic-2.2.2.1.7-13"></a>

###### Systematic review of doxorubicin-based and liposomal doxorubicin chemotherapy

> “There were no randomized controlled trials. According to response evaluation criteria in solid tumors criteria, the response rates of doxorubicin-based regimens and liposomal doxorubicin were 44% (28.6-54) and 33.3% (0-75) on average, respectively.”
> “The rates of G3 or G4 complications according to common terminology criteria for adverse events were 28% and 13% with doxorubicin-based and liposomal doxorubicin chemotherapy, respectively, including neutropenia or cardiac dysfunction.”
> “We weakly recommend doxorubicin-based chemotherapy for patients with extra-abdominal desmoid-type fibromatosis in cases resistant to other treatments.”

Source: [Shimizu et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32700733/)

<a id="topic-2.2.2.1.7-14"></a>

###### Anthracycline-containing regimens compared with sorafenib in a retrospective multi-institutional analysis

> “The authors conducted a multi-institutional retrospective analysis of desmoid tumor patients treated with either sorafenib or an anthracycline-containing regimen over 1 year.”
> “From 2005 to 2022, 80 patients received sorafenib and 51 received an anthracycline-containing regimen with similar baseline characteristics. The 1-year ORR was 37% for anthracycline and 13% for sorafenib (p = .016).”
> “One-year PFS was 73% (95% CI, 60-86) for anthracycline and 59% (95% CI, 47-71) for sorafenib (p = .3).”
> “Grade 3 events were higher in the anthracycline group, 27% versus 14% (p < .05).”

Source: [Costa et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39543805/)

<a id="topic-2.2.2.1.7-15"></a>

###### Pegylated liposomal doxorubicin in a placebo-controlled phase 3 trial

> “In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles.”
> “From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo.”
> “The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002).”
> “Seven (14.9%) patients experienced grade 3 or 4 AEs in the PLD group, including neutrophil count decreased (10.6%), mucositis oral (6.4%), white cell decreased (4.3%), and palmar–plantar erythrodysesthesia syndrome (2.1%). No patients reported cardiotoxicity.”
> “First, the interpretation of our results is limited by a single-center design and relatively small sample size, which had the potential to introduce bias, although these aspects are consistent with other phase III trials in this rare disease.”
> “Lastly, the current follow-up period may not be sufficient to adequately assess the cardiotoxicity associated with low cumulative doses of PLD.”

Source: [Xu et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13223540/)

<a id="topic-2.2.2.1.7-16"></a>

###### Chemotherapy use and sequence in the United Kingdom

> “Clinical expert advice to the EAG was that vinorelbine is used as first-line chemotherapy for desmoid tumours, and doxorubicin as second-line chemotherapy. The EAG noted that methotrexate plus vinblastine was not commonly used in the UK, but it was not aware of any high-quality evidence for more relevant chemotherapies.”
> “They thought that off-label chemotherapy would be used in about 30% to 50% of cases, particularly for sporadic tumours (see section 3.2).”
> “The clinical and patient experts highlighted that pegylated liposomal doxorubicin is not used for desmoid tumours in the UK and has significant side effects.”
> “The committee noted that the effect estimate observed in Xu et al. for chemotherapy versus placebo was implausibly large (with a hazard ratio of 0.05) and did not align with clinical expert experience.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.1.7-17"></a>

###### Chemotherapy agents reported by study participants

| Systemic treatments | n (%) |
| --- | --- |
| “Chemotherapeutics” | “87 (31)” |
| “Methotrexate” | “32 (37)” |
| “Vinblastine” | “26 (30)” |
| “Doxorubicin” | “25 (29)” |
| “Liposomal doxorubicin” | “25 (29)” |
| “Vinorelbine” | “6 (7)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

Additional sources: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Kornreich et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37114926/); [Constantinidou et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19767198/)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Nonsteroidal Anti-inflammatory Drugs and Hormonal Therapy

<a id="topic-2.2.2.1.8-1"></a>

###### Desmoid Tumor Working Group position on antihormonal therapies and NSAIDs

> “Beside retrospective case series showing some evidence of activity, some with response rates of 25% with prolonged disease control in as many as 90% of patients, the only prospective phase II study evaluating antihormonal therapy plus NSAID showed limited activity as measured by WHO response criteria and PFS rates. Moreover, a recently published paper found no clear relationship between size, MRI signal changes and symptom changes with tamoxifen treatment [41]. Therefore, there is no evidence to consider antihormonal therapies and NSAIDs in patients with DT.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.8-2"></a>

###### Hormone antagonists no longer recommended by the Desmoid Tumor Working Group

> “Note that nirogacestat was not approved for use at the time of survey completion [18], and hormone antagonists are no longer recommended by Desmoid Tumor Working Group Consenus Guidelines [13]”
> “The use of NSAIDs and hormone antagonists reported in this study is only recommended for certain circumstances by evidence-based guidelines [14, 16].”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.8-3"></a>

###### NCCN placement of NSAIDs for pain as quoted in a payer policy

> “Sulindac or other nonsteroidal”
> “including celecoxib, are recommended for pain under”
> “Useful in Certain Circumstances”
> “(category 2A).”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.8-4"></a>

###### European consensus position on antihormonal therapy, 2017, superseded in 2020

> “Anti-hormonal agents such as tamoxifen may be used—alone [60] or in combination with NSAIDs [61]—as first medical treatment, mainly because of their limited toxicity, rare adverse events and low costs [62] (III, B). However, response rates have been found to be low and no clear relationship between symptom changes, size or MRI signal changes could be demonstrated [63]. Therefore, a general recommendation for its use cannot be given.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.8-5"></a>

###### High-dose tamoxifen plus sulindac in a German institutional series

> “Since 1992, 25 patients at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of tamoxifen and sulindac.”
> “In the current study, 17 patients with FAP-associated and 8 patients with sporadic desmoid tumors received 120 mg of tamoxifen and 300 mg of sulindac daily.”
> “Of the group of patients who received tamoxifen and sulindac as a primary treatment, all three patients with sporadic desmoid tumors demonstrated cessation of growth, and 10 of the 13 patients with FAP-associated tumors achieved either a PR or CR.”
> “Based on this experience, the authors recommended high-dose tamoxifen and sulindac as the primary treatment for patients with FAP-associated desmoid tumors.”

Source: [Hansmann et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14745880/)

<a id="topic-2.2.2.1.8-6"></a>

###### High-dose selective estrogen receptor modulators plus sulindac in an institutional cohort

> “This study included all desmoid patients that were treated and followed at our institution and had completed at least 1 year of treatment.”
> “A total of 134 patients were included. 64 (47.8 %) patients had a confirmed diagnosis of FAP, 69 (51.5 %) patients were sporadic. Overall 114 (85.1 %) patients showed regressive or stable desmoid size.”
> “Response was defined as stable size or regression of desmoid size between two CT or MRI scans.”

Source: [Quast et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26275868/)

<a id="topic-2.2.2.1.8-7"></a>

###### Tamoxifen plus sulindac in children in a Children's Oncology Group phase 2 study

> “We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children’s Oncology Group.”
> “No life-threatening toxicity was reported. Twelve (40%) of 30 females developed ovarian cysts, which were asymptomatic in 11 cases. Ten patients completed therapy without disease progression or discontinuing treatment. Responses included four partial and one complete (5/59, 8%). The estimated 2-year PFS and survival rates were 36% (95% confidence interval: 0.23–0.48) and 96%, respectively.”
> “However, the combination showed relatively little activity as measured by response and PFS rates.”

Source: [Skapek et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4646066/)

<a id="topic-2.2.2.1.8-8"></a>

###### Toremifene in a retrospective reference-institution series

> “We retrospectively reviewed all patients treated with toremifene between 2005 and 2012 at a reference institution.”
> “Forty-four patients were treated with toremifene 180 mg daily, 20 for radiological progression, 16 for pain and 8 for both.”
> “PFS was 89.6% at 2 years. According to Response Evaluation Criteria in Solid Tumours, partial response, stable disease and disease progression were observed in 25%, 65% and 10% of the patients, respectively. Symptomatic relief was obtained in 75% of patients.”
> “Adverse events G≥2 according to National Cancer Institute Common Toxicity Criteria were recorded in ten patients.”

Source: [Fiore et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26602014/)

<a id="topic-2.2.2.1.8-9"></a>

###### Toremifene at two dose levels in a prospective phase 2 study

> “In order to test the dose efficacy and assess activity and safety of toremifene in DF, we conducted this prospective phase 2 study (NCT02353429).”
> “The 6 and 12 months progression-free survival (PFS) probability was 14.4% (95% CI, 5.1-41.1) and 4.8% (95% CI, 0.7-32.6) for patients receiving 60 mg compared with 72.0% (95% CI, 54.2-96.2) and 52.5% (95% CI, 33.1-83.3) for those receiving 180 mg.”
> “No toremifene-related serious adverse events were observed.”
> “Toremifene at 60 mg daily is ineffective in this patient population. However, clinical benefit was observed at 180 mg in selected cases.”

Source: [Colombo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41903360/)

<a id="topic-2.2.2.1.8-10"></a>

###### Systematic review of anti-oestrogen therapy

> “Data on 168 DTs treated with anti-oestrogen agents, alone or in combination with nonsteroidal anti-inflammatory drugs, were identified with an overall response rate of 51%. There was no difference in response according to the type of DTs or between different anti-oestrogen therapies. Combination with anti-inflammatory drugs did not improve the outcome.”
> “Despite potential inaccuracies in the methodology, the results of the review indicate that anti-oestrogen therapy produces some effect in about one half of patients with DTs.”

Source: [Bocale et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21831172/)

<a id="topic-2.2.2.1.8-11"></a>

###### Meloxicam response and CTNNB1 mutation status

> “Of the 33 patients with meloxicam treatment, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD).”
> “S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017), whereas the other mutations had no impact on efficacy.”

Source: [Hamada et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4006838/)

<a id="topic-2.2.2.1.8-12"></a>

###### NSAID and hormone antagonist agents reported by study participants

| Systemic treatments | n (%) |
| --- | --- |
| “NSAIDS (with sulindac and celecoxib)” | “112 (40)” |
| “Sulindac” | “46 (41)” |
| “Celecoxib” | “23 (21)” |
| “Hormone antagonists” | “47 (17)” |
| “Antihormonal agent (e.g., tamoxifen)” | “41 (87)” |
| “Toremifene” | “4 (9)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

Additional sources: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary: limitations of active surveillance and local therapies

- Active surveillance: in a pooled analysis of 282 participants, 93 (33.0%) received active treatment after initial surveillance, and the 5-year crude cumulative incidence of RECIST progression was 34%. In a United Kingdom cohort of 168 participants, 46% proceeded to treatment, for pain (32%), progression (31%), or both (13%). Guidelines call for a first MRI within 1-2 months and then imaging at 3-6 month intervals, and surveillance may not be appropriate if progression could “be life-threatening or pose a risk for mutilation”.
- Surgery: NCCN and Desmoid Tumor Working Group guidelines “no longer support surgery as the first-line option in most situations” because of high postsurgical recurrence rates. Reported postsurgical recurrence reaches 50% to 88%, and 30%-90% for extremity tumors; after complete gross resection, 23% of patients had recurrence. In unfavorable locations, 2-year event-free survival was 25% after initial surgery and 52% with wait-and-see. Amputation was reported by 7% (12/163) of survey participants who had surgery, and 83% of them reported regrowth or recurrence afterward.
- Radiotherapy: in the EORTC 62991-22998 phase II trial (44 participants), the 3-year local control rate was 81.5% and response was slow. A review of 317 participants treated with definitive radiation reported local control in 79.8%, frequent late fibrosis, contracture, joint stiffness, skin disorders, lymphedema, and pain, and 6 secondary malignancies in the radiation field. The evidence for adjuvant radiotherapy is low, and it carries a risk of radiation-induced sarcoma “in this young patient population”.
- Ablation: in CRYODESMO-01 (50 participants), the 12-month non-progression rate was 86%, and grade 3-4 toxicity occurred in 22%. A systematic review of 146 participants reported major complications in 13.3-30%, and across 694 lesions treated with cryoablation, HIFU, or microwave ablation, severe nerve injury was the most common major complication (26.3%). Cryoablation is of limited use for larger tumors involving vital structures, and ablative approaches are not available in every center and require particular expertise.

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/); [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/); [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Alberta Health Services clinical practice guideline SAR-004 (2025)](https://www.ahs.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar004-desmoid.pdf); [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/); [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf); [Fernandez et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37099290/); [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/); [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/); [Keus et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23868907/); [Matsunobu et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32115624/); [Kurtz et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33290994/); [Cazzato et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35237861/); [Huang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10585570/); [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.9-2"></a>

###### Summary: limitations of systemic therapies

- Comparative evidence: the Desmoid Tumor Working Group stated that “due to the lack of comparative studies” no definitive sequence of systemic treatments could be proposed, with randomized data then existing for sorafenib, pazopanib, and methotrexate plus vinblastine. The NCCN guidelines (version 1.2025, as restated in a Cigna policy) list nirogacestat and sorafenib as category 1 and the other listed agents as category 2A.
- Gamma secretase inhibitors: in DeFi, dose reductions due to adverse events occurred in 42% of nirogacestat recipients (0% with placebo) and discontinuation due to adverse events in 20% (1% with placebo); ovarian dysfunction occurred in 27 of 36 women of childbearing potential (75%), with resolution reported in 78% (21 of 27) as of October 24, 2022, including all 11 who stopped treatment. The label carries warnings for diarrhea, ovarian toxicity, hepatotoxicity, non-melanoma skin cancers, electrolyte abnormalities, hypersensitivity reactions (added in August 2026), and embryo-fetal toxicity, and advises avoiding strong or moderate CYP3A inhibitors and inducers and gastric acid reducing agents. The appropriate treatment duration is unknown, and nirogacestat is “still not widely available outside of the United States”.
- Tyrosine kinase inhibitors are used off label and are not commissioned in the NHS in England for desmoid tumours. In the sorafenib phase 3 trial, adverse events led to discontinuation in 20% (no placebo patients), dose reductions due to toxic effects occurred in 31% vs 11%, and grade 1 or 2 rash occurred in 73%. In an 11-institution cohort of 142 participants treated with sorafenib or pazopanib, 59.9% discontinued treatment, mainly for toxicity. Imatinib trials showed response rates of 6–19%, and in DESMOPAZ grade 3 or 4 hypertension occurred in 21% of the pazopanib group.
- Chemotherapy is “not licensed for treating desmoid tumours” (NICE). Response rates are in the range of 35–40% and usually occur several months after the start of therapy. In DESMOPAZ, 45.0% of the methotrexate-vinblastine group had not progressed at 6 months, and neutropenia occurred in 45%. Systematic reviews reported grade 3 or 4 adverse event rates of 31% for low-dose methotrexate plus vinblastine and 28% for doxorubicin-based regimens, and grade 3 events were more frequent with anthracycline regimens than with sorafenib (27% vs 14%). NICE judged the hazard ratio of 0.05 for chemotherapy versus placebo in Xu et al. “implausibly large”, and experts stated that pegylated liposomal doxorubicin is not used for desmoid tumours in the UK.
- Hormonal therapy and NSAIDs: the Desmoid Tumor Working Group found “no evidence to consider antihormonal therapies and NSAIDs”, and hormone antagonists are no longer recommended in its consensus guidelines; NCCN lists sulindac or other NSAIDs for pain as useful in certain circumstances (category 2A). In a Children's Oncology Group phase II study of tamoxifen plus sulindac, responses occurred in 8% (5/59), 2-year PFS was 36%, and 12 of 30 females (40%) developed ovarian cysts. Toremifene 60 mg daily was ineffective (12-month PFS 4.8%), and the S45F mutation was associated with poor response to meloxicam.

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf); [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/); [Loggers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38703010/); [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf); [Ratan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13378759/); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation); [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/); [Noujaim et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38759389/); [Toulmonde et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31331699/); [Shimizu et al. (2020a)](https://pubmed.ncbi.nlm.nih.gov/31845730/); [Shimizu et al. (2020b)](https://pubmed.ncbi.nlm.nih.gov/32700733/); [Costa et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39543805/); [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/); [Skapek et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4646066/); [Colombo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41903360/); [Hamada et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4006838/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary

- The NDA under FDA review proposes varegacestat “for the treatment of adults with desmoid tumors”.
- The Desmoid Tumor Working Group considers active surveillance the first step after diagnosis in the majority of patients and proposes active treatment only in case of persistent progression. Treatment choice is guided by anatomical site: surgery remains the first option at progression for abdominal wall tumors, systemic therapy is the first option for intra-abdominal, retroperitoneal, and pelvic tumors, and medical therapy is preferred for extremity, girdle, and chest wall tumors and is first line for head and neck and intrathoracic tumors. The group states that no definitive sequence of systemic treatments can be proposed because comparative studies are lacking.
- The 2023 global consensus update addressed the positioning of gamma secretase inhibitors, with nirogacestat the first approved drug for desmoid tumors. NCCN soft tissue sarcoma guidelines version 1.2025, as quoted in a Cigna coverage policy, list Ogsiveo and sorafenib as category 1 and methotrexate-based, imatinib, pazopanib, and doxorubicin-based regimens as category 2A.
- The approved gamma secretase inhibitor, OGSIVEO (nirogacestat), is indicated for adult patients with progressing desmoid tumors who require systemic treatment, at 150 mg orally twice daily until disease progression or unacceptable toxicity. NICE recommends nirogacestat within its marketing authorisation; in its appraisal, current options in England are off-label chemotherapy, off-label tyrosine kinase inhibitors, and surgery, and nirogacestat is expected to displace chemotherapy and best supportive care.
- RINGSIDE Part B enrolled 156 participants with progressive disease (tumor growth of at least 20% within the past 12 months) who were either treatment-naïve with tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.
- Immunome states that systemic therapy is recommended for about 75% of tumors after progression during initial active surveillance, that gamma secretase inhibitors “may ultimately capture much of the market for desmoid tumor therapy”, and that it aims to “Become Standard of Care treatment of Desmoid Tumors”. It describes varegacestat as oral and once daily, estimates “10-11k Actively Managed Patients (US)”, and anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Immunome plans to commercialize in the United States through a targeted sales force designed to reach specialized treatment centers, and its corporate presentation names about 85 sarcoma centers of excellence.

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/); [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf); [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf); [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation); [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.2.2-2"></a>

###### Proposed indication under FDA review

> “today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.2.2.2-3"></a>

###### Active surveillance as the first step and active treatment after persistent progression

> “Thus, being cautious and avoiding potential harm in experienced hands, this approach is now considered the first step after diagnosis in majority of the patients.”
> “Neither surgery nor other forms of active treatments are proposed as primary therapy at diagnosis. Considering the biology and unpredictable course of the disease, active treatments should be considered only in case of persistent progression.”
> “A decision towards an active treatment should be postponed until the occurrence of subsequent progression or increase of symptoms burden, assessed with at least two further assessments and possibly not before one year from diagnosis in the absence of fulfilling RECIST progressive disease.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “An initial watchful waiting approach is useful to document actual tumor progression. Active therapies need to be individualized on a multidisciplinary basis for patients with clearly progressing disease.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.2-4"></a>

###### Treatment choice by anatomical site in the global consensus algorithm

> “As depicted in the treatment algorithm in Fig. 3, the type of further treatment is generally guided according to the anatomical site and the decision should be made with the patients in a stepwise approach: For abdominal wall DT, surgery is still the first option in case of progression. For intra-abdominal/retroperitoneal/pelvic DT, systemic therapy should be considered as the first treatment option. For extremity/girdles/chest wall DT, again surgery should not be the first treatment option unless the expected morbidity is very low (and only following MDT discussion); medical therapy should be administered preferably.”
> “For head & neck/intrathoracic DT, medical therapy is generally considered the first line option.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.2-5"></a>

###### Positioning of gamma secretase inhibitors in the 2023 global consensus update

> “The 2023 update of the global evidence-based consensus guideline focused on the positioning of local therapies alongside surgery and radiotherapy in the treatment algorithm as well as the positioning of the newest class of medical agents, such as γ-secretase inhibitors.”
> “The 2023 consensus guideline is informed by a number of new aspects, including data for local ablative therapies such as cryotherapy; other indications for surgery; and the γ-secretase inhibitor nirogacestat, the first representative of the newest class of medical agents and first approved drug for DT.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

<a id="topic-2.2.2.2-6"></a>

###### Sequence of systemic therapies

> “In summary, due to the lack of comparative studies we are still not able to propose a definitive sequence of the existing systemic treatment options.”
> “In general, it is reasonable to employ less toxic therapy initially followed by more toxic agents in a stepwise fashion. Out of the variety of possible systemic treatment options, one can be chosen taking into account the (1) level of evidence, (2) overall response rate, (3) PFS rate, (4) ease of administration and (5) expected toxicity of the administered drug following a 5-dimensional model (Fig. 4).”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.2-7"></a>

###### NCCN preferred systemic regimens for desmoid tumors

> “The National Comprehensive Cancer Network (NCCN) soft tissue sarcoma guidelines (version 1.2025 – May 2, 2025) recommend the following therapies as”
> “regimens for desmoid tumors (aggressive fibromatosis):”
> “Ogsiveo (category 1), sorafenib (category 1), methotrexate and vinorelbine, methotrexate and vinblastine, imatinib, pazopanib, doxorubicin ± dacarbazine, and Doxil® (liposomal doxorubicin for intravenous injection) [except for Ogsiveo and sorafenib, all other agents listed are category 2A recommendations].”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.2-8"></a>

###### Labeled population and dosing of the approved gamma secretase inhibitor

> “OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.”
> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

> “Nirogacestat can be used, within its marketing authorisation, as an option to treat progressing desmoid tumours that need systemic treatment in adults.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

<a id="topic-2.2.2.2-9"></a>

###### Treatment pathway and displaced treatments in England

> “When tumours are asymptomatic and non-threatening, management consists of active surveillance with monitoring and no immediate treatment. If tumours become symptomatic, progress, or threaten function, active treatment may be indicated.”
> “Current treatment options include off-label chemotherapy, off-label tyrosine kinase inhibitors (TKIs) and surgery.”
> “The committee noted that treatment decisions largely depend on the location of the desmoid tumour and its associated symptoms, with treatment options varying across the NHS.”
> “The basket comparator reflected the estimated mix of treatments that nirogacestat is expected to displace in NHS clinical practice, with the proportions of people having chemotherapy and best supportive care adding up to 100%.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.2-10"></a>

###### RINGSIDE Part B population of treatment-naive and previously treated progressing disease

> “One hundred fifty-six participants with histologically confirmed desmoid tumors with progressive disease (defined as tumor growth of at least 20% within the past 12 months as measured by RECIST v1.1) were enrolled.”
> “Enrolled participants were either treatment-naïve with desmoid tumors not amenable to surgery or had refractory or recurrent disease after at least one line of therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.2.2-11"></a>

###### Company statements of anticipated use

> “Following progression during initial active surveillance, systemic therapy is recommended for ~75% of tumors based on location.”
> “Treatment considerations include tumor progression, symptoms, risk of morbidity, surgical risk, and the need for a fast response. The uptake of OGSIVEO® in the United States in the treatment of desmoid tumors demonstrates the potential for GSIs to address unmet need, and we believe that GSIs may ultimately capture much of the market for desmoid tumor therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “Elevating an Established Class and Solidifying the Role of GSIs in Desmoid Tumor Treatment”
> “Become Standard of Care treatment of Desmoid Tumors”
> “10-11k Actively Managed Patients (US)”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “These findings confirm varegacestat could become standard of care in the treatment of desmoid tumors.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-2.2.2.2-12"></a>

###### Oral once-daily administration and anticipated treatment duration

> “Varegacestat is an investigational, oral, once-daily GSI therapy under evaluation for the treatment of desmoid tumors.”
> “Participants who progress while on study are eligible to enter an open-label extension whereby they may receive varegacestat at a dose of 1.2 mg once daily until disease progression or unacceptable toxicity.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “SUPPORT Sustained benefit and adherence with a once-daily treatment”
> “~50% of patients have desmoid tumors for more than 5 years”
> “A Long, Chronic, Treatment Journey”
> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.2.2-13"></a>

###### Care setting in sarcoma centers and specialized treatment centers

> “In the United States, we expect to commercialize the product through a focused internal commercial organization, which would include capabilities in marketing, analytics, market access, and a targeted sales force designed to reach specialized treatment centers.”
> “patient identification and market education efforts focused on the treating community; early market access planning intended to support appropriate patient access; and a build-out of patient support capabilities aligned with the chronic nature of treatment in this population.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “~85 Sarcoma Centers-of-Excellence”
> “SCALE Efficiently expand reach across the community through treatment center growth”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.2.2.2-14"></a>

###### Other products in development for desmoid tumors

> “Parabilis is evaluating the small molecule zolucatetide in a Phase 1/2 study that includes patients with desmoid tumors and plans to initiate a phase 3 registrational trial in 2027.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### RINGSIDE Part B progression-free survival across subgroups

> “PFS consistently favored VAR in all subgroups analyzed.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “The PFS benefit observed with varegacestat vs. placebo was consistent across key subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

> “Consistent PFS Benefit with Varegacestat Across Subgroups”
> “Post-hoc subgroup analysis to evaluate patients with poor prognosis”
> “Hazard ratio estimated from Cox proportional hazards model stratified by tumor location (intra-abdominal vs extra-abdominal)”

Source: [Gounder (2026b)](https://investors.immunome.com/wp-content/uploads/2026/05/ASCO-2026_RINGSIDE-B_pres_final_white.pdf)

> “PFS consistently favored varegacestat in all subgroups analyzed”
> “Age ≤30 / >30 years”
> “Tumor location intra-/extra-abdominal”
> “CTNNB1 mutation (S45F+S45P T41A)”
> “Baseline tumor size >10 / ≤10 cm”
> “Prior systemic DT therapy (yes/no)”

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

<a id="topic-2.2.2.3-2"></a>

###### RINGSIDE Part A objective response by subgroup

> “We performed descriptive analyses of objective response rate (ORR) in the following subgroups with at least 5 participants: age (≤40 years vs. >40 years), tumor size (<70 mm vs. ≥70 mm), prior lines of therapy (0, 1, or 2+), tumor location (intra-abdominal vs. extra-abdominal) and mutational biomarkers (APC vs CTNNB1). Subgroups were analyzed by pooling across dose regimens.”
> “ORR ranged from 43% to 78% across age, tumor size, prior therapy, tumor location and mutation subgroups (Table). Response rates were comparable across all subgroups examined.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

| Subgroup | ORR, responders (%) |
| --- | --- |
| Age | “Age ≤40 years (n=22) vs. >40 years (n=14)” “13 (59) vs. 10 (71)” |
| Tumor size | “Tumor size <70 mm (n=18) vs. ≥70 mm (n=14)” “13 (72) vs. 9 (64)” |
| Prior lines of therapy | “Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9)” “6 (55), 10 (63), 7 (78)” |
| Tumor location | “Intra-abdominal (n=9) vs. extra-abdominal (n=27)” “4 (44) vs. 19 (70)” |
| Mutation | “APC (n=7) vs CTNNB1 (n=19) mutation” “3 (43) vs. 13 (68)” |

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-2.2.2.3-3"></a>

###### DeFi progression-free survival across prespecified subgroups

> “Between-group differences in progression-free survival were consistent across prespecified subgroups.”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.2.2.3-4"></a>

###### Baseline pain control and pain response with nirogacestat

> “At technical engagement, the company clarified that 39% of people in the nirogacestat group and 43% in the placebo group in De-Fi had uncontrolled pain at baseline. The company provided a post-hoc analysis for subgroups with controlled and uncontrolled pain at baseline. It reported that both groups showed clinically meaningfully improved pain at cycle 10 (each cycle in De-Fi was 28 days). But the improvement was greater in the group that had uncontrolled pain at baseline.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.3-5"></a>

###### CTNNB1 S45F mutation and recurrence after surgery

> “The estimated 5-year recurrence-free survival rate was 23% (95% CI, 10 to 40%) for patients with 45F mutation compared to 57% (95% CI, 43 to 69%), and 65% (95% CI, 38 to 83%) for 41A mutation and nonmutated CTNNB1, respectively.”

Source: [Lazar et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2570141/)

> “The estimated 3-year and 5-year RFS rates were 0.49 and 0.45, respectively, for patients who had tumors with the S45F mutation; 0.91 and 0.91, respectively, for patients who had wild-type tumors; and 0.70 and 0.66, respectively, for all others”
> “This series confirmed that primary, completely resected, sporadic DTs with the S45F mutation have a greater tendency for local recurrence.”

Source: [Colombo et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23913621/)

<a id="topic-2.2.2.3-6"></a>

###### CTNNB1 mutation, tumor size, and location during active surveillance

> “In multivariable analysis, larger tumor size, mutation type, and tumor locations were associated with lower TFS. The specific mutation (S45F), larger tumor size, and extremity and trunk locations were all associated with a lower probability of spontaneous RECIST regression.”
> “Initial tumor size, CTNNB1 mutation, and location should be factored into the initial decision-making process.”

Source: [Colombo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788647/)

<a id="topic-2.2.2.3-7"></a>

###### Tumor location and outcome of surgery compared with a wait-and-see approach

> “The 2-year EFS was 66% for favourable locations (abdominal wall, intra-abdominal, breast, digestive viscera and lower limb) and 41% for unfavourable locations. Among patients with favourable locations, the 2-year EFS was similar in patients treated by both surgery (70%) and the wait-and-see approach (63%; p = 0.413). Among patients with unfavourable locations, the 2-year EFS was significantly enhanced in patients initially managed with the wait-and-see approach (52%) compared with those who underwent initial surgery (25%; p = 0.001).”

Source: [Penel et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28735069/)

<a id="topic-2.2.2.3-8"></a>

###### Age, tumor site, and tumor size and recurrence after resection

> “In multivariate analysis, factors associated with recurrence were extremity location, young age, and large tumor size, but not margin. Abdominal wall tumors had the best outcome (5-year LRFS 91%).”
> “Systemic therapies may be appropriate for young patients with large, extremity desmoids, but surgery alone is curative for most abdominal wall lesions.”

Source: [Crago et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4096320/)

<a id="topic-2.2.2.3-9"></a>

###### Familial adenomatous polyposis-associated and intra-abdominal desmoid tumors

> “FAP-associated DT (Gardner syndrome) seems to be more aggressive and multifocal and, therefore, tends to be treated more aggressively in terms of medical management.”
> “FAP patients should be jointly managed by sarcoma specialists and experts in gastrointestinal cancer.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “They stated that for extra-abdominal desmoid tumours, which are usually sporadic, chemotherapy would be used to manage symptoms.”
> “Intra-abdominal desmoid tumours, which are usually FAP-associated, are less likely to cause pain, and treatment focuses more on removing obstructions. In these cases, fewer people have chemotherapy and people are more likely to have surgery. One clinical expert noted that FAP-associated desmoid tumours that are treated with chemotherapy have good responses.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

<a id="topic-2.2.2.3-10"></a>

###### Age and reproductive potential in the selection of a gamma secretase inhibitor

> “One key factor influencing treatment selection is patient age and reproductive potential. For women of childbearing age, providers weigh the potential risk of ovarian toxicity associated with nirogacestat.”
> “That is a much harder decision for a younger woman. For older women or male patients, the decision is more straightforward.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

> “Varegacestat 56% | Placebo 5% of premenopausal women”
> “No women discontinued varegacestat due to ovarian toxicity”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Management in designated referral centers with a multidisciplinary tumor board

> “Management of DT is complex and should be carried out exclusively in designated DT referral centers equipped with a multidisciplinary tumor board. Selection of the appropriate strategy should consider DT-related symptoms, associated risks, tumor location, disease morbidities, available treatment options, and preferences of individual patients.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

> “Clearly, patients need to be referred to centres with experience in DT to minimize the risk of active surveillance and avoid unnecessarily debilitating or mutilating surgery when possibly needed. Surgery by surgeons without significant experience in the management of DT is strongly discouraged. Similarly, referral to experienced multidisciplinary teams is recommended at the time of initial diagnosis, for optimal advice on safety of an initial observation strategy.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “A multidisciplinary discussion in soft tissue tumor boards is necessary to propose a personalized management; furthermore, a discussion with the patient is also necessary for tailoring this proposal to its objectives given the natural course of the disease.”
> “Second opinion by an expert pathologist as well as clinical management by an expert team is highly recommended”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcomas and the Desmoid Tumor Working Group (DTWG) Global Consensus Paper Guidelines state that diagnosis and treatment be informed and supported by a multidisciplinary team”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.4-2"></a>

###### Imaging schedule during active surveillance

> “Active surveillance means that patients need to be continuously monitored with a first MRI (or alternatively CT if MRI is not possible) within 1-2 months, then in 3-6 months intervals.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.4-3"></a>

###### Supportive care, pregnancy, and family planning

> “Comprehensive programmes for DT patients should include physical, psychological and social support. A DT is not a contraindication for future pregnancies in favourable evolution and pregnant DT patients should be followed closely by obstetricians and desmoid clinicians.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “Individualized counseling is essential for managing risks of progression and recurrence, supporting informed fertility decisions. Referral to specialized centers is recommended to optimize DF management during family planning and pregnancy.”

Source: [Fiore et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40328165/)

<a id="topic-2.2.2.4-4"></a>

###### Monitoring requirements in the approved gamma secretase inhibitor label

> “Diarrhea: Severe diarrhea can occur. Monitor and dose modify for Grade 3-4 diarrhea.”
> “Ovarian Toxicity: Female reproductive function and fertility may be impaired. Advise females of reproductive potential of the potential risk prior to treatment and monitor routinely.”
> “Hepatotoxicity: Elevated AST and ALT can occur. Monitor AST and ALT regularly and modify dose as recommended.”
> “Non-Melanoma Skin Cancers: Perform dermatologic examination prior to initiation of OGSIVEO and routinely during treatment.”
> “Electrolyte Abnormalities: Monitor phosphate and potassium regularly and modify dose as recommended.”
> “Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.2.2.4-5"></a>

###### Diarrhea management with nirogacestat in oncology practices

> “Proactive management strategies, including early patient education, dietary guidance, appropriate pharmacologic intervention, and clear escalation protocols, are essential to ensuring safety and treatment continuity.”
> “We advise patients to stay well hydrated, avoid trigger foods like spicy, greasy, or high-fiber meals, and discontinue stool softeners or laxatives. If symptoms begin, they may take loperamide, but they should reach out if it persists.”
> “We train our nurses to instruct patients on proper loperamide use: two tablets at the onset and one tablet after each episode, with a maximum of eight tablets in a day. If they reach that maximum, they are calling the clinic.”
> “Uncontrolled diarrhea may require treatment interruption or dose reduction.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

<a id="topic-2.2.2.4-6"></a>

###### Ovarian toxicity monitoring and fertility counseling

> “Prior to initiating nirogacestat, baseline reproductive hormone levels, including anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol, should be collected. Monitoring continues periodically throughout treatment, and clinicians remain alert to menstrual irregularities and symptoms of estrogen deficiency, including hot flashes, night sweats, and vaginal dryness.”
> “In addition to symptom monitoring, clinicians discuss fertility preservation with all patients of reproductive potential.”
> “Menstrual changes are tracked during monthly assessments, and symptoms may prompt temporary treatment holds or dose modifications.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

> “The EAG's clinical experts explained that ovarian dysfunction is also a risk with chemotherapy. This is explained to people with childbearing potential and they are offered ovarian preservation. The EAG's clinical experts expected that the same process would be in place for nirogacestat.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

> “Off-treatment resolution was reported in all 11 patients (100%) who stopped nirogacestat treatment; of these, all nine with available menstruation information experienced return of menstruation and eight had FSH WNL at last reported assessment.”

Source: [Loggers et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38703010/)

> “Out of nine female patients, two elected to undergo oocyte cryopreservation prior to starting therapy.”

Source: [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)

<a id="topic-2.2.2.4-7"></a>

###### Visit and laboratory frequency during nirogacestat treatment

> “Early in therapy, the practices increase visit frequency to assess tolerance and establish a baseline.”
> “I may see them every two to three weeks initially and get lab work accordingly, following what is in the PQI.”
> “upon every clinical visit, we are going to do a CBC and CMP, and a thorough review of systems.”
> “Laboratory assessments typically include liver function tests (LFTs) and phosphorus.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

<a id="topic-2.2.2.4-8"></a>

###### Dose modification to maintain gamma secretase inhibitor treatment

> “Nirogacestat is associated with several well-documented adverse events, and dose reductions are common.”
> “if you need a dose reduced or a treatment holiday, that is part of the clinical course and should not be seen as a setback. Staying on therapy at a tolerable dose is the goal.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

> “Thirteen patients (24%) required dose reduction: 11 for digestive adverse events (85%), 1 for mucositis, and 1 for fatigue with hypertension.”

Source: [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)

> “While dose modifications were common, discontinuations were infrequent, making it possible for patients to remain on treatment and achieve continued efficacy benefit.”
> “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months”
> “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months”
> “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.2.2.4-9"></a>

###### Onset of adverse events with varegacestat in RINGSIDE Part B

| Adverse event (varegacestat, N=79) | All grades, n (%) | Median time to onset (days) |
| --- | --- | --- |
| Diarrhea | “65 (82.3)” | “14.0” |
| Nausea | “28 (35.4)” | “8.0” |
| Rash | “56 (70.9)” | “24.0” |
| Fatigue | “46 (58.2)” | “27.5” |
| Hypophosphatemia | “27 (34.2)” | “29.0” |
| Ovarian toxicity | “20 (25.3)” | “56.5” |

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.2.2.4-10"></a>

###### Commercial payer prior authorization criteria for nirogacestat

> “Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):”
> “A) Patient is ≥ 18 years of age; AND”
> “B) According to the prescriber, the patient has progressing desmoid tumors; AND”
> “Note: Progressing desmoid tumors are defined as ≥ 20% progression within 12 months.”
> “C) The desmoid tumors are not amenable to surgery or radiotherapy; AND”
> “D) According to the prescriber, the patient requires systemic treatment.”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

> “Approve for 1 year if the patient meets the following (A, B, C, and D):”
> “C) The desmoid tumors are not amenable to surgery or radiotherapy; AND”

Source: [Express Scripts nirogacestat criteria (2023)](https://express-scripts.com/sites/default/files/policies/Oncology%20-%20Ogsiveo%20PA%20Policy.pdf)

> “Ogsiveo may be considered medically necessary if the conditions indicated below are met.”
> “Patient requires systemic treatment”
> “Females of reproductive potential only: patient will be advised to use effective contraception during treatment with Ogsiveo and for 1 week after the last dose”
> “NO disease progression or unacceptable toxicity”
> “300 mg per day”
> “Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Ogsiveo while maintaining optimal therapeutic outcomes.”

Source: [FEP Blue nirogacestat policy 5.21.217 (2026)](https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/October/Pharmacy-Policies/Remove-and-Replace-Update/521217-Ogsiveo-nirogacestat.pdf)

<a id="topic-2.2.2.4-11"></a>

###### State Medicaid prior authorization criteria for nirogacestat and new antineoplastics

> “LENGTH OF AUTHORIZATION: Varies; Maximum of one year”
> “Adult patients with progressing desmoid tumors that require systemic treatment.”
> “60 per 30 days (100mg and 150mg)”

Source: [Florida Medicaid oncology prior authorization criteria (2026)](https://ahca.myflorida.com/file/medicaid/Oncology_Criteria_10.01.2026.pdf)

> “To ensure appropriate use for oncology medications based on FDA-approved and compendia-recommended (i.e., National Comprehensive Cancer Network® [NCCN]) indications.”
> “Are there equally or higher recommended alternative agents based on NCCN categories of evidence (Table 1) for the requested indication and place in therapy?”
> “When efficacy is similar, the choice of agent should be determined by safety, and then cost.”
> “New Antineoplastics are immediately subject to the policy and will be added to this table at the next P&T Meeting”

Source: [Oregon Medicaid prior authorization criteria (2025)](https://www.oregon.gov/oha/HSD/OHP/Tools/Oregon%20Medicaid%20PA%20Criteria%20October%201,%202025.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary

- Treatment of progressing desmoid tumors aims to control tumor growth and relieve symptoms. NICE describes it as “non-curative and aims to control tumour growth and alleviate symptoms”, the 2023 consensus update calls for selecting each patient's management strategy to optimize tumor control and enhance quality of life, and Immunome states that treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function.
- Tumor control with varegacestat in RINGSIDE Part B (data cutoff October 7, 2025): PFS of 94% at 1 year and 89% at 2 years with varegacestat, compared with 66% and 57% with placebo; a hazard ratio of 0.16 (95% CI 0.071, 0.375) and a confirmed objective response rate of 56% versus 9% in Immunome's ESMO release; and a median time to response of 8.2 months among varegacestat responders.
- Symptom outcomes in RINGSIDE Part B: Immunome reports a worst pain difference of more than 2 points from the first evaluation at week 4. At week 48, least-squares mean changes were -1.50 with varegacestat and +0.59 with placebo on the GODDESS TSS-5 symptom score, and +3.90 and -3.04 on PROMIS Physical Function.
- Treatment duration: median exposure in RINGSIDE Part B was 20.3 months with varegacestat as of October 7, 2025, and median time on treatment in RINGSIDE phase 2 as of April 10, 2024 was 23.1 months in one abstract and 25.4 months in another. Immunome anticipates that patients may receive about 1.5 to 2 years of treatment, pause, and return for treatment.
- Pauses and retreatment: in the NICE appraisal of nirogacestat, clinical experts supported stopping after 2 years if treatment could continue while the tumor was still shrinking or restart if it grew again. The company reported that less than 1% of people in its compassionate use programme continued beyond year 2, and the committee assumed that most patients stop after 2 years. The long-term nirogacestat follow-up publication (Ratan et al. 2025) states that optimal duration and responses after discontinuation are not well defined. The Desmoid Tumor Working Group states that shrinkage can continue after withdrawal, that long-term disease control is achieved in up to 50–70% of patients, and that treatment can be repeated at recurrence.
- Long-term continuous nirogacestat: in long-term follow-up of participants randomly assigned to nirogacestat, the objective response rate was 34.3%, 41.4%, 44.3%, and 45.7% with up to 1, 2, 3, and 4 years of treatment, with no additional progression or death events after year 2. In the French DeNi real-world study, median treatment duration was 16 months, the 1-year PFS rate was 76.2%, and 38 of 49 participants with baseline pain (78%) reported pain improvement.

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion); [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/); [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/); [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf); [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/); [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506); [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516); [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf); [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/); [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext); [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/); [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-2.2.2.7-2"></a>

###### Treatment goals in guidelines and health technology assessment

> “It is imperative to carefully select the management strategy for each patient with DT to optimize tumor control and enhance quality of life.”

Source: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

> “In this setting, treatment is non-curative and aims to control tumour growth and alleviate symptoms rather than address the underlying cause of the disease.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

> “Usual treatment for progressing desmoid tumours that need systemic treatment is non-curative and aims to manage symptoms.”

Source: [NICE TA1199 recommendations (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/1-Recommendation)

> “The goals, she said, are clear:”
> “to shrink the tumor, reduce pain, and improve mobility.”

Source: [NCODA PQI in Action, nirogacestat (2025)](https://www.ncoda.org/wp-content/uploads/2025/10/ogsiveo_pqiia_final_digital-1.pdf)

<a id="topic-2.2.2.7-3"></a>

###### Company-stated treatment goals for varegacestat

> “For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-2.2.2.7-4"></a>

###### Expected tumor control with varegacestat in RINGSIDE Part B

| Arm | Progression-free at 1 year | Progression-free at 2 years |
| --- | --- | --- |
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |

Source: [Kasper et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_3_ESMO-2026_RINGSIDE-B_Topline-T2W_POS_final.pdf)

> “The confirmed objective response rate (ORR) based on RECIST v1.1 was 56% with varegacestat vs. 9% with placebo (p<0.0001), as assessed by blinded independent central review.”
> “Varegacestat improved progression-free survival (PFS) vs. placebo, with an 84% reduction in the risk of disease progression or death (hazard ratio [HR] = 0.16, 95% confidence interval [CI]: 0.071, 0.375; p<0.0001).”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

> “Among responders treated with varegacestat, median time to response was 8.2 months (range: 2.6-28.0 months) vs. 16.7 months (range: 8.1-30.2 months) for responders receiving placebo.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

<a id="topic-2.2.2.7-5"></a>

###### Expected symptom relief with varegacestat in RINGSIDE Part B

> “A clinically significant difference of more than 2 points was observed as early as the first evaluation at week 4.”

Source: [Immunome press release, RINGSIDE data at ASCO 2026 (2026)](https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/)

> “At week 48, patients treated with varegacestat had a least-squares mean change from baseline in the GODDESS TSS-5 symptom score of -1.50 vs. +0.59 for patients receiving placebo, with lower scores indicating lower symptom burden. On the PROMIS Physical Function measure, where higher scores indicate better function, the least-squares mean change from baseline was +3.90 with varegacestat vs. -3.04 with placebo at week 48.”

Source: [Immunome press release, ESMO 2026 data (2026)](https://investors.immunome.com/immunome-presents-additional-clinical-data-for-varegacestat-in-desmoid-tumors-at-esmo-2026/)

<a id="topic-2.2.2.7-6"></a>

###### Treatment duration in RINGSIDE

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

> “RINGSIDE Phase 2 enrolled 42 participants, of whom 29 (69%) entered the OLE. As of April 10, 2024, median time on treatment was 23.1 months (range 0.7 – 26.6) and 23 participants (55%) were still on treatment.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-2.2.2.7-7"></a>

###### Treatment duration, pauses, and retreatment with gamma secretase inhibitors

> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “The EAG noted that clinical experts broadly supported stopping treatment after 2 years. But it added that this was only if there was flexibility to continue for longer if the tumour was still shrinking, or restart if, for example, the tumour started growing again.”
> “The company provided data on tumour size plateaus. It said that by year 2, 100% of tumours had plateaued in people with complete and partial response. In people with stable disease, more than 75% of tumours had plateaued.”
> “It recalled that retreatment with nirogacestat was not permitted in De-Fi, so the trial did not provide evidence on restarting treatment after stopping.”
> “The company highlighted that based on data from its compassionate use programme (up to April 2025), less than 1% of people having nirogacestat continue treatment beyond year 2.”
> “They explained that people in their practice usually stop nirogacestat after about 1 year, very few would continue beyond year 2 and the number of people needing retreatment is low.”
> “So, the committee concluded that while it would not recommend a stopping rule, the model should assume that most patients stop treatment after 2 years to align with clinical practice, with a proportion of people continuing or restarting treatment.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

> “Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined. In the setting of limited data, decisions on treatment duration, discontinuation, and rechallenge with nirogacestat are best made in collaboration between patients and their treating clinicians.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

> “Shrinkage can continue even after treatment withdrawal, and long-term disease control is usually achieved in up to 50–70% of the patients depending on the series. Of note, at recurrence, and especially if the patients responded to the therapy, the treatment can be repeated with substantial benefit.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.7-8"></a>

###### Long-term outcomes with continuous gamma secretase inhibitor treatment

> “No additional events (progression or death) occurred with additional exposure after year 2”
> “The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.”
> “For patients continuing treatment after the first year, the incidence and severity of frequently reported TEAEs decreased through subsequent years.”

Source: [Ratan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12634144/)

> “All patients who achieved a PR continue to maintain responses between 47.9 and 73+ months. Four patients stopped treatment yet remain free of progression between 11 and 53+ months.”

Source: [Villalobos et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28887726/)

<a id="topic-2.2.2.7-9"></a>

###### Real-world outcomes with nirogacestat

> “The estimated median duration of nirogacestat treatment was 16 months. Partial response and stable disease were observed in 33 (60%) and 17 patients (31%), respectively. The 1-year PFS rate was 76.2%, and 77.0% of patients remained without treatment change at 1 year, including patients with dose reductions. Of the 49 patients with baseline pain, 38 (78%) experienced pain improvement under nirogacestat; 35 (71%) reduced or discontinued analgesics.”

Source: [Kubicek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42522292/)

> “Eight out of nine evaluable patients (88%) demonstrated a reduction in tumor volume and improvement in magnetic resonance imaging (MRI) T2-weighted signal intensity. Nine out of 10 patients who presented with pain (90%) reported rapid improvement.”

Source: [Rutherford et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42500920/)

<a id="topic-2.2.2.7-10"></a>

###### Reduced need for supportive procedures in intra-abdominal disease

> “The clinical expert also explained that people with desmoid tumours, particularly intra-abdominal tumours, may need stomas, ureteric stents and home intravenous nutrition. The need for these may be reduced if nirogacestat was available.”

Source: [NICE TA1199 committee discussion (2026)](https://www.nice.org.uk/guidance/ta1199/chapter/3-Committee-discussion)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
